hydrazine and amg531
hydrazine has been researched along with amg531 in 640 studies
Research
Studies (640)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 51 (7.97) | 29.6817 |
| 2010's | 396 (61.88) | 24.3611 |
| 2020's | 193 (30.16) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Collins, D; Deng, Y; Erickson-Miller, CL; Jenkins, JM; Kitchen, V; Uhl, J; Williams, D | 1 |
| Kurata, Y | 1 |
| Panzer, S | 2 |
| Afdhal, NH; Berg, T; Blackman, N; Bourliere, M; Campbell, FM; Dusheiko, G; Gordon, SC; Jenkins, J; McHutchison, JG; Rodriguez-Torres, M; Shiffman, ML; Sigal, S; Theodore, D | 1 |
| Arning, M; Bussel, JB; Cheng, G; Hassani, H; Jenkins, JM; Kloczko, J; Kovaleva, L; Mayer, B; Meddeb, B; Provan, D; Psaila, B; Saleh, MN; Stone, NL | 1 |
| Schwartz, RS | 1 |
| Abrams, CS; Metjian, A | 1 |
| Kuter, DJ | 5 |
| Newland, A | 3 |
| Amadori, S; Buccisano, F; Evangelista, ML; Stasi, R; Stipa, E; Venditti, A | 1 |
| Lawson, A | 1 |
| Andrès, E; Hentges, F; Zimmer, J | 1 |
| Amadori, S; Evangelista, ML; Stasi, R | 1 |
| Bussel, JB; Kobos, R | 1 |
| Birgens, H; Brown, Pde N; Dalseg, AM; Dufva, IH; Hasselbalch, HC; Jensen, MK; Vangsted, A | 1 |
| Giannini, EG; Savarino, V | 1 |
| Jackson, SP; Wei, A | 1 |
| Tomiyama, Y | 2 |
| Arnason, JE; Bussel, JB; Levy, B | 1 |
| Godeau, B | 1 |
| Delorme, E; Duffy, KJ; Erickson-Miller, CL; Hopson, CB; Jenkins, JM; Landis, AJ; Luengo, JI; Miller, SG; Rosen, J; Sellers, TS; Tian, SS; Valoret, EI | 1 |
| Burzynski, J | 1 |
| McHutchison, JG; Patel, K; Tillmann, HL | 1 |
| Antipas, AS; Blumberg, LC; Brissette, WH; Brown, MF; Casavant, JM; Doty, JL; Driscoll, J; Harris, TM; Jones, CS; Li, Q; Linde, RG; Lira, PD; Marfat, A; McCurdy, SP; McElroy, E; Mitton-Fry, M; Munchhof, MJ; Reiter, LA; Ripp, SL; Shavnya, A; Thomasco, LM; Trevena, KA; Wolf-Gouveia, LA | 1 |
| Morrow, T | 1 |
| Francesco, R | 1 |
| Pabinger, I; Panzer, S | 1 |
| Arning, M; Bussel, JB; Cheng, G; Jenkins, JM; Kovaleva, L; Mayer, B; Provan, D; Psaila, B; Roychowdhury, D; Salama, A; Shamsi, T; Stone, N | 1 |
| Vadhan-Raj, S | 1 |
| Nurden, AT; Nurden, P; Viallard, JF | 1 |
| Garnock-Jones, KP; Keam, SJ | 1 |
| Diez-Ewald, M; Vizcaíno, G; Vizcaíno-Carruyo, J | 1 |
| Arnold, DM; Kelton, JG; Nazi, I | 1 |
| Bailey, CK; Collins, DA; Deng, Y; Jenkins, JM; Kapsi, SG; Park, JW; Peng, B; Williams, DD; Wire, MB | 1 |
| Hussar, DA | 1 |
| Lam, MS | 1 |
| Dusheiko, G | 1 |
| Abboud, M; Aivado, M; Erhardt, JA; Erickson-Miller, CL; Pillarisetti, K; Toomey, JR | 1 |
| Aivado, MA; Bruns, I; Erickson-Miller, CL; Kawahara, M; Luciano, JP; Parekh, S; Steidl, U; Verma, A; Will, B | 1 |
| Collins, DA; Deng, Y; Jenkins, J; Kitchen, VS; Williams, D | 1 |
| Miyakawa, Y | 1 |
| Nonoyama, S | 1 |
| Sekeres, MA | 1 |
| Leitch, HA; Vickars, LM | 1 |
| Dmytrijuk, A; Pazdur, R; Rieves, D; Robie-Suh, K | 1 |
| Bussel, JB | 1 |
| Carraway, HE; Gore, SD; Loaiza-Bonilla, A | 1 |
| Aivado, M; Chadderton, A; Erickson-Miller, CL; Kirchner, J; May, R; Payne, P | 1 |
| Molineux, G; Newland, A | 1 |
| Keating, MJ; Koehrer, S; Wierda, WG | 1 |
| Olsson, B; Wadenvik, H | 1 |
| Chitlur, M; Nugent, DJ; Roganovic, J; Tamary, H | 1 |
| Imbach, P; Kühne, T | 1 |
| Ferrer-Marin, F; Gutti, RK; Liu, ZJ; Sallmon, H; Sola-Visner, MC | 1 |
| Bowen, C; Jenkins, J; Matthys, G; McGuire, S; Park, JW; Peng, B; Williams, D; Wire, MB | 1 |
| Corman, SL; Mohammad, RA | 1 |
| Giagounidis, A; Greinacher, A; Hiller, E; Kiefel, V; Matzdorff, A; Müller-Beissenhirtz, H; Ostermann, H; Rummel, M; Sachs, UJ; Salama, A | 1 |
| Cenci, T; Foà, R; Giona, F; Larocca, LM; Leone, G; Martini, M; Teofili, L; Torti, L | 1 |
| Andrade, J; Cablewski, T; Condie, G; Haylock, D; Meagher, L; Riches, A; Tarasova, A; Werkmeister, J; White, J; Winkler, D | 1 |
| Chouhan, JD; Herrington, JD | 1 |
| Bussel, JB; Kuter, DJ | 1 |
| Bowen, C; Jenkins, JM; Matthys, G; McGuire, S; Park, JW; Peng, B; Williams, D; Wire, MB; Zhang, J | 1 |
| Sperati, CJ; Streiff, MB | 1 |
| Bauman, JW; Park, JW; Peng, B; Vincent, CT; Williams, DD; Wire, MB | 1 |
| Gibiansky, E; Ouellet, D; Wang, Z; Williams, D; Zhang, J | 1 |
| Kalpadakis, C; Kozana, A; Mavroudi, I; Papadaki, HA; Pavlaki, K; Pontikoglou, C; Psyllaki, M; Pyrovolaki, K | 1 |
| Cook, L; Cooper, N | 1 |
| Bondarenko, IN; Jagiello-Gruszfeld, A; Kellum, A; Messam, C; Mostafa Kamel, Y; Patwardhan, R | 1 |
| Aivado, M; Arning, M; Bussel, JB; Cheng, G; Marcher, C; Mayer, B; Saleh, MN; Stone, NL; Vasey, S | 1 |
| Nurden, AT | 1 |
| Bowen, CJ; Ferguson, J; Lobb, KM; Park, JW; Sanderson, B | 1 |
| Balduini, CL; Bozzi, V; Fierro, T; Gresele, P; Klersy, C; Melazzini, F; Mezzasoma, AM; Noris, P; Pecci, A; Savoia, A | 1 |
| Abe, M; Hirayama, F; Itoh, H; Kawasaki, T; Koga, Y; Naganuma, S; Sakata, C; Sugasawa, K; Suzuki, K | 1 |
| Bussel, JB; Pinheiro, MP | 1 |
| Stasi, R | 2 |
| Rhodes, E; Stasi, R | 1 |
| Gibiansky, E; Hayes, S; Ouellet, D; Wire, MB; Zhang, J | 1 |
| Birgens, HS; Frederiksen, H; Gudbrandsdottir, S; Hasselbalch, HC; Nielsen, CH; Nielsen, OJ; Stentoft, J | 1 |
| Benham, L; Guo, L; Turner, R | 1 |
| Salama, A | 1 |
| Cela, I; Katz, RS; Miller, IJ; Rizman, A; Shammo, JM | 1 |
| Bosworth, J; Lown, R; Rhodes, E; Shannon, MS; Stasi, R | 1 |
| Meyer, O; Salama, A | 1 |
| Barsam, SJ; Beer, JH; Bussel, JB; Forestier, M; Gernsheimer, TB; Geyer, JT; Page, LK; Psaila, B; Ruisi, MM; Sloane, PA; Villarica, GO | 1 |
| Horikawa, M; Ishiwata, N; Kato, Y; Matsubara, K; Nakamichi, N; Silver, DL; Sugiura, T; Takeuchi, K; Umeda, S | 1 |
| Allred, AJ; Bowen, CJ; Lee, E; Park, JW; Peng, B; Williams, DD; Wire, MB | 1 |
| Brainsky, A; Grotzinger, KM; Signorovitch, J | 1 |
| Ay, C; Haselboeck, J; Koder, S; Pabinger, I; Panzer, S | 1 |
| Matsuki, E; Miyakawa, Y; Okamoto, S; Yamane, A | 1 |
| Boyers, D; Crowther, M; Fraser, C; Jenkinson, D; Jia, X; Mowatt, G | 1 |
| Fukunaga, S; Hori, A; Ono, S; Tanimoto, T; Yagasaki, F | 1 |
| Bowen, C; Deng, Y; Gorycki, F; Gorycki, PD; Levy, M; Madatian, A; Park, JW; Peng, B; Schubert, E; Williams, D; Wire, MB | 1 |
| Bershas, D; Chen, EP; Deng, Y; Gorycki, PD; Ho, M; Qian, Y; Rogers, M; Serabjit-Singh, C; Shi, W; Sychterz, C; Talley, K | 1 |
| Cheng, G | 1 |
| Abadie, E; Brown, D; Calvo, G; Feldschreiber, P; Hudson, I; Lay, G; Lee, CC; Nieto, M; Pignatti, F; Thomas, A; Valeri, A | 1 |
| Duan, X; Ni, X; Xu, J; Zeng, Y | 1 |
| Garnock-Jones, KP | 2 |
| Duic, JP; Grewal, J; Haas, J; Kesari, S; McConie, K; Staszewski, H | 1 |
| Crowther, M; Imbach, P | 1 |
| Boiocchi, L; Bussel, JB; Feng, X; Geyer, JT; Ghanima, W; Gudbrandsdottir, S; Hasselbalch, HC; Junker, P; Orazi, A | 1 |
| Steensma, DP | 1 |
| Kolesar, JM; Zhang, Y | 1 |
| Bolton-Maggs, PH; Collins, R; Emohare, O; Kaczmarski, R; Myers, B; Scully, M | 1 |
| Frederiksen, H; Gudbrandsdottir, S; Hasselbalch, H | 1 |
| Fernández, A; Grande, C; Jarque, I; López, MF; Martínez, R; Mingot, ME; Monteagudo, E; Ribera, JM; Sanz, MÁ; Valcárcel, D; Vicente García, V | 1 |
| Calvo, G; Catalá-López, F; Corrales, I; Martín-Serrano, G; Tobías, A | 1 |
| Lou, LG; Xie, CY; Xu, YP; Zhao, HB | 1 |
| Babula, B; Barnard, MR; Bussel, JB; Frelinger, AL; Li, Y; Linden, MD; Mathur, K; Michelson, AD; Psaila, B; Tate, C | 1 |
| Brainsky, A; Bruce, J; Gauvin, J; McGuire, S; Pendry, CJ; Qian, Y; Wire, MB | 1 |
| McLean, HB; Park, JW; Pendry, C; Peng, B; Theodore, D; Wire, MB | 1 |
| Balduini, CL; Barozzi, S; d'Amico, S; Pecci, A | 1 |
| Hattori, T; Ikeda, Y; Kanakura, Y; Katsura, K; Katsutani, S; Kimura, A; Kosugi, H; Miyakawa, Y; Ninomiya, H; Nomura, S; Okamoto, S; Okoshi, Y; Ozaki, K; Tomiyama, Y | 1 |
| Boyers, D; Jenkinson, D; Jia, X; Mowatt, G | 1 |
| Bateman, C; Batty, P; Ebdon, C; Homeida, S; Jackson, B; Kolade, S; Peng, YY; Stasi, R | 1 |
| Becker, M; Bennett, JM; Chen, Y; Liesveld, J; Milner, L; Phillips, GL; Reid, R | 1 |
| Aoki, T; Harada, Y; Kasai, M; Matsubara, E; Ogura, M; Oyama, T; Suzuki, T; Uchida, T | 1 |
| Barreyro, L; Bartholdy, B; Mitsiades, CS; Narayanagari, S; Roth, M; Simkin, G; Steidl, U; Tamari, R; Verma, A; Will, B | 1 |
| Fujiyama, S; Hattori, T; Katsura, K; Kawaguchi, T; Komori, A; Nakamuta, M; Oketani, M; Sakisaka, S; Sasaki, Y; Sata, M; Seike, M; Tanaka, M; Watanabe, H | 1 |
| Chen, Y; Liesveld, J; Nowak, I; Sun, H; Tsai, Y | 1 |
| Altomare, I; Pullarkat, V; Wasser, J | 1 |
| Brümmendorf, TH; Ehninger, G; Jakob, C; Platzbecker, U; Schleyer, E; Siegert, G; Trautmann, K; von Grünhagen, U | 1 |
| Biancotto, A; Calvo, KR; Desmond, R; Dumitriu, B; Dunbar, CE; Feng, X; Lozier, J; Olnes, MJ; Parikh, AR; Scheinberg, P; Soto, S; Tang, Y; Wu, CO; Young, NS | 1 |
| Metcalf, D | 1 |
| Fujita, S; Hotta, M; Ishii, K; Ito, T; Nakamichi, N; Nakanishi, T; Nomura, S; Tamaki, T; Yoshimura, H | 1 |
| Barsam, S; Bussel, JB; Ghanima, W; Lee, SY; Miller, A; Sandset, PM | 1 |
| Ruggeri, M | 1 |
| Arnold, DM | 2 |
| Rodeghiero, F | 2 |
| Joshi, A; Noronha, V; Philip, SD; Prabhash, K | 1 |
| Basciano, PA; Bussel, JB | 1 |
| Aggarwal, S; Randhawa, H; Sharma, A; Sharma, V | 1 |
| Afdhal, NH; Andriulli, A; Brainsky, A; Campbell, F; Chen, PJ; Giannini, EG; Han, KH; Hyde, D; Jeffers, L; Lee, JW; McHutchison, J; Mohsin, A; Tayyab, G; Theodore, D | 1 |
| Erickson-Miller, CL; Figueroa, DJ; Kamel, YM; Kirchner, J; Liu, Y; Martin, AM; Messam, C; Ottesen, L; Pillarisetti, K | 1 |
| Akehurst, R; Cooper, KL; Dillingham, K; Fitzgerald, P; Helme, K | 1 |
| Flores, B; Jonsson, B; Pignatti, F | 1 |
| Korman, T; Lee, LY; Quach, H; Smith, B; Woolley, IJ | 1 |
| Aiba, K; Furukawa, K; Futagawa, Y; Ito, R; Misawa, T; Uwagawa, T; Yahagi, Y; Yanaga, K | 1 |
| Holbro, A; Meyer, SC; Rovó, A; Scherer, K; Tichelli, A; Tsakiris, DA | 1 |
| Basciano, PA; Bussel, J; Christos, PJ; Giannakakou, P; Hafeez, Z | 1 |
| Arning, M; Bailey, CK; Brainsky, A; Bussel, JB; Cheng, G; Meyer, O; Saleh, MN | 1 |
| Carroll, M; Gewirtz, AM; Kalota, A; Sugita, M | 1 |
| Aisa, Y; Ito, C; Mihara, A; Nakazato, T | 1 |
| Catani, L; Iacobucci, I; Martinelli, G; Palandri, F; Polverelli, N; Vianelli, N | 1 |
| Arning, M; Bussel, JB; Mayer, B; Saleh, MN; Stone, NL; Vasey, SY | 1 |
| Levitov, AB; Mulla, CM; Rashidi, A | 1 |
| Akay, OM; Andic, N; Gunduz, E; Şahin, D; Teke, HÜ | 1 |
| Ruiz-Arguelles, GJ; Ruiz-Delgado, GJ; Velázquez-Sánchez-de-Cima, S; Zamora-Ortiz, G | 1 |
| Chumsri, S; Zimrin, A | 1 |
| Haselboeck, J; Kaider, A; Pabinger, I; Panzer, S | 1 |
| Bakshi, KK; Brainsky, A; Tarantino, MD | 1 |
| D'Arena, G; Guariglia, R; Lerose, R; Mansueto, G; Martorelli, MC; Musto, P; Pietrantuono, G; Villani, O | 1 |
| Abgrall, JF; Audia, S; Bierling, P; Boutboul, D; Cheze, S; Dauriac, C; Durand, JM; Fain, O; Godeau, B; Gyan, E; Hamidou, M; Khellaf, M; Languille, L; Lefort, S; Lefrere, F; Michel, M; Michot, JM; Niault, M; Roudot-Thoraval, F; Viallard, JF | 1 |
| Arnold, DM; Ghadaki, B; Kelton, JG; Nazi, I | 1 |
| Afdhal, NH; Giannini, EG | 1 |
| Brainsky, A; Fogarty, P; Mayer, B; Tarantino, MD; Vasey, SY | 1 |
| Chawla, SP; Hendifar, A; Kamel, YM; Messam, CA; Patwardhan, R; Staddon, A | 1 |
| Aguilar, C | 1 |
| Gibiansky, E; Hayes, S; Johnson, BM; Mudd, PN; Ouellet, D; Williams, D | 1 |
| Deveci, B; Karakuş, V; Kurtoğlu, E | 1 |
| Crowther, M; Cuker, A; Siegal, D | 1 |
| Hallam, S; Newland, AC; Provan, D | 1 |
| Hino, M; Kanashima, H; Kumura, T; Manabe, M; Nakane, T; Nakao, T; Ogawa, Y; Ohta, T; Yamamura, R; Yamane, T; Yoshida, M | 1 |
| Amaddii, G; Billio, A; Cortelazzo, S; Natolino, F; Piccin, A | 1 |
| Brereton, N; Deuson, R; Hirst, A; Kutikova, L; Lee, D; Thornton, P | 1 |
| Aotsuka, N; Hara, S; Imai, H; Inokuchi, K; Koizumi, M; Komatsu, T; Kumagai, K; Matsuura, Y; Nakaseko, C; Takeuchi, M; Tanaka, H; Tsukamoto, S; Wakita, H; Yokota, A | 1 |
| Braunstein, I; Elenitsas, R; Frey, N; Rosenbach, M; Wanat, KA; Xu, X | 1 |
| Hattori, T; Ikeda, Y; Ishii, K; Kanakura, Y; Katsura, K; Katsutani, S; Kimura, A; Kosugi, H; Miyakawa, Y; Ninomiya, H; Okamoto, S; Okoshi, Y; Tomiyama, Y | 1 |
| Kuter, DJ; Makar, RS; Sahud, MA; Zhukov, OS | 1 |
| Denoyelle, F; Favier, M; Favier, R; Feriel, J; Martignetti, JA | 1 |
| Kanda, M; Kondo, M; Mukai, M; Yamamoto, S | 1 |
| Cardamone, D; Frey, NV; Glaser, L; Kricka, LJ; Milone, MC | 1 |
| Au, WY; Chow, PC; Kan, YT; Ma, ES | 1 |
| Farrell, C; Hayes, SC; Wire, M; Zhang, J | 1 |
| Andolina, JR; Becker, M; Chen, Y; Constine, LS; Dawson, KL; DeBolt, J; Erickson-Miller, CL; Friedberg, J; Hyrien, O; Johnson, BM; Liesveld, JL; Milner, LA; Phillips, GL; Smudzin, T | 1 |
| Candiotto, L; Ruggeri, M; Sartori, R; Tagariello, G | 1 |
| Afdhal, NH; Bakulin, I; Brainsky, A; Campbell, FM; Chen, PJ; Dusheiko, GM; Geib, J; Giannini, EG; Han, KH; Kamel, YM; Lawitz, E; Mohsin, A; Patwardhan, R; Poordad, F; Rodriguez-Torres, M; Rugina, S; Shiffman, ML; Tayyab, GU; Theodore, D; Vasey, SY | 1 |
| Pathak, S; Roth, M; Steidl, U; Verma, A | 1 |
| Kulasekararaj, AG; Marsh, JC | 1 |
| Bevans, M; Broder, K; Calvo, KR; Desmond, R; Dumitriu, B; Dunbar, CE; Olnes, MJ; Parikh, AR; Scheinberg, P; Townsley, DM; Wu, CO; Young, NS | 1 |
| Feld, JJ; Leber, A | 1 |
| Brainsky, A; Fogarty, PF; Shah, P; Tarantino, MD | 1 |
| Horikawa, M; Ishiwata, N; Kato, Y; Masuo, Y; Matsubara, K; Nakamichi, N; Sato, R; Shimizu, T; Sugiura, T; Takeuchi, K | 1 |
| Nakao, S | 2 |
| Fujimura, K | 1 |
| Alonso, A; Arefi, M; Barez, A; Calbacho, M; de Cabo, E; Galan, P; González-López, TJ; González-Porras, JR; Jiménez-Bárcenas, R; Martín-Salces, M; Pascual, C; Sánchez-González, B | 1 |
| Alvarez Román, MT; Arias-Salgado, EG; Butta, NV; Fernández Bello, I; Jiménez Yuste, V; Martín Salces, M; Rivas Pollmar, MI | 1 |
| Mishra, S; Shukla, A; Tripathi, AK; Yadav, DK; Yadav, YS | 1 |
| Gauchan, D; Gedeon, D; Maroules, M; Shaaban, H | 1 |
| Álvarez Román, MT; Arias-Salgado, EG; Butta, NV; de Paz, R; Fernández Bello, I; Jiménez Yuste, V; Martín Salces, M | 1 |
| Bhagat, T; Braunschweig, I; Roth, M; Schinke, C; Steidl, U; Tamari, R; Verma, A; Will, B | 1 |
| Marsh, JC; Mufti, GJ | 1 |
| Bierling, P; Ebbo, M; Fain, O; Godeau, B; Khellaf, M; Languille, L; Limal, N; Mahévas, M; Michel, M; Roudot-Thoraval, F; Schleinitz, N | 1 |
| Barbosa, LS; Scheinberg, M; Scheinberg, P; Singulane, CC | 1 |
| Katayama, Y; Komada, T; Kusagawa, H; Shomura, S | 1 |
| Cantú-Rodríguez, OG; Gómez-Almaguer, D; Gómez-De León, A; Gutiérrez-Aguirre, CH; Hernández-Reyes, J; Herrera-Rojas, MA; Jaime-Pérez, JC; Ruiz-Arguelles, GJ; Tarín-Arzaga, L | 1 |
| Arumugaswamy, A; Brotchie, J; Grigg, A; He, S; Quach, H | 1 |
| Cherif, H; Chowdhury, O; Garelius, H; Hellström-Lindberg, E; Jacobsen, SE; Lorenz, F; Saft, L; Svensson, T | 1 |
| Bussel, JB; Hsieh, L; Leven, E; Nugent, D; Ramaswamy, K; Thompson, MV | 1 |
| Gajula, R; Maddela, R; Maddela, S; Makula, A; Pilli, NR; Siddiraju, S | 1 |
| Buchanan, GR | 1 |
| Catani, L; Palandri, F; Polverelli, N; Sollazzo, D; Vianelli, N | 1 |
| Jolliffe, E; Romeril, K | 1 |
| Gauchan, D; Maroules, M; Modi, Y; Shaaban, H | 1 |
| Boulad, N; Bussel, JB; Edison, MN; Josefsson, EC; Kaplan, D; Karpoff, M; Kile, BT; Mitchell, WB; Pinheiro, MP; Psaila, B; White, MJ | 1 |
| Fang, L; Hussaini, A; Kleha, JF; Theodore, D; Wire, MB | 1 |
| Forget, F; Hartner, L; Johnson, BM; Karaszewska, B; Kumar, K; Mayer, B; Messam, CA; Mostafa Kamel, Y; Ramlau, R; Richards, DA; Safran, H; Winer, ES | 1 |
| Boura, P; Hatzitolios, A; Kaiafa, G; Onoufriadis, I; Perifanis, V; Sousos, N; Vlachaki, E | 1 |
| Cervera, R; Enríquez, H; Espinosa, G; Esteve, J; Magnano, L | 1 |
| Bryan, J; Kadia, TM; Rexwinkle, A; Willis, L | 1 |
| Al-Banwan, K; Al-Jafar, HA; Al-Khaldi, J; Alduaij, A | 1 |
| Flegel, WA; Leitman, SF; West, KA | 1 |
| Bagheri, H; Baldin, B; Béné, J; Bres, V; Favrelière, S; Grandvuillemin, A; Guy, C; Jonville-Bera, AP; Lapeyre-Mestre, M; Laroche, ML; Mauprivez, C; Montastruc, JL; Moulis, G; Petitpain, N; Sailler, L; Tebacher-Alt, M; Veyrac, G; Villeval-Federici, L; Weber, E | 1 |
| Cipăian, RC; Mihăilă, RG | 1 |
| Kashiwagi, H; Tomiyama, Y | 1 |
| Burness, CB | 1 |
| Bart-Smith, EE; Kordasti, S; Kulasekararaj, AG; Marsh, JC; Mufti, GJ; Richardson, D | 1 |
| De Fabritiis, P; Giovannini, M; Niscola, P; Perrotti, A; Scaramucci, L; Tendas, A | 1 |
| Aguilar, C; Alonso, A; Alonso, R; Álvarez-Román, MT; Andrade, MM; Arratibel, MC; Beneit, P; Bernat, S; Calbacho, M; Caparrós, I; Casaus, A; Coria, E; Cortés, M; Cortti, MJ; de Cabo, E; de Cos, C; Fernández-Canal, C; Fernández-Fuertes, F; Fernández-Miñano, C; Fernández-Rodríguez, A; Fisac, R; Fuertes-Palacio, MA; Galán, P; Garcia-Frade, J; Gómez-Núñez, M; González-López, TJ; González-Porras, JR; González-Silva, M; Gutierrez-Jomarrón, I; Hernández-Rivas, JA; Jarque, I; Jiménez, R; Luaña, A; Martín-Salces, M; Martínez-Robles, V; Mingot-Castellano, ME; Olivera, PE; Pascual, C; Paz Martínez-Badas, M; Peñarrubia, MJ; Perera, M; Pérez-Crespo, S; Pérez-Rus, G; Sainz, A; Sánchez-González, B; Solán, L; Valcarce, I; Vázquez-Paganini, JA | 1 |
| Andersen, JC; Dhar, JP; Maroun, MC; Ososki, R | 1 |
| Höchsmann, B; Körper, S; Schrezenmeier, H | 1 |
| El Rassy, E; Georges, S; Haddad, E; Kourie, HR; Nasnas, R; Nasr, F; Nehme, W | 1 |
| Aufderheide, TP; Baker, JE; Dhanasekaran, A; Gross, GJ; Koprowski, S; Su, J | 1 |
| Alonso, R; Alvarez-Román, MT; Andrade, MM; Arratibel, MC; Bernat, S; Calbacho, M; Caparrós, I; Cortés, M; Cortti, MJ; Díaz-Gálvez, FJ; Fernández-Fuertes, F; Fernández-Miñano, C; Fuertes-Palacio, MA; Garcia-Frade, J; González-López, TJ; González-Porras, JR; Jarque, I; Martínez-Robles, V; Mingot-Castellano, ME; Olivera, PE; Pascual, C; Sánchez-González, B; Vázquez-Paganini, JA | 1 |
| Farrell, C; Thapar, M; Wire, MB; Zhang, J | 1 |
| Desmond, R; Dunbar, C; Townsley, DM; Young, NS | 1 |
| Dawson, KL; Grotzinger, KM; Kuter, DJ; Macahilig, C; Poston, SA; Wang, PF; Ward, M | 1 |
| Bilgin, R; Karaselek, MA; Uğur Bilgin, A | 1 |
| Avorn, J; Franklin, JM; Kesselheim, AS; Landon, JE; Sarpatwari, A; Seeger, JD | 1 |
| McCormack, PL | 1 |
| Chang, H; Shih, LY | 1 |
| Hattori, H; Karasuno, T; Kuwayama, M; Nishiura, N; Takamori, H | 1 |
| Bailey, CK; Bakshi, KK; Brynes, RK; Burgess, P; Orazi, A; Thein, MM; Theodore, D | 1 |
| Abayasekara, N; Berliner, N; Jeong, JY; Laubach, J; Levine, MS; Vanasse, GJ | 1 |
| Akgün Çağlıyan, G; Alacacıoğlu, İ; Arslan, Ö; Bilgir, O; Bolaman, Z; Büyükkeçeci, F; Ceylan, C; Gökgöz, Z; Görgün, G; Kabukçu, G; Kabukçu, S; Kadıköylü, G; Kahraman, S; Keskin, A; Kiper, HD; Özcan, MA; Özdemirkıran, F; Payzın, B; Şahin, F; Saydam, G; Sevindik, ÖG; Tombuloğlu, M; Vural, F | 1 |
| Farrell, C; Guo, H; Hayes, S; Hou, M; Thapar, M; Wu, K; Zhang, J | 1 |
| Hassan, MN; Waller, EK | 1 |
| Akhtari, M; Piatek, C | 1 |
| Fujimi, A; Hashimoto, A; Hayasaka, N; Iyama, S; Kamihara, Y; Kanisawa, Y; Kato, J; Minami, S; Nakajima, C; Okuda, T; Ono, K; Yamada, S | 1 |
| Cerezuela Fuentes, P; García Coronel, M; García Lagunar, MH; Gutiérrez-Meca Maestre, DP; Martínez Ortiz, MJ; Martínez Penella, M | 1 |
| Catalá-López, F; Corrales, I; de la Fuente-Honrubia, C; González-Bermejo, D; Martín-Serrano, G; Montero, D; Saint-Gerons, DM | 1 |
| Hanada, R; Kato, M; Koh, K; Mori, M | 1 |
| Anter, HA; Khanfar, AA; Obeidat, AR; Saleh, MI | 1 |
| Annichiarico, BE; Coretti, S; Giannini, EG; Lidonnici, D; Marchetti, M; Rodeghiero, F; Romano, F; Ruggeri, M; Sacchini, D | 1 |
| Almasio, PL; Boccaccio, V; Bruno, S; Giannini, EG; Russo, ML; Sewpaul, P | 1 |
| Barnard, MR; Berny-Lang, MA; Brigstocke, SL; Bussel, JB; Carmichael, SL; Frelinger, AL; Gerrits, AJ; Leven, EA; Michelson, AD; Mitchell, WB; Revel-Vilk, S; Tamary, H | 1 |
| Bailey, CK; Bakshi, KK; Bussel, JB; Chagin, KD; Chan, GW; Chotsampancharoen, T; Donyush, E; Drelichman, G; Grainger, JD; Holzhauer, S; Iyengar, M; Komvilaisak, P; Lebedev, V; Lemons, R; Locatelli, F; Marcello, LM; Pongtanakul, B; Pospisilova, D; Ramenghi, U; Sirachainan, N; Sosothikul, D; Theodore, D | 1 |
| Eser, A; Firatli-Tuglular, T; Kara, O; Kaygusuz-Atagunduz, I; Noyan-Atalay, F; Ozgumus, T; Pepedil-Tanrikulu, F; Sezgin, A; Toptas, T; Yilmaz, G | 1 |
| Lapeyre-Mestre, M; Montastruc, F; Moulis, G; Nguyen, TT; Palmaro, A | 1 |
| Locatelli, F; Merli, P; Palumbo, G; Strocchio, L; Vinti, L | 1 |
| Fukunaga, K; Iwasaki, K; Kohno, K; Kurokawa, T; Murata, S; Ohkohchi, N; Zheng, YW | 1 |
| Audia, S; Bonnotte, B; Godeau, B | 1 |
| Bai, LY; Chang, YF; Chen, CG; Chen, TY; Chiou, TJ; Hsueh, EJ; Kao, CW; Lan, YJ; Lin, HY; Lin, SF; Sung, YC; Wang, MC | 1 |
| Gounden, V; Zhao, Z | 1 |
| Naithani, R; Sachdev, M; Uttam, R | 1 |
| Kambhampati, S; Li, W; Morrone, K; Steidl, U; Verma, A; Will, B | 1 |
| de Knegt, RJ; Maan, R; Veldt, BJ | 1 |
| Arai, N; Ariizumi, H; Fujiwara, S; Harada, H; Hattori, N; Kabasawa, N; Kawaguchi, Y; Mori, H; Nakamaki, T; Saito, B; Shiozawa, E; Tsukamoto, H; Uto, Y; Yanagisawa, K | 1 |
| John, JM; Malhotra, P | 1 |
| Gunes, H; Kivrak, T | 1 |
| Bown, N; Cavenagh, J; Dokal, I; Foukaneli, T; Hill, A; Hillmen, P; Ireland, R; Killick, SB; Kulasekararaj, A; Marsh, JC; Mufti, G; Samarasinghe, S; Snowden, JA; Wood, A | 1 |
| Cascavilla, N; Di Renzo, N; Mazza, P; Melpignano, A; Minoia, C; Polimeno, G; Specchia, G | 1 |
| Li, AM; Wang, XL | 1 |
| Abboud, C; Araujo, S; Bennett, J; Chan, G; Chen, CY; Cheng, G; Chiou, TJ; Dougherty, S; Feigert, J; Giagounidis, A; Gorin, NC; Götze, K; Greenberg, P; Jang, JH; Johnson, B; Kambhampati, S; Kamel, YM; Kim, YJ; Lee, JH; Lyons, R; Mannino, F; Platzbecker, U; Ruggeri, M; Santini, V; Stone, N; Verma, A; Wong, RS; Yeh, SP | 1 |
| Bailey, CK; Bakshi, KK; Blanchette, VS; Boayue, KB; Bussel, JB; Chagin, KD; Chan, GW; Connor, P; David, M; de Miguel, PG; Despotovic, JM; Grainger, JD; Iyengar, M; Krishnamurti, L; Lambert, MP; Marcello, LM; Matthews, DC; Sevilla, J; Theodore, D | 1 |
| Aguilar, C; Alvarez-Román, MT; Andrade, MM; Bárez, A; Bernat, S; Cortés, M; de Cabo, E; Fernández-Fuentes, F; Fernández-Miñano, C; Fernández-Rodríguez, A; Fisac, R; Fuertes-Palacio, MA; García-Frade, LJ; Gómez-Nuñez, M; González-López, TJ; González-Porras, JR; Hernández-Rivas, JA; Jarque, I; Martínez-Robles, V; Olivera, P; Pascual, C; Peñarrubia, MJ; Pérez-Crespo, S; Pérez-Rus, G; Sánchez-González, B | 1 |
| Baysal, B; Danalioglu, A; Kayar, Y; Kocaman, O; Senturk, H | 1 |
| Bührer, C; Cremer, M; Dame, C; Kling, PJ; Sallmon, H | 1 |
| Fuji, S; Fukuda, T; Inamoto, Y; Kim, SW; Kurosawa, S; Okinaka, K; Tanaka, T; Tanosaki, R; Yamashita, T | 1 |
| Aggarwal, D; Auerbach, H; Mandaliya, R | 1 |
| Barcellini, W; Cantoni, S; Caparrotti, G; Carpenedo, M; Carrai, V; Crea, E; Di Nicola, M; Di Renzo, N; Fanin, R; Ferla, V; Liberati, AM; Paoloni, F; Santoro, C; Simonetti, F; Tuniz, E; Veneri, D; Volpetti, S; Zaja, F | 1 |
| Miyahara, M; Ureshino, H | 1 |
| Chen, PJ; Giannini, EG; Grotzinger, KM; Rendas-Baum, R; Theodore, D; Younossi, ZM | 1 |
| Allan, DS; Bredeson, C; Dyba, J; Matthews, J; Tinmouth, A | 1 |
| Häckel, A | 1 |
| Barcellini, W; Carrabba, M; Fabio, G | 1 |
| Fabritiis, Pd; Giovannini, M; Niscola, P; Palombi, M; Scaramucci, L; Tendas, A | 1 |
| Gill, H; Kwong, YL; Leung, GM; Lopes, D | 1 |
| Adams, DF; Sellers, TS | 1 |
| Bennett, C; Brown, T; Despotovic, J; Forbes, PW; Grace, RF; Haley, K; Klaassen, R; Lambert, MP; Neunert, C; Nottage, K; Pastore, Y; Shimano, K; Stine, K; Thompson, A | 1 |
| Burness, CB; Garnock-Jones, KP; Keating, GM | 1 |
| Abe, R; Fujiwara, N; Horikoshi, A; Ito, E; Takaku, T; Tsukuda, J | 1 |
| Alessi, MC; Fiore, M; Saut, N; Viallard, JF | 1 |
| Chen, P; Dong, XY; Feng, Q; Gao, C; Hou, M; Li, GS; Liu, S; Liu, XG; Liu, XN; Liu, Y; Ma, C; Peng, J; Qin, P; Sheng, Z; Wei, Y; Zhang, L | 1 |
| Balduini, A; Balduini, CL; Currao, M; Di Buduo, CA; Kaplan, DL; Pecci, A | 1 |
| Al Ali, N; Duong, VH; Komrokji, RS; Lancet, JE; List, AF; Padron, E; Ramadan, H; Zhang, L | 1 |
| Altman, J; Dinner, S; Frankfurt, O; Gao, J; Helenowski, I; McMahon, BJ; Stein, BL; Waisbren, J | 1 |
| Ashal, GE; Elfil, M; Elgebaly, AS; Menshawy, A | 1 |
| Kazemi, T; Martin, S; Worswick, S | 1 |
| Brighton, TA; Joseph, JE; Matthews, GV; Simpson, JD | 1 |
| Bermejo, N; Ibáñez, F; Sigüenza, R | 1 |
| Grenda, R; Jarmużek, W; Latoszyńska, J; Prokurat, S; Rubik, J | 1 |
| Grainger, JD; Lum, SH | 1 |
| Choy, KW; Doery, JC; Wijeratne, N | 1 |
| Bardy, G; Bernard, N; Cathébras, P; Default, A; Durieu, I; Geniaux, H; Godeau, B; Guy, C; Hunault, M; Jonville-Bera, AP; Lioger, B; Mahévas, M; Moachon, L; Moulis, G; Pérault-Pochat, MC; Ramanantsoa, M; Royer, B; Weber, E | 1 |
| Chaimani, A; Desborough, M; Doree, C; Estcourt, LJ; Hadjinicolaou, AV; Hopewell, S; Stanworth, SJ; Trivella, M; Vyas, P | 1 |
| Agard, C; Boisseau, P; Denis, CV; Espitia, O; Fouassier, M; Ternisien, C | 1 |
| Plo, I; Raslova, H; Vainchenker, W | 1 |
| Townsley, DM; Winkler, T | 1 |
| Kurokawa, T; Murata, S; Ohkohchi, N | 1 |
| Özdil, H; Sert, S; Sünbül, M | 1 |
| DaRos, CV; González, KJ; Martí, AC; Rodríguez, PP; Zuluaga, SO | 1 |
| Bastian, TW; Chen, MJ; Connor, JR; Duck, KA; Georgieff, MK; Lanier, LM; Liu, ZJ; Michalopoulos, GC; Sola-Visner, MC | 1 |
| Bakshi, KK; Brynes, RK; Burgess, P; Orazi, A; Thein, MM; Theodore, D; Wong, RS | 1 |
| Ostojic, SK; Rogulj, IM; Vibor, M | 1 |
| Ahmed, KN; Hafeez, M; Khan, RG; Rafe, A; Rasool, G; Sarfraz, T | 1 |
| Feng, Q; Hou, M; Li, GS; Liu, S; Liu, XG; Liu, XN; Liu, Y; Lv, MY; Peng, J; Qu, MM; Zhang, L; Zhang, X; Zhu, YY | 1 |
| Aboud, N; Depré, F; Mayer, B; Salama, A | 2 |
| Alati, C; Avanzini, P; Balleari, E; Bocchia, M; Bova, I; Buccisano, F; Carluccio, P; Cortelezzi, A; Cufari, P; D'Errigo, MG; Fenaux, P; Germing, U; Impera, S; Kulasekararaj, A; Latagliata, R; Liberati, AM; Mancini, S; Molteni, A; Morabito, F; Niscola, P; Oliva, EN; Palumbo, GA; Poloni, A; Salutari, P; Salvi, F; Sanpaolo, G; Santacaterina, I; Santini, V; Spiriti, MA; Stamatoullas, A; Voso, MT; Zini, G | 1 |
| Kwiatkowski, JL; Lambert, MP; Witmer, CM | 1 |
| Komrokji, RS | 1 |
| Demina, IM; Dobrynina, J; Ershov, NM; Hachatryan, LA; Ignatova, AA; Kotskaya, NN; Maschan, AA; Novichkova, GA; Orekhova, EV; Panteleev, MA; Pshonkin, AV; Serkova, IV; Suntsova, EV; Supik, ZS; Trubina, NM | 1 |
| Laskou, F; McGuckin, S; Scully, M; Taylor, A; Westwood, JP | 1 |
| Bevans, M; Calvo, KR; Desierto, M; Desmond, R; Dumitriu, B; Dunbar, CE; Feng, X; Larochelle, A; Leuva, H; Lotter, J; Rios, O; Scheinberg, P; Townsley, DM; Valdez, J; Weinstein, B; Winkler, T; Wu, C; Young, NS | 1 |
| Grainger, JD; Thind, S | 1 |
| Kurokawa, T; Ohkohchi, N | 1 |
| Alonso, A; Alonso, R; Alvarez-Román, MT; Arrieta-Cerdán, E; Bastida, JM; Bernat, S; Bolaños, E; Caparrós, I; Entrena, L; Fernández-Fuentes, F; García-Frade, J; Gómez-Nuñez, M; González-López, TJ; González-Porras, JR; Hernández-Rivas, JA; Lopez-Ansoar, E; Martínez-Badas, MP; Martínez-Robles, V; Olivera, P; Pascual, C; Pérez-Rus, G; Sánchez-González, B; Soto, I; Tenorio, M; Yera Cobo, M | 1 |
| Ehrlich, LA; Farrell, AT; Ko, CW; Kwitkowski, VE; Nie, L; Pazdur, R; Reaman, G | 1 |
| Basso, G; Gabelli, M; Marzollo, A; Notarangelo, LD; Putti, MC | 1 |
| Ali, M; Ali, S; Gassas, A; Kirby-Allen, M; Krueger, J; Schechter, T | 1 |
| Aguilar, C; Alvarez-Román, MT; Arrieta-Cerdán, E; Bárez, A; Bernat, S; de Cabo, E; Fernández-Fuertes, F; Fernández-Rodríguez, A; García-Frade, LJ; González-López, TJ; González-Porras, JR; Hernández-Rivas, JA; Martínez-Robles, V; Olivera, P; Pascual, C; Peñarrubia, MJ; Pérez-Rus, G; Sánchez-González, B | 1 |
| Balduini, A; Di Buduo, CA; Kaplan, DL | 1 |
| Gatt, A; Ng, T; Smith, M | 1 |
| Fernández-Fuertes, F; Hernández, MT; Lakhwani, S; Perera, M; Raya, JM; Ríos de Paz, MA; Torres, M | 1 |
| De Carne, C; Elefant, E; Favier, R; Gkalea, V; Lapusneanu, R; Rigouzzo, A | 1 |
| Ai, Y; Li, Y; Liang, Y; Xie, J; Zhang, J; Zheng, W | 1 |
| Chen, YL; Cooper, N; Garbowski, M; Hider, R; Koonyosying, P; Porter, J; Psaila, B; Sola-Visner, M; Vlachodimitropoulou, E | 1 |
| Bauer, S; Burgess, P; Doerfel, S; Forget, F; Kalambakas, S; Karaszewska, B; Khan, D; Mostafa Kamel, Y; Safran, H; Winer, ES | 1 |
| Bonfim, C; George, B; Kumar, R | 1 |
| Babinchak, T; Bilir, SP; Donga, PZ; Little, G; Munakata, J | 1 |
| Desmond, R; Dumitriu, B; Dunbar, CE; Feng, X; Olnes, M; Townsley, DM; Winkler, T; Wu, Z; Young, NS; Zhao, X | 1 |
| Dodillet, H; Kreuzer, KA; Monsef, I; Skoetz, N | 1 |
| Gao, Y; Gong, M; Kong, X; Ma, Y; Zhang, C | 1 |
| Bagai, A; Hashi, A; Sholzberg, M; Taher, A; Teichman, J | 1 |
| Abraham, J; Ades, L; Balsat, M; Berceanu, A; Chaoui, D; Coppo, P; Corm, S; de Fontbrune, FS; de Latour, RP; Drenou, B; Dupriez, B; Guillerm, G; Leblanc, T; Lengline, E; Maillard, N; Peterlin, P; Raffoux, E; Socié, G; Terriou, L; Tournilhac, O | 1 |
| Kiss, C; Kovács, G | 1 |
| Chuai, Y; Dai, G; Nie, W; Wang, A; Zhang, X | 1 |
| Hariyama, Y; Hiraga, J; Kagami, Y; Kishigami, Y; Oguchi, H; Ohashi, H; Suzuki, N; Takagi, Y | 1 |
| Afanasyev, B; Anagnostopoulos, A; Brenner, B; Denzlinger, C; Garcia-Delgado, R; Grosicki, S; Mittelman, M; Nagler, A; Platzbecker, U; Portella, MSO; Rossi, G; Selleslag, D; Wong, RSM; Zhu, Z | 1 |
| Shastri, A; Verma, AK | 1 |
| Agnelli Giacchello, J; Boccadoro, M; Borchiellini, A; Valeri, F | 1 |
| Cantú-Rodríguez, OG; Colunga-Pedraza, PR; Gómez-Almaguer, D; Gómez-De León, A; Gutiérrez-Aguirre, CH; Jaime-Pérez, JC | 1 |
| Kanno, M; Meguro, T; Mitsui, T; Onoda, T; Sato, H | 1 |
| Berdejo, J; Cequier, A; Cubero-Gallego, H; Gomez-Hospital, JA; Gomez-Lara, J; Romaguera, R; Teruel, L | 1 |
| Chan, TSY; Cheung, CYM; Gill, H; Hwang, YY; Kwong, YL; Leung, GMK | 1 |
| Ai, Y; He, R; Li, X; Li, Y; Liang, Y; Xie, J; Zhang, J; Zheng, W | 2 |
| Adam, S; Alharthi, S; Anyfantis, G; Armstrong, L; Barta, T; El-Harouni, AA; Elango, R; Gassner, K; Lako, M; Melguizo-Sanchis, D; Przyborski, S; Samarasinghe, S; Saretzki, G; Taheem, D; Tilgner, K; Wan, T; Xu, Y; Yu, M | 1 |
| Despotovic, J; Kim, TO; Lambert, MP | 1 |
| Brunet, E; Calvet, X; Garcia-Iglesias, P; Martínez de Sola, M | 1 |
| Aslanis, V; Li, X; Ouatas, T; Sallas, W; Wire, MB; Zhang, J | 1 |
| Gilreath, JA; Rodgers, GM | 1 |
| Cheng, Z; Dunbar, CE; Grasmeder, S; Sokoll, LJ; Streiff, M; Sun, Q; Townsley, DM; Winkler, T; Young, NS; Zhao, Z | 1 |
| Ahuja, S; Gupta, A; Matloub, Y; Meyerson, H; Palassery, R | 1 |
| Carlson, A; Lusa, A | 1 |
| Cairoli, S; Cecchetti, C; Cefalo, MG; Di Nardo, M; Falvella, FS; Goffredo, BM; Marano, M; Martinelli, D; Palumbo, G; Pisani, M; Serafinelli, J | 1 |
| Aydin, S; Biale, L; Brunello, L; Bruno, B; Busca, A; Dellacasa, C; Festuccia, M; Giaccone, L; Godio, L; Manetta, S | 1 |
| Caparrós, IS; Casaus García, A; Díaz-Canales, D; Fernández, F; González-Silva, M; Jimenez-Bárcenas, R; Mingot-Castellano, ME; Nieto-Hernandez, MM; Perera-Alvarez, MDM; Rodríguez-Fernandez, MJ; Yera-Cobo, M | 1 |
| Amoura, Z; Audia, S; Bussel, JB; Chaminade, A; Chauveau, D; Godeau, B; Guitton, Z; Hamidou, M; Hie, M; Lega, JC; Lioger, B; Magy-Bertrand, N; Mahevas, M; Michel, M; Nove-Josserand, R; Rosenthal, E; Terriou, L | 1 |
| Lázaro Rodríguez, I; Pérez Alonso, V; Rubio-San-Simón, A; Vázquez Gómez, F; Vivanco Martínez, JL | 1 |
| Bhor, M; Briggs, A; Dolph, M; Forsythe, A; Hearnden, J; Kwon, CS; Roy, A; Tremblay, G | 1 |
| Lai, CY; Pettit, T | 1 |
| Geng, W; Kearney, S; Nelson, S | 1 |
| Al-Ramadhani, HM; Alzubiedi, S; Melhim, SB; Saleh, MI | 1 |
| Lanchote, VL; Neves, DV; Rocha, A; Vieira, CP | 1 |
| Balduini, CL; Pecci, A; Rodeghiero, F | 1 |
| Atsumi, T; Kanda, M | 1 |
| Al-Samkari, H; Kuter, DJ | 3 |
| Areia, ALFA; Carda, J; Ferreira, IJMCF; Moura, JPAS; Ribeiro, L; Sousa, F; Vasco, EM | 1 |
| Campioni, M; Cetin, K; Chandler, D; Eisen, M; Fust, K; Li, X; Lin, J; Parthan, A; Sharma, A; Wang, X; Zhang, X; Zur, R | 1 |
| Gilreath, JA; Kurtti, AL; Rodgers, GM | 1 |
| Scheinberg, P | 4 |
| Fu, L; Li, S; Ma, J; Qin, M; Wang, B; Wu, R; Zhang, L; Zhou, X; Zhu, G | 1 |
| Aslanis, V; Grosch, K; Lomeli, B; Ouatas, T; Zhang, J | 1 |
| Aivalioti, MM; Bussel, JB; Chen, J; Ferreira, M; Kao, YR; Mantzaris, I; Narayanagari, SR; Pallaud, C; Ramos, PM; Shastri, A; Steidl, U; Todorova, TI; Verma, A; Will, B | 1 |
| Birchall, J; Doree, C; Estcourt, LJ; Hopewell, S; Malouf, R; Trivella, M | 1 |
| Bezold, C; Bylsma, LC; Callaghan, F; Cetin, K; Fryzek, JP; Mehta, B; Wasser, JS | 1 |
| Cooper, N; Fanin, R; Lucchini, E; Zaja, F | 1 |
| Alvarado, Y; Assi, R; Borthakur, G; Burger, J; Cortes, J; Daver, NG; Dinardo, CD; Estrov, Z; Ferrajoli, A; Garcia-Manero, G; Hendrickson, S; Jabbour, E; Kadia, TM; Kantarjian, H; Ravandi, F; Wierda, W | 1 |
| Biancotto, A; Candia, J; Cheung, F; Fantoni, G; Feng, X; Giudice, V; Kajigaya, S; Rios, O; Townsley, D; Wu, Z; Young, NS | 1 |
| Barbieri, A; Chaler, EA; Chilelli, C; D'Isa, G; Jurado, V; Kutasz, E; Toscano, A | 1 |
| Young, NS | 1 |
| Arratibel, N; Avendaño, A; Baile, M; Bastida, JM; Caballero, MD; Cabrero, M; Carrillo, J; Gonzalez-Porras, JR; Lopez-Corral, L; Lopez-Parra, M; Martin, A; Perez, E; Rivera, D; Sanchez-Guijo, F; Vazquez, L; Veiga, A | 1 |
| Chen, Y; Hong, Y; Li, N; Li, X; Wan, B | 1 |
| Burger, J; Ferrajoli, A; Jain, N; Keating, M; O'Brien, S; Paul, S; Wierda, W | 1 |
| Argenziano, M; Casale, M; Perrotta, S; Punzo, F; Rossi, F; Tortora, C | 1 |
| Blanchette, VS; Bussel, JB; Grainger, JD; Grotzinger, KM; Roy, A | 1 |
| Neunert, CE | 1 |
| Cacace, F; Cardano, F; Frieri, C; Marano, L; Marotta, S; Pane, F; Ricci, P; Risitano, AM; Simeone, L; Trastulli, F; Vitiello, S | 1 |
| Arshanskaya, EG; Chernikov, MV; Pankrashkina, MM; Ptushkin, VV; Tkachenko, NE; Vinogradova, OY | 1 |
| Buckstein, R | 1 |
| Ahmad, S; Boyd, AM; Goldstein, SC; Mori, S; Nelson, J; Patel, RD; Varela, JC; Yuan, C; Zhu, X | 1 |
| Li, A; Liu, X; Wang, JY; Wang, L; Wang, X | 1 |
| Alarcón, P; Conte, G; López, M | 1 |
| Alvarado, Y; Bodden, K; Borthakur, G; Bueso-Ramos, C; DiNardo, CD; Ferrajoli, A; Garcia-Manero, G; Kadia, TM; Khoury, J; Konopleva, M; Pemmaraju, N; Swaminathan, M; Yearby, B | 1 |
| Alvarado, LJ; Cheng, H; Dunbar, CE; Feng, X; Huntsman, HD; Larochelle, A; Townsley, DM; Winkler, T; Young, NS | 1 |
| Auteri, G; Barcellini, W; Cantoni, S; Carpenedo, M; Consonni, D; D'Adda, M; Fattizzo, B; Gramegna, D; Napolitano, M; Pasquale, R; Rossi, G; Ruggeri, M; Siragusa, S; Vianelli, N | 1 |
| Baydildina, DD; Kalinina, II; Maschan, AA; Novichkova, GA; Petrova, UN; Pshonkin, AV; Suntsova, EV | 1 |
| Caillon, H; Chevallier, P; Dejoie, T; Garnier, A; Guillaume, T; Lebourgeois, A; Peterlin, P; Ropert-Bouchet, M | 1 |
| Atkinson, K | 1 |
| Arnold, L; Barcellini, W; Benson-Quarm, N; Consonni, D; De Lavallade, H; Fattizzo, B; Griffin, M; Hill, A; Hillmen, P; Ireland, R; Kulasekararaj, AG; Marsh, JCW; Mufti, GJ; Munir, T; Potter, V; Riley, K | 1 |
| Cao, J; Cheng, H; Larochelle, A; Wang, X; Xu, KL; Zhou, D | 1 |
| Afanasyev, B; Bonifazi, F; Bosman, P; Bruno, B; Cortelezzi, A; de Latour, RP; Dreger, P; Drénou, B; Drexler, B; Dufour, C; Ecsedi, M; Eikema, DJ; Garnier, A; Giammarco, S; Halkes, CJM; Knol-Bout, C; Lanino, E; Lengline, É; Ljungman, P; Maschan, A; Onofrillo, D; Passweg, J; Patriarca, A; Pioltelli, P; Pulanic, D; Risitano, AM; Rovó, A; Serventi-Seiwerth, R; Tournilhac, O | 1 |
| Ames, NJ; Barb, JJ; Cashion, AK; Childs, R; Faller, LL; Kim, H; Mudra, SE; Paster, BJ; Ranucci, A; Townsley, DM; Wallen, GR | 1 |
| Gernsheimer, TB; Poston, JN | 1 |
| Alvarado, LJ; Burkett, S; Cash, A; Cheruku, PS; Guenther, KL; Larochelle, A; Smith, RH; Townsley, DM; Winkler, T | 1 |
| Calvo, KR; Cooper, J; Desierto, M; Desmond, R; Dunbar, CE; Fan, X; Grasmeder, S; Larochelle, A; Lotter, J; Scheinberg, P; Shalhoub, RN; Townsley, DM; Valdez, J; Winkler, T; Wu, C; Young, DJ; Young, NS | 1 |
| Cai, JP; Cao, J; Chan, CC; Chan, JF; Chik, KK; Choi, GK; Chu, H; Huang, J; Jin, DY; Liang, M; Tsang, TG; Wen, L; Ye, ZW; Yin, F; Yuan, S; Yuen, KY | 1 |
| Balduini, CL; Barozzi, S; Bozzi, V; Gresele, P; Pecci, A; Zaninetti, C | 1 |
| Krause, DS | 1 |
| Bussel, JB; Cooper, N; Ghanima, W; Godeau, B; Rodeghiero, F | 1 |
| Atay, H; Kelkitli, E; Turgut, M | 1 |
| Arman Bilir, Ö; Işık, M; Kaçar, D; Özbek, NY; Yaralı, HN; Yazal Erdem, A | 1 |
| Bastida, JM; Bento, L; Bosch-Vilaseca, A; Cabrera, R; Chinea, A; De Miguel, C; Duarte, R; Espigado, I; Fernández-Avilés, F; García-Cadenas, I; García-Torres, E; González-Porras, JR; Gutiérrez, A; Herrera, C; López, J; Martínez-Muñoz, ME; Rivera, D; Roldán, E; Sampol, A; Solano, C; Valcárcel, D; Vaz, CP; Yáñez, L; Zudaire, T | 1 |
| Roongta, R; Sanil, S; Shobha, V | 1 |
| Barcellini, W; Cavallaro, F; Fattizzo, B; Milesi, G | 1 |
| Fanghong, Z; Hattori, T; Iida, H; Imada, K; Imajo, K; Matsuda, A; Miyamura, K; Nakao, S; Obara, N; Ohta, K; Sasaki, O; Tajima, T; Tokumine, Y; Tomiyama, Y; Usuki, K; Yamazaki, H | 1 |
| Babushok, DV | 2 |
| Frączkiewicz, J; Kazanowska, B; Sęga-Pondel, D; Ussowicz, M | 1 |
| Neunert, CE; Rose, MJ | 1 |
| Caputo, I; D'Amore, F; Da Dalt, G; Friziero, A; Lombardi, AM; Vianello, F | 1 |
| Barcellini, W; Cassin, R; Fattizzo, B; Levati, G | 1 |
| Bussel, JB; Guo, X; West, RB; Xu, L; You, X; Zehnder, JL; Zhang, BM; Zhang, H | 1 |
| Chen, YL; Hsu, LH; Ko, HT; Yang, SY | 1 |
| Czyzewski, K; Debski, R; Krenska, A; Marjanska, A; Styczynski, J; Wysocki, M | 1 |
| Baldacci, E; Canichella, M; Chistolini, A; Di Rocco, A; Ferretti, A; Foà, R; Gabriella Mazzucconi, M; Martelli, M; Miulli, E; Pulsoni, A; Santoro, C; Serrao, A | 1 |
| Attia, J; Ingsathit, A; McEvoy, M; Puavilai, T; Rattanasiri, S; Thadanipon, K; Thakkinstian, A | 1 |
| Andreani, G; Cilloni, D; De Gobbi, M; Dragani, M; Saglio, G | 1 |
| Song, P; Zhang, L | 1 |
| Borchiellini, A; Carli, G; d'Amore, ESG; Lucchini, E; Merli, M; Motta, G; Passamonti, F; Quaresimini, G; Rambaldi, A; Rodeghiero, F; Romano, A; Ruggeri, M; Santi, RM; Valeri, F; Visco, C; Volpetti, S | 1 |
| Chan, MHM; Cheng, THT; Fuke, N; Grote-Koska, D; Kam, RKT; Kwok, JSS; Li, CK; Lit, LCW; Okada, H; Staaden, A; Tsui, TKC; Wong, EYL; Wong, RSM | 1 |
| Fassel, H; Sheth, S | 1 |
| Arcona, S; Cai, B; Li, FY; Li, X; Said, Q | 1 |
| Liang, C; Oda, T; Ohkohchi, N; Takahashi, K | 1 |
| Alvarez-Roman, MT; Bermejo, N; Bolaños, E; Campos-Alvarez, RM; Carreño-Tarragona, G; Casado-Montero, LF; de Andrés, A; González-López, TJ; González-Porras, JR; Jarque, I; Lopez-Fernandez, MF; Lozano, ML; Mingot-Castellano, ME; Novelli, S; Orna-Montero, E; Orts, MI; Perera, MM; Revilla, N; Rodríguez-López, MA; Valcarcel, D; Vicente, V | 1 |
| Moayeri, M; Zakieh, A | 1 |
| Hayashi, K; Honma, M; Iinuma, S; Ishida-Yamamoto, A; Kanno, K; Kinouchi, M; Nagasawa, Y; Obata, M; Sasaki, K; Sugawara, M | 1 |
| Prasad, V; Tao, D | 1 |
| Patel, BJ; Sekeres, MA | 1 |
| Bernat, S; Bolaños, E; Caparrós, I; de Cabo, E; Fernández-Fuertes, F; Fernández-Miñano, C; Fernández-Rodríguez, A; García-Frade, LJ; Gómez-Nuñez, M; González-López, TJ; Hernández-Rivas, JA; Jarque, I; López-Ansoar, E; Martínez Badas, MP; Martínez-Robles, V; Olivera, P; Pascual, C; Peñarrubia, MJ; Perdomo, G; Pérez-Rus, G; Sánchez-González, B; Soto, I; Yera Cobo, M | 1 |
| Baer, P; Cinatl, J; Koch, B; Michaelis, M; Michel, D; Rabenau, H; Rothweiler, F; Schmidt, D; Schmidt, S; Stamminger, T; Vogel, JU | 1 |
| Carillo, S; Cassinat, B; Chachoua, I; Constantinescu, SN; Defour, JP; Leroy, E; Levy, G; Papoular, B; Smith, SO; Varghese, LN; Zini, JM | 1 |
| Chen, N; Hamzeh, I; Kamran, H; Mims, M; Sudhakar, D | 1 |
| Advani, A; Barot, SV; Carraway, HE; Kalaycio, M; Kerr, C; Kuzmanovic, T; Lee, S; Lichtin, A; Maciejewski, JP; Patel, BJ; Patel, S; Przychodzen, BP; Radivoyevitch, T; Sekeres, MA; Thota, S | 1 |
| Antin, J; Bilginsoy, M; Duh, MS; Huynh, L; Ivanova, JI; Peffault de Latour, R; Roy, A; Totev, T | 1 |
| Fagioli, F; Girardi, K; Locatelli, F; Masetti, R; Pession, A; Prete, A; Quarello, P; Vendemini, F | 1 |
| Juvet, F; Kelly, D; Lamb, V | 1 |
| Makris, M | 1 |
| Gao, Q; Guan, D; Hu, J; Liu, X; Zhang, F; Zhu, Y | 1 |
| Carter, SJ; Chappell, MJ; Chouhan, B; Sharma, P | 1 |
| Baricault, B; Cassagne, M; Lafaurie, M; Lapeyre-Mestre, M; Moulis, G; Sailler, L; Soler, V; Sommet, A | 1 |
| Allepuz, A; Bhor, M; Forsythe, A; Kwon, CS; Pham, T; Roy, AN; Said, Q; Schneider, J; Socorro O Portella, MD | 1 |
| Akbayram, S; Albayrak, M; Bör, Ö; Çakmaklı, HF; Celkan, T; Çınar Özel, S; Erduran, E; Gürlek Gökçebay, D; Karakaş, Z; Karaman, S; Koca Yozgat, A; Koçak, Ü; Leblebisatan, G; Malbora, B; Ören, H; Oymak, Y; Özbek, NY; Özdemir, GN; Şaşmaz, İ; Söker, M; Tokgöz, H; Ünal, Ş; Ünüvar, A; Yaralı, N; Yılmaz, Ş; Zengin, E | 1 |
| Hitchcock, IS | 1 |
| Dolph, M; Forsythe, A; Roy, AN; Said, Q; Tremblay, G | 1 |
| Criscuolo, M; Cupelli, E; D'Alò, F; De Stefano, V; Fabiani, E; Falconi, G; Fianchi, L; Hohaus, S; Pagano, L; Zangrilli, I | 1 |
| Al Ali, N; Duong, VH; Komrokji, RS; Lancet, JE; List, AF; Padron, E; Sallman, D; Zhang, L | 1 |
| Alemu, L; Feng, X; Groarke, EM; Kajigaya, S; Patel, BA; Quinones Raffo, D; Young, NS; Zaimoku, Y | 1 |
| Albitar, M; Barranta, ME; Calvo, KR; Desmond, R; Dumitriu, B; Dunbar, CE; Fan, X; Gutierrez-Rodrigues, F; Lotter, J; Sellers, SE; Shalhoub, RN; Townsley, DM; Valdez, J; Winkler, T; Wu, CO; Young, DJ; Young, NS | 1 |
| Hangaishi, A; Hirao, M; Iizuka, H; Kamoda, Y; Kida, M; Uchibori, Y; Usuki, K | 1 |
| Cheng, H; Wang, X; Xu, KL | 1 |
| Bain, BJ; Cooper, N; Holyome, A; Qureshi, A | 1 |
| Babushok, DV; Sun, L | 1 |
| Corallo, PC; Faienza, MF; Giordano, P; Lassandro, G; Palladino, V; Palmieri, VV; Vecchio, GCD | 1 |
| Cerny, J; Lazarus, HM; Litzow, M; Rowe, JM; Rybka, W; Strickland, SA; Tallman, MS; Wang, XV | 1 |
| Grace, RF; Sankaran, VG; Trissal, M; Wahlster, L; Weichert-Leahey, N | 1 |
| Ambrosiani, L; Feltri, M; Gardellini, A; Guidotti, F; Saccà, V; Turrini, M; Zancanella, M | 1 |
| Fukuhara, S; Ito, M; Jo, H; Kanda, S; Maeshima, AM; Ohe, Y; Okuma, Y; Yoshida, T | 1 |
| Gadgeel, M; Lafferty, J; Persaud, Y; Savaşan, S; Seddiq, M | 1 |
| Fu, H; Gao, F; Huang, H; Lai, X; Luo, Y; Shi, J; Tan, Y; Yu, J; Zhao, Y; Zhou, X | 1 |
| Avgerinou, G; Filippidou, M; Katsibardi, K; Kattamis, A; Roka, K; Solomou, E; Tourkantoni, N; Tsipou, H; Vlachou, A | 1 |
| Feng, S; Liu, M; Luan, X; Tian, Z; Wang, H; Wang, Y; Xiao, Y; Zhang, S; Zhang, Z; Zhao, Y; Zhou, R | 1 |
| Bury, L; Gresele, P; Paciullo, F | 1 |
| Abujazar, H; Al-Far, R; Alan, W; Da'na, W; Gale, RP; Halahleh, K; Hashem, H; Ma'koseh, M; Muradi, I; Saadeh, S; Yousef, D | 1 |
| Hosokawa, K; Imi, T; Nakao, S; Sugimori, N; Tanabe, M; Yamazaki, H | 1 |
| Al-Samkari, H; Goodarzi, K | 1 |
| Al Nahedh, M; Alfattani, A; Alfraih, F; Alhayli, S; Alhumaid, M; Aljurf, M; Alkhudair, N; Alsaedi, H; Alseraihy, A; Alsharif, F; Alzahrani, H; Bakshi, N; Devol, E; Hanbali, A; Hashmi, SK; Rasheed, W; Samarkandi, H; Shaheen, M | 1 |
| Erickson, SW; Gatto, G; Gill, J; Gorlick, R; Kolb, EA; Nevil, G; Roth, M; Smith, M; Teicher, B; Zhang, W | 1 |
| Alkindi, S; Bussel, JB; Cheze, S; Ebbo, M; Ghanima, W; Godeau, B; Gonzalez-Lopez, TJ; Michel, M; Ruggeri, M; Terriou, L; Tvedt, THA | 1 |
| Bocchia, M; Cencini, E; Ciofini, S; Defina, M; Sammartano, V; Santoni, A | 1 |
| Bussel, JB; Kuter, D | 1 |
| Hirao, M; Iizuka, H; Ise, M; Kamoda, Y; Kida, M; Usuki, K | 1 |
| Del Pozo Martín, Y | 1 |
| Chen, M; Han, B; Ruan, J; Yang, C; Zuo, W | 1 |
| Aguilar-Calderón, P; Gómez-Almaguer, D; Jaime-Pérez, JC; Jiménez-Castillo, RA; Ramos-Dávila, EM; Salazar-Cavazos, L | 1 |
| Babushok, D; Bagg, A; Hurwitz, SN; Juusola, J; Sklarz, T; Stanley, NL | 1 |
| Abdelmoumen, K; Ballerini, P; Bordet, JC; Dargaud, Y; Ducastelle-Lepretre, S; Fabre, M; Favier, R | 1 |
| Borthakur, G; Cortes, J; Garcia-Manero, G; Jabbour, E; Kadia, T; Masarova, L; Matthews, J; Naqvi, K; Ravandi, F; Sasaki, K; Shoukier, M; Verstovsek, S | 1 |
| Fang, JP; Huang, K; Li, Y; Liao, XY; Qiu, KY; Weng, WJ; Wu, RH; Xu, HG; Xu, LH; Zhou, DH | 1 |
| Anguita, E; González-Porras, JR; Parrondo García, FJ | 1 |
| Calado, RT; Catto, LFB; Quintino de Oliveira, B; Santana, BAA; Scheinberg, P; Scheucher, PS; Tellechea, MF | 1 |
| Fanghong, Z; Hombo, Y; Iida, H; Imada, K; Imajo, K; Kumagai, A; Maeda, T; Matsuda, A; Nakao, S; Obara, N; Tajima, T; Usuki, K | 1 |
| Albitar, M; Barranta, E; Calvo, KR; Dunbar, CE; Feng, X; Giudice, V; Groarke, E; Gutierrez-Rodrigues, F; Kajigaya, S; Lotter, J; Olnes, MJ; Parikh, AR; Patel, BA; Scheinberg, P; Shalhoub, R; Townsley, DM; Vicente, A; Weinstein, B; Winkler, T; Wu, CO; Young, NS | 1 |
| Gordon, DJ; Goss, KL; Koppenhafer, SL; Terry, WW; Waters, T | 1 |
| Leng, Q; Wang, W; Wang, Y; Wu, L | 1 |
| Chiba, S; Doki, K; Homma, M; Obara, N; Sakata-Yanagimoto, M; Yanagimachi, N | 1 |
| Akyay, A; Öncül, Y | 1 |
| Chen, M; Fang, JP; Li, XY; Lin, SF; Xu, LH; Zhou, CX | 1 |
| Argenziano, M; Di Paola, A; Merli, P; Palumbo, G; Perrotta, S; Roberti, D; Rossi, F; Santoro, C; Strocchio, L; Tortora, C | 1 |
| Abbinante, VM; Barreca, G; Masciocchi, N; Zampieri, M | 1 |
| Argenziano, M; Di Martino, M; Di Paola, A; Di Pinto, D; Perrotta, S; Pota, E; Punzo, F; Rossi, F; Tortora, C | 1 |
| Farsa, O; Zubáč, P | 1 |
| Olson, TS | 1 |
| Baldoni, D; Groarke, EM; Gutierrez-Rodrigues, F; Lotter, J; Patel, BA; Rios, O; Shalhoub, R; St Pierre, A; Townsley, DM; Wu, CO; Young, NS | 1 |
| Aladjidi, N; Barlogis, V; Benadiba, J; Blouin, P; Ducassou, S; Fahd, M; Fernandes, H; Jeziorski, E; Leblanc, T; Leverger, G; Michel, M; Nolla, M; Pasquet, M; Pondarre, C | 1 |
| Chiu, V; Hermel, D; Martynova, A; Mert, M; Weitz, IC | 1 |
| Anak, S; Bayram, N; Bilgen, H; Elli, M; Nepesov, S; Özdilli, K; Şahin, Ş; Yaman, Y | 1 |
| Alamome, I; Barrot, A; Elong, C; Langs, JC; Lefevre, P; Mathiaux, F; Parent, X | 1 |
| Locatelli, F; Merli, P; Quintarelli, C; Strocchio, L | 1 |
| Feng, Q; Hu, X; Li, N; Liu, A; Ma, S; Peng, J; Sheng, Z; Zhang, Y | 1 |
| Castelli, R; Gidaro, A; Lambertenghi Deliliers, G | 1 |
| Aydin Koker, S; Çalişkan Polat, A | 1 |
| Garner, TP; Gavathiotis, E; Reyna, DE; Spitz, AZ; Zacharioudakis, E | 1 |
| Fu, J; Peng, C; She, P; Wu, Y; Zhu, J | 1 |
| Cheng, L; He, G; He, Y; Hong, M; Li, J; Liu, X; Lu, R; Zhang, J; Zhang, R | 1 |
| Auteri, G; Barcellini, W; Boggio, E; Carli, G; Carpenedo, M; Celli, M; Consoli, U; Crea, E; Dianzani, U; Fanin, R; Giardini, I; Gigliotti, CL; Lucchini, E; Palandri, F; Paoloni, F; Patriarca, A; Rodeghiero, F; Rossi, E; Santoro, C; Valeri, F; Vianelli, N; Vignetti, M; Volpetti, S; Zaja, F | 1 |
| Chen, B; Ge, X; Lu, Y; Shen, P; Sun, L; Wang, J; Wang, Y; Yang, N; Zuo, S | 1 |
| Chen, Z; Fu, L; Gu, H; Ma, J; Wei, Y; Wu, R | 1 |
| Alonso, L; Benitez-Carabante, MI; Diaz-de-Heredia, C; Oliveras, M; Renedo, B; Uria-Oficialdegui, ML | 1 |
| Chen, S; Dai, M; Fu, Q; Wang, J | 1 |
| Chen, J; Hu, Y; Jiang, B; Lou, H; Ruan, Z; Shao, R; Xu, Y; Yang, D | 1 |
| Maeda, Y; Tamai, Y; Yamamoto, D | 1 |
| Bradbury, C; Cooper, N; Grainger, J; Hill, QA; Provan, D; Ramscar, N; Roy, A; Thachil, J; Westwood, JP | 1 |
| Cheng, X; Fu, L; He, Y; Jie, M; Li, S; Wu, R; Yao, J; Zhang, L; Zhang, R; Zheng, J | 1 |
| Choy, JS; Hakami, W; Keyvanfar, K; Larochelle, A; Li, Y; Linask, K; Qanash, H; Smith, RH; Young-Baird, S; Zou, J | 1 |
| Ghosh, SA; Maw, KZ; Patrick, J | 1 |
| Majewska, R; Tomiyama, Y; Wong, TF | 1 |
| Boals, M; Ding, J; Gray, N; Hale, M; Jacobs, T; Kang, G; Lesmana, H; Lewis, S; Reiss, U; Wang, W; Weiss, M; Wlodarski, M | 1 |
| Bacigalupo, A; Busca, A; Chiusolo, P; Giammarco, S; Laurenti, L; Martino, M; Metafuni, E; Risitano, A; Sica, S; Sorá, F; Vallejo, C | 1 |
| Auteri, G; Baldacci, E; Barcellini, W; Bartoletti, D; Borchiellini, A; Cantoni, S; Caocci, G; Carli, G; Carpenedo, M; Carrai, V; Cavo, M; Chiurazzi, F; Consoli, U; De Stefano, V; Ferretti, A; Giuffrida, G; Lucchini, E; Mazzucconi, MG; Nicolosi, D; Oliva, EN; Palandri, F; Patriarca, A; Rivolti, E; Rodeghiero, F; Rossi, E; Ruggeri, M; Sutto, E; Vianelli, N; Zaja, F | 1 |
| Feng, X; Groarke, EM; Patel, BA; Shalhoub, R; Wu, CO; Young, NS; Zaimoku, Y | 1 |
| De Latour, RP; Dufour, C; Rovó, A; Tichelli, A | 1 |
| Ahmed, S; Alousi, AM; Andersson, BS; Bashir, Q; Bassett, R; Champlin, R; Ciurea, S; Hosing, C; Jones, R; Kebriaei, P; Khouri, I; Kim, S; Konoplev, S; Nieto, Y; Olson, A; Oran, B; Parmar, S; Poon, MC; Popat, U; Qazilbash, MH; Rezvani, K; Shah, N; Shpall, EJ; Valdez, B | 1 |
| Abematsu, T; Iwamoto, J; Kawano, Y; Kodama, Y; Moriyama, M; Nakagawa, S; Nakamura, T; Nishikawa, T; Okamoto, Y | 1 |
| Balayn, N; Ballerini, P; Basso-Valentina, F; Boussard, C; Constantinescu, SN; Favier, R; Levy, G; Marty, C; Neven, B; Oufadem, M; Plo, I; Raslova, H; Vainchenker, W; Varghese, LN | 1 |
| Avni, B; Israeli, M; Pasvolsky, O; Raanani, P; Ram, R; Rozovski, U; Shapira, MY; Shargian, L; Shpilberg, O; Stepensky, P; Vidal-Fisher, L; Wolach, O; Yeshurun, M | 1 |
| Ceglie, G; Clemente, V; De Gennaro, F; Di Mauro, M; Nocentini, G; Palumbo, G | 1 |
| Balduini, A; Balduini, CL; Barozzi, S; Biunno, I; Bussel, JB; Di Buduo, CA; Kaplan, DL; La Spada, A; Laurent, PA; Lordier, L; Ntai, A; Pecci, A; Raslova, H; Soprano, PM; Zaninetti, C | 1 |
| Chen, L; Han, S; Liu, J; Peng, Y; Wang, H; Wu, Y; Zhang, J | 1 |
| Gerbitz, A; Ho, L; Kim, DDH; Kumar, R; Lam, W; Law, AD; Lipton, JH; Mattsson, J; McEwan, C; Michelis, FV; Nampoothiri, RV; Pasic, I; Thyagu, S; Viswabandya, A | 1 |
| Despotovic, J; Devaraj, S; Garnett, E; Poventud-Fuentes, I | 1 |
| Ades, PL; Al Jijakli, A; Azerad, MA; Berceanu, A; Beyne-Rauzy, O; Broner, J; Cherait, A; Cluzeau, T; Comont, T; Cony-Makhoul, P; Dimicoli, S; Fenaux, P; Gaudin, C; Giraud, JT; Gruson, B; Guerveno, C; Guillaume, T; Gyan, E; Jachiet, V; Laribi, K; Le Clech, L; Meunier, M; Sanhes, L; Santana, C; Slama, B; Torregrosa, J | 1 |
| Bussel, JB; Lee, EJ; Seshadri, M | 1 |
| Huan Ng, C; Jang-Milligan, F; Schultz, KR | 1 |
| Bubalo, J; Gilreath, J; Lo, M | 1 |
| Baş, V; Baysal, M; Demir, AM; Kırkızlar, HO; Ümit, E | 1 |
| Bilgir, O; Doğan, EE; Eren, R; Namdaroğlu, S; Nizam, N; Turan Erkek, E; Uğur, MC | 1 |
| Altrock, E; Boch, T; Danner, J; Darwich, A; Flach, J; Haselmann, V; Hofmann, WK; Jann, JC; Jawhar, A; Jawhar, M; Knaflic, A; Marx, A; Mehralivand, A; Metzgeroth, G; Nolte, F; Nowak, D; Nowak, V; Obländer, J; Palme, I; Riabov, V; Schmitt, N; Steiner, L; Streuer, A; Uhlig, S; Weimer, N; Weis, CA; Xu, Q | 1 |
| Álvarez-Roman, MT; Butta, N; Coma, M; González-Porras, JR; Gutiérrez, L; Lozano, ML; Segú-Vergés, C; Valcárcel, D | 1 |
| Jayagopal, B; Murugesh, S | 1 |
| Arslan, Ş; Avcı, R; Bayar, N; Ersoysal, MR; Özgünoğlu, EC | 1 |
| Miao, W; Zhang, P | 1 |
| Fu, H; Gao, F; Gao, Y; Huang, H; Shi, J; Zhao, Y | 1 |
| Chang, HH; Chou, SW; Jou, ST; Lin, DT; Lin, KH; Lu, MY; Su, MY; Yang, YL | 1 |
| Bennett, CM; Despotovic, JM; Grace, RF; Klaassen, RJ; London, WB; Ma, C; Neufeld, EJ; Neunert, C; Shimano, KA | 1 |
| Bussel, JB; Khelif, A; Maier, J; Meyer, O; Saleh, MN; Stankovic, M; Wong, RSM | 1 |
| Ferdjallah, A; Hermann, E | 1 |
| Cuker, A; Geevarghese, L; Lal, LS; Landsteiner, A; Le, L; Nandal, S; Patwardhan, P | 1 |
| Baldacci, E; Botta, C; Caracciolo, D; Ferretti, A; Gentile, M; Lucia, E; Martino, E; Mendicino, F; Morelli, M; Muto, B; Santoro, C; Vigna, E | 1 |
| Groarke, EM; Gutierrez-Rodrigues, F; Lotter, J; Patel, BA; Quinones Raffo, D; Rios, O; Shalhoub, R; Wu, CO; Young, NS | 1 |
| Lebioda, A; Meyer, O; Richter, H; Schill, M | 1 |
| Chen, Z; Cheng, X; Fu, L; Gu, H; Ma, J; Wang, X; Wu, R; Zhao, L | 1 |
| Bussel, J; Cooper, N; Deschmann, E; Feldman, HA; Georgieff, M; Liu, ZJ; Porter, J; Psaila, B; Ramsey, HE; Sola-Visner, M; Vlachodimitropoulou, E | 1 |
| Dong, H; Hu, H; Li, Y; Liu, Q; Liu, W; Shen, Y; Wu, D; Ye, B; Zhao, Y; Zhou, Y | 1 |
| Cracowski, JL; Imbert, B; Khouri, C; Park, S; Perez, J | 1 |
| Ambrosiani, L; Feltri, M; Gardellini, A; Guidotti, F; Maino, E; Turrini, M; Zancanella, M | 1 |
| Ito, S; Kamihara, S; Kiyohara, K; Kowata, S; Maeta, T; Miyajima, S; Nishiya, M; Okano, Y; Oyake, T; Sasaki, R; Sugawara, N; Takano, M | 1 |
| Aroichane, M; Audia, S; Beyne-Rauzy, O; Chèze, S; Comont, T; Ebbo, M; Germain, J; Godeau, B; Lafaurie, M; Lapeyre-Mestre, M; Leclerc-Teffahi, S; Mahévas, M; Michel, M; Moulis, G; Rueter, M; Sommet, A; Viallard, JF | 1 |
| Arnold, DM; Blostein, M; Carruthers, J; Cook, RJ; Heddle, NM; Hsia, C; Jamula, E; Kassis, J; Kaur, MN; Larratt, L; Li, N; Lin, Y; Liu, Y; Sholzberg, M; Tinmouth, A; Xie, F | 1 |
| Becattini, C; Maraziti, G | 1 |
| Gu, C; Kong, D; Li, Y; Tian, H; Wang, Z; Wu, D; Yin, J; Yu, Z | 1 |
| Fu, R; Huang, L; Liu, C; Liu, Z; Tian, M | 1 |
| Dichtwald, S; Ifrach, N; Meyer, A | 1 |
| Autore, F; Chiusolo, P; Colangelo, M; Minnella, G; Rossi, E; Sica, S; Sora', F | 1 |
| Argenziano, M; Catanoso, M; Ceglie, G; Di Leva, C; Di Paola, A; Locatelli, F; Palumbo, G; Perrotta, S; Rossi, F; Tortora, C | 1 |
| Angelucci, E; Barcellini, W; Barraco, F; Cacace, F; Cavenagh, J; Clement, L; Cook, R; Daguindau, E; de Groot, MR; Drexler, B; Dufour, C; Forcade, E; Frieri, C; Griffin, M; Halkes, CJM; Hill, A; Iacobelli, S; Iori, AP; Jarque, I; Kulasekararaj, A; La Rocca, U; Marano, L; Marotta, S; Marsh, JCW; Mear, JB; Mufti, GJ; Munir, T; Muus, P; Nur, E; Palmisani, E; Passweg, JR; Peffault de Latour, R; Praire, A; Rabian, F; Raymakers, RAP; Recher, C; Risitano, AM; Russell, NH; Sánchez-Ortega, I; Sicre de Fontbrune, F; Smith, AE; Socié, G; Sureda, A; Tavitian, S; Terriou, L; Terwel, SR; Tjon, JML; Vallejo, JC; van Lint, MT; Xicoy, B | 1 |
| Bao, X; Ji, C; Yuan, C; Zhang, N | 1 |
| Li, MJ; Liu, XJ; Song, YP; Wei, XD; Xiong, YY; Yuan, FF; Zhang, LN; Zhang, QL; Zhou, H | 1 |
| Grabowski, DR; Guan, Y; Hasipek, M; Jha, BK; Jiang, D; Kongkiatkamon, S; LaFramboise, T; Lindner, D; Maciejewski, JP; Mian, OY; Pagliuca, S; Parker, Y; Patel, B; Saunthararajah, Y; Sekeres, MA; Singh, S; Tiwari, AD | 1 |
| Eguchi, H; Eguchi, K; Ishimura, M; Kakiuchi, T; Koga, D; Matsuo, M; Nishi, M; Sonoda, M | 1 |
| Will, B | 1 |
| Calvo, KR; Desmond, R; Dunbar, CE; Fan, X; Groarke, EM; Larochelle, A; Patel, B; Winkler, T; Young, DJ; Young, NS | 1 |
| Chen, Y; Huang, F; Li, JY; Qiao, C; Shen, WY; Wang, R; Wang, Y; Zha, Q | 1 |
| Horiuchi, T; Izumi, T; Kawamura, T; Kimura, F; Kobayashi, S; Sato, K; Takano, K | 1 |
| Chan, FHY; Chan, KP; Chan, TSY; Hwang, YY; Kho, B; Kwong, YL; Lau, CK; Lau, CWP; Lau, GWN; Lau, JSM; Leung, KH; Lin, SY; Luk, YY; Mak, V; Sim, JPY; Yip, SF | 1 |
| Huang, TL; Ren, P; Zhang, XW | 1 |
| Argilés, B; Astigarraga, I; Berrueco, R; Cervera, Á; Dapena, JL; Dasí, MÁ; Monteagudo, E; Sastre, A; Sebastián, E; Solsona, M | 1 |
| He, GS; Huang, LF; Jia, JS; Li, L; Lin, SY; Meng, FK; Yang, Y; Zhang, DH | 1 |
| Jiang, JJ; Li, J; Zhao, B | 1 |
| Akyürek, N; Aydın Kaynar, L; Bostankolu Değirmenci, B; Dikyar, A; Özkurt, ZN; Uyar Göçün, P; Yegin, ZA | 1 |
| Arita, K; Hosono, N; Imi, T; Iwaki, N; Murakami, J; Nakao, S; Nannya, Y; Ogawa, S; Okazawa, H; Tasaki, T; Tsujikawa, T | 1 |
| Al-Samkari, H; Park, AK; Park, JC | 1 |
| Arif, AR; Chen, W; Luo, S; Wang, Y; Xue, M; Zhao, M | 1 |
| Kumalo, HM; Mtambo, SE | 1 |
| Boucher, R; Bowen, D; Cargo, C; Coulthard, HC; Culligan, D; Dennis, M; Jackson, A; Metzner, M; Moore, R; O'Sullivan, J; Raghavan, M; Sternberg, A; Vyas, P | 1 |
| Chen, M; Han, B; Liu, B; Zhang, B; Zuo, W | 1 |
| Fu, R; Han, B; Jiao, W; Lei, M; Liu, L; Liu, R; Miao, M; Wu, D; Zhang, F; Zhang, L; Zhang, Y; Zhao, X | 1 |
| He, G; Jia, J; Jin, Y; Li, J; Li, R; Lin, S; Yang, Y; Zhang, D | 1 |
| Angchaisuksiri, P; Elghandour, A; Frueh, JA; Goldbrunner, M; Ingles, S; Jang, JH; Mattar, M; Ozcan, M; Rahman, M; Tarkun, P; Wei, X; Wong, RSM; Yang, R; Yassin, MA; Yavaşoğlu, İ; Yoon, SS | 1 |
| Aksu, S; Büyükaşık, Y; Çınar, OE; Demiroğlu, H; Erdoğdu, B; Göker, H; Haznedaroğlu, İC; Karadeniz, M; Karataş, A; Malkan, ÜY; Özcebe, Oİ; Sayınalp, N; Velet, M | 1 |
| Bolster, L; Goodyear, MD; Patterson, JM; Podstawka, J; Rydz, N; Sun, HL; Wall, E | 1 |
| Li, F; Luo, S; Xu, Y; Yang, F; Zhang, X; Zong, H | 1 |
| Cai, X; Chang, Y; Fu, H; Huang, X; Jiang, Q; Lu, J; Zhang, X; Zhao, X | 1 |
| Feng, CX; Geng, QC; Lin, X; Liu, Y; Su, J; Zhang, HX | 1 |
| Feng, X; Hua, B; Li, W; Ma, L; Wang, D; Wang, F; Wang, H; Zhu, Y | 1 |
| Fijnheer, R; Huisman, A; Koene, HR; Poolen, GC; Schutgens, REG; Thielen, N; Urbanus, RT; van Bladel, ER; van Dijk, WEM; van Galen, KPM | 1 |
| Carmi, O; Garra, W; Kivity, S; Levy, Y | 1 |
| Bátorová, A; Bodó, I; Červinek, L; Ionita, I; Lissitchkov, T; Melikyan, A; Podolak-Dawidziak, M; Pulanić, D | 1 |
| Li, T; Liu, J; Liu, Q; Pu, T; Zhang, A | 1 |
| Chen, Z; Cheng, X; Dong, S; Hu, Y; Liu, Y; Ma, J; Meng, J; Wang, L; Wang, Z; Wu, R | 1 |
| Borchiellini, A; Dufour, C; Farruggia, P; Giona, F; Giordano, P; Ladogana, S; Palumbo, G; Perrotta, S; Pession, A; Ramenghi, U; Russo, G; Spinelli, M; Zecca, M | 1 |
| Grosicki, S; Lawniczek, T; Mittelman, M; Platzbecker, U; Selleslag, D; Zhu, Z | 1 |
| Bussel, JB; Jamieson, BD; Lee, EJ; Tarantino, MD | 1 |
| Kulasekararaj, AG; Trikha, R | 1 |
| Bastiaanse, M; Daykin-Pont, O; Eriksson, D; Geldman, E; Gerard Jansen, AJ; McDonald, V; Morgan, M; Newland, A; Prince, S; Wilson, K; Zwaginga, JJ | 1 |
| Barth, D; Benitez, LL; Bixby, D; Buhlinger, KM; Burke, P; Desai, R; Marini, BL; Perissinotti, AJ; Pettit, K; Reid, JH; Shinn, LT; Soule, A; Stump, SE; van Deventer, H; Wagner, CB; Weis, TM; Zacholski, K | 1 |
| Chang, H; Fu, R; Han, B; He, G; Jin, H; Li, F; Li, T; Liu, L; Mittal, H; Zhang, F | 1 |
Reviews
133 review(s) available for hydrazine and amg531
| Article | Year |
|---|---|
[Recent advances in the treatment of idiopathic thrombocytopenic purpura].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Benzoates; Carrier Proteins; Clinical Trials as Topic; Helicobacter Infections; Helicobacter pylori; Humans; Hydrazines; Immunoglobulin G; Laparoscopy; Platelet Transfusion; Practice Guidelines as Topic; Prednisolone; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Recombinant Fusion Proteins; Rituximab; Splenectomy; Thrombopoietin | 2007 |
New therapeutic options for adult chronic immune thrombocytopenic purpura: a brief review.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antilymphocyte Serum; B-Lymphocytes; Benzoates; Carrier Proteins; Chronic Disease; Clinical Trials as Topic; Humans; Hydrazines; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Recombinant Fusion Proteins; Rituximab; Splenectomy; Thrombopoietin | 2008 |
New insights and therapeutics for immune-mediated thrombocytopenia.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Benzoates; Carrier Proteins; CD40 Ligand; Dexamethasone; Humans; Hydrazines; Immunosuppressive Agents; Molecular Mimicry; Polyethylene Glycols; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Recombinant Proteins; Rituximab; Thrombopoiesis; Thrombopoietin | 2008 |
New drugs for familiar therapeutic targets: thrombopoietin receptor agonists and immune thrombocytopenic purpura.
Topics: Antibodies, Monoclonal; Benzoates; Blood Platelets; Carrier Proteins; Humans; Hydrazines; Polyethylene Glycols; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Recombinant Proteins; Thrombopoiesis; Thrombopoietin | 2008 |
Emerging strategies to treat chronic immune thrombocytopenic purpura.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Benzoates; Chronic Disease; Humans; Hydrazines; Immunoglobulins, Intravenous; Intercellular Signaling Peptides and Proteins; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Rituximab; Splenectomy; Thrombopoiesis; Thrombopoietin | 2008 |
Idiopathic thrombocytopenic purpura: current concepts in pathophysiology and management.
Topics: Animals; Autoantibodies; B-Lymphocytes; Benzoates; Blood Platelets; Carrier Proteins; Cell Communication; Glucocorticoids; Hematologic Agents; Humans; Hydrazines; Immune Tolerance; Immunoglobulins, Intravenous; Immunologic Factors; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Recombinant Fusion Proteins; Splenectomy; T-Lymphocytes; Thrombopoiesis; Thrombopoietin; Treatment Failure | 2008 |
Novel thrombopoietic agents: a review of their use in idiopathic thrombocytopenic purpura.
Topics: Benzoates; Carrier Proteins; Humans; Hydrazines; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thrombopoiesis; Thrombopoietin | 2008 |
Overview of thrombopoietic agents in the treatment of thrombocytopenia.
Topics: Animals; Benzoates; Carrier Proteins; Humans; Hydrazines; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Recombinant Fusion Proteins; Recombinant Proteins; Thrombocytopenia; Thrombopoiesis; Thrombopoietin | 2008 |
[Novel medical treatment modalities in hematology].
Topics: Aminoglycosides; Anemia, Hemolytic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Benzamides; Benzoates; Boronic Acids; Bortezomib; Carbazoles; Carrier Proteins; Cyclophosphamide; Dasatinib; Furans; Gemtuzumab; Hematologic Diseases; Humans; Hydrazines; Imatinib Mesylate; Immunologic Factors; Indoles; Lenalidomide; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lymphoma; Multiple Myeloma; Myelodysplastic Syndromes; Piperazines; Purpura, Thrombocytopenic; Pyrazines; Pyrazoles; Pyrimidines; Receptors, Fc; Recombinant Fusion Proteins; Rituximab; Thalidomide; Thiazoles; Thrombopoietin; Vidarabine | 2008 |
Thrombocytopenia in liver disease.
Topics: Benzoates; Embolization, Therapeutic; Humans; Hydrazines; Liver Diseases; Pyrazoles; Splenectomy; Thrombocytopenia | 2008 |
[Autoimmune (idiopathic) thrombocytopenic purpura].
Topics: Acute Disease; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Autoantibodies; Benzoates; Biomarkers; Blood Platelets; Chronic Disease; Female; Humans; Hydrazines; Immunoglobulin G; Immunosuppressive Agents; Male; Platelet Glycoprotein GPIb-IX Complex; Platelet Glycoprotein GPIIb-IIIa Complex; Prednisolone; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Rituximab; Splenectomy | 2008 |
The use of second-generation thrombopoietic agents for chemotherapy-induced thrombocytopenia.
Topics: Benzoates; Blood Platelets; Carrier Proteins; Chronic Disease; Clinical Trials as Topic; Hemorrhage; Hepatitis C; Humans; Hydrazines; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Recombinant Fusion Proteins; Thrombocytopenia; Thrombopoiesis; Thrombopoietin; Treatment Outcome | 2008 |
Two new drugs for chronic ITP.
Topics: Benzoates; Carrier Proteins; Clinical Trials as Topic; Dose-Response Relationship, Drug; Humans; Hydrazines; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Recombinant Fusion Proteins; Thrombopoietin | 2009 |
Management of chemotherapy-induced thrombocytopenia: current status of thrombopoietic agents.
Topics: Benzoates; Carrier Proteins; Clinical Trials as Topic; Humans; Hydrazines; Interleukin-11; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Recombinant Fusion Proteins; Thrombopoiesis; Thrombopoietin | 2009 |
New-generation drugs that stimulate platelet production in chronic immune thrombocytopenic purpura.
Topics: Benzoates; Carrier Proteins; Chronic Disease; Drug Approval; Hemorrhage; Humans; Hydrazines; Megakaryocytes; Methacrylates; Patient Selection; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Safety; Thiazoles; Thiophenes; Thrombopoiesis; Thrombopoietin; Treatment Outcome; United States; United States Food and Drug Administration | 2009 |
Eltrombopag in chronic idiopathic thrombocytopenic purpura and HCV-related thrombocytopenia.
Topics: Benzoates; Chronic Disease; Dose-Response Relationship, Drug; Hepacivirus; Humans; Hydrazines; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin; Thrombocytopenia | 2009 |
[Treatment of chronic immune thrombocytopenic purpura. Looking for something better. Review].
Topics: Adrenal Cortex Hormones; Antigens, Human Platelet; Autoantibodies; Benzoates; Blood Platelets; Clinical Trials as Topic; Combined Modality Therapy; Cost-Benefit Analysis; Dapsone; Helicobacter Infections; Helicobacter pylori; Humans; Hydrazines; Immunoglobulins, Intravenous; Immunologic Factors; Immunosuppressive Agents; Models, Immunological; Molecular Mimicry; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Splenectomy; Thrombopoiesis | 2009 |
New treatments for idiopathic thrombocytopenic purpura: rethinking old hypotheses.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Benzoates; Blood Platelets; Carrier Proteins; Drugs, Investigational; Humans; Hydrazines; Immunologic Factors; Models, Biological; Models, Immunological; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Rituximab; Thrombopoietin | 2009 |
Review article: second-generation thrombopoietin agents for treatment of chronic idiopathic thrombocytopenic purpura in adults.
Topics: Adult; Animals; Benzoates; Chronic Disease; Controlled Clinical Trials as Topic; Humans; Hydrazines; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin; Thrombopoietin | 2010 |
Thrombopoietin receptor agonists in the treatment of thrombocytopenia.
Topics: Benzoates; Carrier Proteins; Humans; Hydrazines; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thrombocytopenia; Thrombopoietin | 2009 |
Thrombopoietin agonists for the treatment of thrombocytopenia in liver disease and hepatitis C.
Topics: Benzoates; Bone Marrow; Carrier Proteins; Hematologic Agents; Hepatitis C; Humans; Hydrazines; Liver Cirrhosis; Liver Diseases; Pyrazoles; Receptors, Fc; Recombinant Fusion Proteins; Thrombocytopenia; Thrombopoietin | 2009 |
Thrombopoietin and thrombopoietin mimetics in the treatment of thrombocytopenia.
Topics: Benzoates; Carrier Proteins; Humans; Hydrazines; Pyrazoles; Receptors, Fc; Recombinant Fusion Proteins; Thrombocytopenia; Thrombopoietin | 2009 |
New thrombopoietic growth factors.
Topics: Benzoates; Clinical Trials as Topic; Hematology; Humans; Hydrazines; Intercellular Signaling Peptides and Proteins; Models, Biological; Models, Chemical; Peptides; Platelet Count; Pyrazoles; Receptors, Fc; Recombinant Fusion Proteins; Thrombocytopenia; Thrombopoiesis; Thrombopoietin; Time Factors; Treatment Outcome | 2009 |
[Development of thrombopoietin receptor agonists].
Topics: Animals; Benzoates; Clinical Trials as Topic; Drug Discovery; Humans; Hydrazines; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Signal Transduction; Thrombocytopenia; Thrombopoietin | 2009 |
[Wiskott-Aldrich syndrome: recent progress in diagnosis and treatment].
Topics: Animals; Benzoates; Bone Marrow Transplantation; Cytoskeletal Proteins; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Intracellular Signaling Peptides and Proteins; Mutation; Pyrazoles; Severity of Illness Index; Wiskott-Aldrich Syndrome; Wiskott-Aldrich Syndrome Protein | 2009 |
Treatment of MDS: something old, something new, something borrowed...
Topics: Azacitidine; Benzoates; Blood Transfusion; Bone Marrow Diseases; Chromosome Deletion; Chromosomes, Human, Pair 5; Clinical Trials as Topic; Combined Modality Therapy; Decitabine; DNA-Cytosine Methylases; Glutathione; Hematinics; Humans; Hydrazines; Immunologic Factors; Lenalidomide; Myelodysplastic Syndromes; Pyrazoles; Randomized Controlled Trials as Topic; Receptors, Fc; Recombinant Fusion Proteins; Risk; Thalidomide; Thrombopoietin | 2009 |
Supportive care and chelation therapy in MDS: are we saving lives or just lowering iron?
Topics: Aged; Anemia; Benzoates; Blood Component Transfusion; Chelation Therapy; Combined Modality Therapy; Deferoxamine; Hematopoietic Cell Growth Factors; Humans; Hydrazines; Iron; Iron Chelating Agents; Iron Overload; Middle Aged; Myelodysplastic Syndromes; Neutropenia; Off-Label Use; Phlebotomy; Practice Guidelines as Topic; Pyrazoles; Receptors, Fc; Recombinant Fusion Proteins; Thrombocytopenia; Thrombopoietin | 2009 |
Novel approaches for myelodysplastic syndromes: beyond hypomethylating agents.
Topics: Antineoplastic Agents; Benzoates; Enzyme Inhibitors; Humans; Hydrazines; Lenalidomide; Methyltransferases; Myelodysplastic Syndromes; Pyrazoles; Quality of Life; Thalidomide; Treatment Outcome | 2010 |
Development of romiplostim for the treatment of patients with chronic immune thrombocytopenia: from bench to bedside.
Topics: Adult; Aged; Aged, 80 and over; Animals; Benzoates; Chronic Disease; Clinical Trials as Topic; Drug Discovery; History, 18th Century; History, 19th Century; History, 20th Century; History, 21st Century; Humans; Hydrazines; Mice; Middle Aged; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Recombinant Fusion Proteins; Thrombopoietin; Young Adult | 2010 |
Moving towards a new era in the management of chronic immune thrombocytopenia.
Topics: Benzoates; Chronic Disease; Hemorrhage; Hydrazines; Medication Therapy Management; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thrombopoietin | 2010 |
Eltrombopag: an update on the novel, non-peptide thrombopoietin receptor agonist for the treatment of immune thrombocytopenia.
Topics: Benzoates; Hemorrhage; Humans; Hydrazines; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin; Thrombocytopenia; Thrombopoietin | 2010 |
Eltrombopag: a novel oral thrombopoietin receptor agonist.
Topics: Administration, Oral; Animals; Benzoates; Humans; Hydrazines; Pyrazoles; Randomized Controlled Trials as Topic; Receptors, Thrombopoietin; Thrombocytopenia | 2010 |
Treatment options for chronic refractory idiopathic thrombocytopenic purpura in adults: focus on romiplostim and eltrombopag.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Benzoates; Chronic Disease; Clinical Trials, Phase III as Topic; Humans; Hydrazines; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Recombinant Fusion Proteins; Rituximab; Thrombopoiesis; Thrombopoietin | 2010 |
Eltrombopag--a novel approach for the treatment of chronic immune thrombocytopenic purpura: review and safety considerations.
Topics: Animals; Benzoates; Blood Platelets; Chronic Disease; Humans; Hydrazines; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Randomized Controlled Trials as Topic | 2010 |
Eltrombopag.
Topics: Animals; Benzoates; Clinical Trials as Topic; Humans; Hydrazines; Mice; Neoplasms; Pyrazoles; Thrombocytopenia | 2011 |
Eltrombopag for the treatment of idiopathic thrombocytopenic purpura.
Topics: Benzoates; Humans; Hydrazines; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Thrombopoiesis | 2008 |
Current status of thrombopoietic agents.
Topics: Benzoates; Clinical Trials as Topic; Humans; Hydrazines; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thrombocytopenia; Thrombopoietin | 2010 |
Current treatment options for primary immune thrombocytopenia.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Azathioprine; Benzoates; Humans; Hydrazines; Immunoglobulins, Intravenous; Isoantibodies; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Rho(D) Immune Globulin; Rituximab; Thrombocytopenia; Thrombopoietin | 2011 |
Acquired amegakaryocytic thrombocytopenia: potential role of thrombopoietin receptor agonists.
Topics: Benzoates; Bone Marrow Diseases; Humans; Hydrazines; Purpura, Thrombocytopenic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Salvage Therapy; Thrombopoietin | 2010 |
Eltrombopag for the treatment of chronic idiopathic (immune) thrombocytopenic purpura (ITP).
Topics: Benzoates; Chronic Disease; Cost-Benefit Analysis; Humans; Hydrazines; Meta-Analysis as Topic; Models, Economic; Platelet Count; Pyrazoles; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Splenectomy; Thrombocythemia, Essential; Thrombopoietin | 2011 |
The European Medicines Agency review of eltrombopag (Revolade) for the treatment of adult chronic immune (idiopathic) thrombocytopenic purpura: summary of the scientific assessment of the Committee for Medicinal Products for Human Use.
Topics: Adult; Animals; Benzoates; Clinical Trials, Phase III as Topic; Humans; Hydrazines; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Risk Assessment; Treatment Outcome | 2011 |
TPO receptor agonist for chronic idiopathic thrombocytopenic purpura.
Topics: Benzoates; Chronic Disease; Humans; Hydrazines; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Randomized Controlled Trials as Topic; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thrombopoietin | 2011 |
Eltrombopag: a review of its use in treatment-refractory chronic primary immune thrombocytopenia.
Topics: Adult; Animals; Benzoates; Chronic Disease; Drug Interactions; Hemorrhage; Humans; Hydrazines; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin; Time Factors | 2011 |
Thrombopoietin-receptor agonists for primary immune thrombocytopenia.
Topics: Adult; Autoimmune Diseases; Benzoates; Female; Humans; Hydrazines; Platelet Count; Practice Guidelines as Topic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thrombocytopenia; Thrombopoietin | 2011 |
[Management of refractory ITP with thrombopoietin receptor agonists].
Topics: Animals; Benzoates; Clinical Trials as Topic; Drug Design; Humans; Hydrazines; Molecular Targeted Therapy; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Recombinant Proteins; Thrombopoietin | 2011 |
Hematopoietic growth factors in myelodysplastic syndromes.
Topics: Benzoates; Colony-Stimulating Factors; Darbepoetin alfa; Drug-Related Side Effects and Adverse Reactions; Epoetin Alfa; Erythropoietin; Filgrastim; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Hematinics; Humans; Hydrazines; Myelodysplastic Syndromes; Patient Selection; Polyethylene Glycols; Pyrazoles; Receptors, Fc; Recombinant Fusion Proteins; Recombinant Proteins; Thrombopoietin | 2011 |
Spotlight on eltrombopag in treatment-refractory chronic primary immune thrombocytopenia.
Topics: Benzoates; Chronic Disease; Clinical Trials as Topic; Humans; Hydrazines; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin | 2011 |
Eltrombopag: an oral thrombopoietin receptor agonist for the treatment of idiopathic thrombocytopenic purpura.
Topics: Benzoates; Drug Interactions; Humans; Hydrazines; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin | 2011 |
What is the potential for thrombopoietic agents in acute leukemia?
Topics: Adult; Benzoates; Blood Platelets; Clinical Trials as Topic; Consolidation Chemotherapy; Humans; Hydrazines; Leukemia, Myeloid, Acute; Molecular Mimicry; Platelet Count; Polyethylene Glycols; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Recombinant Proteins; Remission Induction; Thrombocytopenia; Thrombopoiesis; Thrombopoietin; Time Factors | 2011 |
Risk of thromboembolism with thrombopoietin receptor agonists in adult patients with thrombocytopenia: systematic review and meta-analysis of randomized controlled trials.
Topics: Adult; Benzoates; Hematologic Agents; Humans; Hydrazines; Pyrazoles; Randomized Controlled Trials as Topic; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Risk Factors; Thrombocytopenia; Thromboembolism; Thrombopoietin | 2012 |
Eltrombopag for the treatment of chronic immune or idiopathic thrombocytopenic purpura: a NICE single technology appraisal.
Topics: Benzoates; Cost-Benefit Analysis; Decision Making; Humans; Hydrazines; Models, Economic; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Receptors, Fc; Recombinant Fusion Proteins; Splenectomy; Technology Assessment, Biomedical; Thrombopoietin; Time Factors | 2012 |
New thrombopoietin receptor agonists for platelet disorders.
Topics: Animals; Benzoates; Blood Platelet Disorders; Blood Platelets; Evidence-Based Medicine; Humans; Hydrazines; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thrombopoietin; Treatment Outcome | 2012 |
Bleeding and mortality outcomes in ITP clinical trials: a review of thrombopoietin mimetics data.
Topics: Benzoates; Clinical Trials as Topic; Hemorrhage; Humans; Hydrazines; Incidence; Platelet Count; Proportional Hazards Models; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Randomized Controlled Trials as Topic; Receptors, Fc; Recombinant Fusion Proteins; Research Design; Standard of Care; Thrombopoietin; Treatment Outcome | 2012 |
Thrombopoietin-receptor agonists.
Topics: Benzoates; Humans; Hydrazines; Pyrazoles; Quality of Life; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thrombocytopenia; Thrombopoietin | 2012 |
Eltrombopag--an oral thrombopoietin agonist.
Topics: Administration, Oral; Benzoates; Humans; Hydrazines; Liver Cirrhosis; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin | 2012 |
Romiplostim and eltrombopag for immune thrombocytopenia: methods for indirect comparison.
Topics: Bayes Theorem; Benzoates; Databases, Factual; Female; Humans; Hydrazines; Male; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Recombinant Fusion Proteins; Thrombopoietin | 2012 |
Positioning new treatments in the management of immune thrombocytopenia.
Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Benzoates; Blood Platelets; Child; Hemorrhage; Humans; Hydrazines; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Rituximab; Thrombopoiesis; Thrombopoietin | 2013 |
Eltrombopag in patients with chronic liver disease.
Topics: Animals; Benzoates; Chronic Disease; Hematologic Agents; Humans; Hydrazines; Liver Diseases; Pyrazoles; Receptors, Thrombopoietin; Thrombocytopenia; Thrombopoiesis; Treatment Outcome | 2013 |
Potential usefulness of thrombopoietin receptor agonists in haemophiliacs with thrombocytopaenia due to chronic liver disease.
Topics: Benzoates; Blood Platelets; Chronic Disease; Drug Dosage Calculations; Hemophilia A; Hemorrhage; Hepatitis C, Chronic; Humans; Hydrazines; Liver Cirrhosis; Platelet Count; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Risk Factors; Thrombocytopenia; Thrombopoietin | 2013 |
Thrombopoietin receptor agonists in primary immune thrombocytopenia.
Topics: Benzoates; Clinical Trials, Phase III as Topic; Humans; Hydrazines; Pyrazoles; Randomized Controlled Trials as Topic; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thrombocytopenia; Thrombopoiesis; Thrombopoietin | 2013 |
Immune thrombocytopenia -- what are the new treatment options?
Topics: Benzoates; Disease Management; Humans; Hydrazines; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thrombopoietin | 2013 |
Eltrombopag for the treatment of thrombocytopenia in patients with malignant and non-malignant hematologic disorders.
Topics: Antineoplastic Agents; Benzoates; Clinical Trials, Phase III as Topic; Drug Evaluation, Preclinical; Hematologic Diseases; Humans; Hydrazines; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Pyrazoles; Randomized Controlled Trials as Topic; Receptors, Thrombopoietin; Thrombocytopenia | 2013 |
Management of the refractory aplastic anemia patient: what are the options?
Topics: Adult; Age Factors; Alemtuzumab; Allografts; Anemia, Aplastic; Antibodies, Monoclonal, Humanized; Antilymphocyte Serum; Antineoplastic Agents; Benzoates; Bone Marrow Diseases; Bone Marrow Failure Disorders; Cyclosporine; Disease-Free Survival; Hematopoietic Stem Cell Transplantation; Hemoglobinuria, Paroxysmal; Humans; Hydrazines; Immunosuppression Therapy; Immunosuppressive Agents; Middle Aged; Pyrazoles; Siblings; Survival Rate; Unrelated Donors | 2013 |
[Recent issues and prospects of the treatment of aplastic anemia].
Topics: Anemia, Aplastic; Animals; Antilymphocyte Serum; Benzoates; Biomarkers; Cyclosporine; Drug Therapy, Combination; Herpesvirus 4, Human; Humans; Hydrazines; Immunosuppressive Agents; Lymphoproliferative Disorders; Prednisolone; Pyrazoles; Receptors, Thrombopoietin; Risk; Severity of Illness Index; Thrombopoietin | 2014 |
[Pathogenesis and management of immune thrombocytopenia].
Topics: Adrenocorticotropic Hormone; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Autoantibodies; Benzoates; Blood Platelets; Dexamethasone; Drug Administration Schedule; Female; Helicobacter Infections; Helicobacter pylori; Humans; Hydrazines; Immunoglobulins, Intravenous; Immunosuppressive Agents; Male; Middle Aged; Platelet Count; Pyrazoles; Receptors, Thrombopoietin; Rituximab; Splenectomy; Thrombocytopenia | 2014 |
Recent developments in drug therapy for aplastic anemia.
Topics: Alemtuzumab; Anemia, Aplastic; Animals; Antibodies, Monoclonal, Humanized; Antilymphocyte Serum; Benzoates; Clinical Trials as Topic; Cyclosporine; Daclizumab; Humans; Hydrazines; Immunoglobulin G; Immunosuppressive Agents; Pyrazoles; Recurrence; Salvage Therapy; Survival Rate | 2014 |
Eltrombopag in chronic hepatitis C.
Topics: Antiviral Agents; Benzoates; Blood Platelets; Hematologic Agents; Hepatitis C, Chronic; Humans; Hydrazines; Pyrazoles; Receptors, Thrombopoietin; Risk Factors; Signal Transduction; Thrombocytopenia; Thrombopoiesis; Treatment Outcome | 2014 |
[Recent progress in the management of aplastic anemia].
Topics: Acute Disease; Anemia, Aplastic; Antilymphocyte Serum; Benzoates; Chronic Disease; Cyclosporine; Disease Progression; Hematopoiesis; Humans; Hydrazines; Immunosuppressive Agents; Pyrazoles | 2014 |
[Management of idiopathic thrombocytopenic purpura (primary immune thrombocytopenia, ITP)].
Topics: Antibodies, Monoclonal, Murine-Derived; Benzoates; Biomarkers; Dexamethasone; Drug Therapy, Combination; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Hydrazines; Platelet Glycoprotein GPIb-IX Complex; Platelet Glycoprotein GPIIb-IIIa Complex; Prednisolone; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Rituximab; Splenectomy; Thrombopoietin | 2014 |
Eltrombopag: a review of its use in the treatment of thrombocytopenia in patients with chronic hepatitis C.
Topics: Benzoates; Hepatitis C, Chronic; Humans; Hydrazines; Pyrazoles; Thrombocytopenia | 2014 |
[Aplastic anemia].
Topics: Anemia, Aplastic; Antilymphocyte Serum; Benzoates; DNA Mutational Analysis; Drug Therapy, Combination; Early Medical Intervention; Hematopoietic Stem Cell Transplantation; Hemoglobinuria, Paroxysmal; Humans; Hydrazines; Immunosuppressive Agents; Myelodysplastic Syndromes; Prognosis; Pyrazoles; Randomized Controlled Trials as Topic; Shelterin Complex; Telomerase; Telomere-Binding Proteins; Transplantation Conditioning | 2014 |
Eltrombopag in aplastic anemia.
Topics: Anemia, Aplastic; Animals; Benzoates; Hematopoiesis; Humans; Hydrazines; Pyrazoles; Recurrence; Risk Factors; Thrombopoietin | 2015 |
Eltrombopag: a review of its use in patients with severe aplastic anaemia.
Topics: Anemia, Aplastic; Animals; Benzoates; Hematinics; Hematopoiesis; Humans; Hydrazines; Practice Guidelines as Topic; Pyrazoles; Receptors, Thrombopoietin; Severity of Illness Index | 2015 |
Managing thrombocytopenia associated with cancer chemotherapy.
Topics: Antineoplastic Agents; Benzoates; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Evidence-Based Medicine; Gemcitabine; Humans; Hydrazines; Neoplasms; Platelet Count; Platelet Transfusion; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thrombocytopenia; Thrombopoiesis; Thrombopoietin; Treatment Outcome | 2015 |
Risk of thromboembolism with thrombopoietin receptor agonists in adult patients with thrombocytopenia: Systematic review and meta-analysis of randomized controlled trials.
Topics: Adult; Benzoates; Hematologic Agents; Humans; Hydrazines; Models, Statistical; Pyrazoles; Randomized Controlled Trials as Topic; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thrombocytopenia; Thromboembolism; Thrombopoietin | 2015 |
Eltrombopag for treatment of thrombocytopenia-associated disorders.
Topics: Anemia, Aplastic; Animals; Benzoates; Chronic Disease; Clinical Trials as Topic; Hematopoietic Stem Cell Transplantation; Hepatitis, Chronic; Humans; Hydrazines; Myelodysplastic Syndromes; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin; Thrombocytopenia; Thrombopoiesis | 2015 |
Thrombocytopenia in MDS: epidemiology, mechanisms, clinical consequences and novel therapeutic strategies.
Topics: Antineoplastic Agents; Benzoates; Blood Platelets; Cell Differentiation; Gene Expression Regulation, Neoplastic; Hemorrhage; Humans; Hydrazines; Megakaryocytes; Myelodysplastic Syndromes; Platelet Transfusion; Prognosis; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Signal Transduction; Thrombocytopenia; Thrombopoietin | 2016 |
Management of Thrombocytopenia in Chronic Liver Disease: Focus on Pharmacotherapeutic Strategies.
Topics: Benzoates; Chronic Disease; Disease Management; Hepatitis C, Chronic; Humans; Hydrazines; Liver Diseases; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thiazoles; Thiophenes; Thrombocytopenia; Thrombopoietin | 2015 |
Is ITP a thrombophilic disorder?
Topics: Benzoates; Humans; Hydrazines; Incidence; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Risk; Splenectomy; Thrombopoietin; Thrombosis | 2016 |
Successful use of eltrombopag in a child with refractory immune thrombocytopenia: case study and literature review.
Topics: Benzoates; Child; Female; Humans; Hydrazines; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles | 2016 |
Thrombocytopenia and platelet transfusion in the neonate.
Topics: Benzoates; Clinical Decision-Making; Hematologic Agents; Humans; Hydrazines; Infant, Newborn; Intensive Care, Neonatal; Platelet Transfusion; Pyrazoles; Receptors, Fc; Recombinant Fusion Proteins; Thrombocytopenia; Thrombopoiesis; Thrombopoietin | 2016 |
Eltrombopag after allogeneic haematopoietic cell transplantation in a case of poor graft function and systematic review of the literature.
Topics: Acute Disease; Allografts; Benzoates; Delayed Graft Function; Female; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Leukemia; Middle Aged; Pyrazoles | 2016 |
Eltrombopag: A Review in Paediatric Chronic Immune Thrombocytopenia.
Topics: Adolescent; Benzoates; Blood Platelets; Child; Child, Preschool; Chronic Disease; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Double-Blind Method; Hemorrhage; Humans; Hydrazines; Infant; Multicenter Studies as Topic; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Randomized Controlled Trials as Topic; Receptors, Thrombopoietin | 2016 |
Tolerability and Efficacy of Eltrombopag in Chronic Immune Thrombocytopenia: Meta-Analysis of Randomized Controlled Trials.
Topics: Adolescent; Adult; Benzoates; Child; Child, Preschool; Chronic Disease; Female; Humans; Hydrazines; Infant; Male; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Randomized Controlled Trials as Topic | 2017 |
Eltrombopag for the treatment of aplastic anemia: current perspectives.
Topics: Alemtuzumab; Anemia, Aplastic; Antibodies, Monoclonal, Humanized; Antilymphocyte Serum; Benzoates; Cyclophosphamide; Cyclosporine; Hematopoietic Stem Cells; Humans; Hydrazines; Immunosuppressive Agents; Pyrazoles | 2016 |
Alternative agents to prophylactic platelet transfusion for preventing bleeding in people with thrombocytopenia due to chronic bone marrow failure: a meta-analysis and systematic review.
Topics: Benzoates; Bone Marrow Diseases; Chronic Disease; Deamino Arginine Vasopressin; Hemorrhage; Hemostatics; Humans; Hydrazines; Platelet Transfusion; Pyrazoles; Randomized Controlled Trials as Topic; Receptors, Fc; Recombinant Fusion Proteins; Thrombocytopenia; Thrombopoietin; Tranexamic Acid | 2016 |
Nontransplant therapy for bone marrow failure.
Topics: Anemia, Aplastic; Anemia, Refractory; Benzoates; Danazol; Humans; Hydrazines; Immunosuppression Therapy; Pyrazoles | 2016 |
Is there any Role for Splenectomy in Adulthood Onset Chronic Immun e Thrombocytopenia in the Era of TPO Receptors Agonists? A Critic al Overview.
Topics: Adult; Benzoates; Blood Platelets; Chronic Disease; Humans; Hydrazines; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Splenectomy; Thrombopoietin | 2017 |
A practical guide to the use of eltrombopag in children with chronic immune thrombocytopenia.
Topics: Adolescent; Benzoates; Child; Child, Preschool; Chronic Disease; Female; Humans; Hydrazines; Infant; Infant, Newborn; Male; Practice Guidelines as Topic; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles | 2017 |
Platelets in liver disease, cancer and regeneration.
Topics: Animals; Benzoates; Blood Platelets; Cell Movement; Clinical Trials as Topic; End Stage Liver Disease; Fibrosis; Hepatic Stellate Cells; Humans; Hydrazines; Killer Cells, Natural; Liver; Liver Diseases; Liver Regeneration; Neoplasm Metastasis; Neoplasms; Pyrazoles; Regeneration; Shear Strength; Thrombocytopenia; Thrombopoietin | 2017 |
In vitro generation of platelets: Where do we stand?
Topics: Animals; Benzoates; Bioreactors; Blood Platelets; Bone Marrow; Cell Culture Techniques; Cells, Cultured; Cellular Microenvironment; Health Services Needs and Demand; Humans; Hydrazines; Megakaryocytes; Models, Animal; Platelet Transfusion; Pyrazoles; Thrombocytopenia; Thrombopoiesis | 2017 |
Thrombopoietin-receptor agonists for children with immune thrombocytopenia: a systematic review.
Topics: Benzoates; Child; Hemorrhage; Humans; Hydrazines; Incidence; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Randomized Controlled Trials as Topic; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thrombopoietin | 2017 |
Hematopoietic cell transplantation for aplastic anemia.
Topics: Allografts; Anemia, Aplastic; Benzoates; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Immunosuppression Therapy; Practice Guidelines as Topic; Pyrazoles | 2017 |
Thrombopoietin mimetics for patients with myelodysplastic syndromes.
Topics: Adult; Azacitidine; Benzoates; Blood Transfusion; Decitabine; Female; Hemorrhage; Humans; Hydrazines; Lenalidomide; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Pyrazoles; Quality of Life; Randomized Controlled Trials as Topic; Receptors, Fc; Recombinant Fusion Proteins; Thalidomide; Thrombocytopenia; Thrombopoietin | 2017 |
Thrombopoietin receptor agonists for prevention and treatment of chemotherapy-induced thrombocytopenia in patients with solid tumours.
Topics: Adult; Aged; Antineoplastic Agents; Benzoates; Humans; Hydrazines; Middle Aged; Neoplasms; Pyrazoles; Randomized Controlled Trials as Topic; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thrombocytopenia; Thrombopoietin | 2017 |
Eltrombopag versus romiplostim in treatment of children with persistent or chronic immune thrombocytopenia: a systematic review incorporating an indirect-comparison meta-analysis.
Topics: Adolescent; Benzoates; Child; Child, Preschool; Female; Humans; Hydrazines; Infant; Male; Pyrazoles; Randomized Controlled Trials as Topic; Receptors, Fc; Recombinant Fusion Proteins; Thrombocytopenia; Thrombopoietin; Treatment Outcome | 2018 |
Eltrombopag for use in children with immune thrombocytopenia.
Topics: Benzoates; Child; Hemorrhage; Humans; Hydrazines; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin | 2018 |
Immune thrombocytopenic purpura associated with Crohn's disease with complete response to infliximab.
Topics: Adrenal Cortex Hormones; Antirheumatic Agents; Azathioprine; Benzoates; Crohn Disease; Humans; Hydrazines; Immunosuppressive Agents; Infliximab; Male; Middle Aged; Pancreatitis; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Remission Induction | 2019 |
Eltrombopag versus romiplostim in treatment of adult patients with immune thrombocytopenia: A systematic review incorporating an indirect-comparison meta-analysis.
Topics: Adult; Benzoates; Blood Platelets; Hemorrhage; Humans; Hydrazines; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Randomized Controlled Trials as Topic; Receptors, Fc; Recombinant Fusion Proteins; Thrombopoietin; Treatment Outcome | 2018 |
Thrombopoietin receptor agonists in hereditary thrombocytopenias.
Topics: Benzoates; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Genetic Association Studies; Genetic Heterogeneity; Genetic Predisposition to Disease; Hematologic Neoplasms; Humans; Hydrazines; Primary Myelofibrosis; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Risk; Thrombocytopenia; Thrombophilia; Thrombopoiesis; Thrombopoietin | 2018 |
Recent Advances and Long-Term Results of Medical Treatment of Acquired Aplastic Anemia: Are Patients Cured?
Topics: Alemtuzumab; Anemia, Aplastic; Animals; Antilymphocyte Serum; Benzoates; Cyclosporine; Humans; Hydrazines; Immunosuppression Therapy; Immunosuppressive Agents; Pyrazoles; Recurrence; Treatment Outcome | 2018 |
Prophylactic platelet transfusions prior to surgery for people with a low platelet count.
Topics: Adult; Benzoates; Deamino Arginine Vasopressin; Hemostatics; Humans; Hydrazines; Plasma; Platelet Transfusion; Postoperative Care; Postoperative Hemorrhage; Pyrazoles; Randomized Controlled Trials as Topic; Receptors, Fc; Recombinant Fusion Proteins; Thrombocytopenia; Thrombopoietin | 2018 |
Systematic literature review of treatments used for adult immune thrombocytopenia in the second-line setting.
Topics: Adult; Benzoates; Case-Control Studies; Cohort Studies; Combined Modality Therapy; Double-Blind Method; Drug Therapy, Combination; Humans; Hydrazines; Immunosuppressive Agents; Multicenter Studies as Topic; Observational Studies as Topic; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Randomized Controlled Trials as Topic; Receptors, Fc; Recombinant Fusion Proteins; Rituximab; Splenectomy; Thrombopoietin | 2019 |
Management of immune thrombocytopenia in elderly patients.
Topics: Aged; Benzoates; Humans; Hydrazines; Immunoglobulins, Intravenous; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Randomized Controlled Trials as Topic; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Rituximab; Splenectomy; Thrombopoietin | 2018 |
Aplastic Anemia.
Topics: Adult; Algorithms; Anemia, Aplastic; Benzoates; Bone Marrow Transplantation; Child; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Immunosuppressive Agents; Pyrazoles; Receptors, Thrombopoietin; Transplantation, Homologous | 2018 |
Efficacy and Safety of Eltrombopag for Aplastic Anemia: A Systematic Review and Meta-analysis.
Topics: Anemia, Aplastic; Benzoates; Humans; Hydrazines; Immunosuppressive Agents; Pyrazoles | 2019 |
Activity of eltrombopag in severe aplastic anemia.
Topics: Anemia, Aplastic; Benzoates; Blood Cell Count; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Hydrazines; Immunosuppressive Agents; Pyrazoles; Receptors, Thrombopoietin | 2018 |
Activity of eltrombopag in severe aplastic anemia.
Topics: Anemia, Aplastic; Antilymphocyte Serum; Benzoates; Cyclosporine; Disease-Free Survival; Humans; Hydrazines; Pyrazoles; Severity of Illness Index; Survival Rate | 2018 |
Thrombopoietin Receptor Agonist Use for Immune Thrombocytopaenia.
Topics: Administration, Oral; Adult; Benzoates; Child; Child, Preschool; Clinical Trials as Topic; Hemorrhage; Humans; Hydrazines; Immunosuppression Therapy; Infant; Infant, Newborn; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Quality of Life; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Safety; Splenectomy; Thrombopoiesis; Thrombopoietin | 2019 |
Successful discontinuation of eltrombopag in one child with refractory primary immune thrombocytopenia and literature review.
Topics: Benzoates; Child; Female; Humans; Hydrazines; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin; Substance Withdrawal Syndrome; Treatment Outcome | 2019 |
Thrombopoietin Receptor Agonists: Eltrombopag and Romiplostim for the Treatment of Chronic Immune Thrombocytopenia Purpura.
Topics: Adult; Benzoates; Child; Chronic Disease; Humans; Hydrazines; Patient Education as Topic; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thrombopoietin | 2019 |
Thrombopoietin receptor agonists: ten years later.
Topics: Animals; Benzoates; Biomarkers; Blood Coagulation; Clinical Trials as Topic; Disease Susceptibility; Humans; Hydrazines; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Signal Transduction; Thrombopoietin; Treatment Outcome | 2019 |
Romiplostim for the management of pediatric immune thrombocytopenia: drug development and current practice.
Topics: Adrenal Cortex Hormones; Benzoates; Child, Preschool; Clinical Trials as Topic; Cloning, Organism; Drug Development; Hemorrhage; History, 20th Century; Humans; Hydrazines; Immunoglobulins; Infant; Injections, Subcutaneous; Platelet Count; Practice Guidelines as Topic; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Safety; Splenectomy; Thrombocytopenia, Neonatal Alloimmune; Thrombopoietin; United States; United States Food and Drug Administration | 2019 |
Eltrombopag in Immune Thrombocytopenia, Aplastic Anemia, and Myelodysplastic Syndrome: From Megakaryopoiesis to Immunomodulation.
Topics: Anemia, Aplastic; Benzoates; Humans; Hydrazines; Immunomodulation; Immunosuppression Therapy; Megakaryocytes; Myelodysplastic Syndromes; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin | 2019 |
Treatment efficacy for adult persistent immune thrombocytopenia: a systematic review and network meta-analysis.
Topics: Adult; Benzoates; Drug Therapy, Combination; Female; Humans; Hydrazines; Male; Platelet Count; Prospective Studies; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Randomized Controlled Trials as Topic; Receptors, Fc; Recombinant Fusion Proteins; Rituximab; Thrombopoietin | 2020 |
Synergistic effect of eltrombopag and deferasirox in aplastic anemia: a clinical case and review of the literature.
Topics: Anemia, Aplastic; Benzoates; Deferasirox; Humans; Hydrazines; Pyrazoles | 2020 |
Bone Marrow Failure in Children: Approach to Diagnosis and Treatment.
Topics: Androgens; Benzoates; Bone Marrow; Bone Marrow Failure Disorders; Bone Marrow Transplantation; Child; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Immunosuppression Therapy; Immunosuppressive Agents; Pyrazoles | 2020 |
Platelet and liver regeneration after liver surgery.
Topics: Allografts; Benzoates; Blood Platelets; Cell Proliferation; Hepatectomy; Hepatocyte Growth Factor; Hepatocytes; Humans; Hydrazines; Insulin-Like Growth Factor I; Liver Failure; Liver Regeneration; Liver Transplantation; Platelet Transfusion; Postoperative Complications; Primary Graft Dysfunction; Pyrazoles; Receptors, Thrombopoietin; Treatment Outcome; Vascular Endothelial Growth Factor A | 2020 |
Lowering the boom on lower-risk myelodysplastic syndromes.
Topics: Activin Receptors, Type II; Aged; Antilymphocyte Serum; Benzoates; Bone Marrow Cells; Female; Hematinics; Humans; Hydrazines; Immunoglobulin Fc Fragments; Lenalidomide; Mutation; Myelodysplastic Syndromes; Pyrazoles; Recombinant Fusion Proteins; Risk Factors; Thrombocytopenia | 2019 |
Allo-HSCT compared with immunosuppressive therapy for acquired aplastic anemia: a system review and meta-analysis.
Topics: Anemia, Aplastic; Animals; Benzoates; Combined Modality Therapy; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Immunosuppression Therapy; Pyrazoles; Transplantation, Homologous | 2020 |
Thrombopoietin Receptor Agonists in Children with Immune Thrombocytopenia: A New Therapeutic Era.
Topics: Adolescent; Age Factors; Benzoates; Blood Platelets; Child; Child, Preschool; Evidence-Based Medicine; Female; Humans; Hydrazines; Infant; Male; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Quality of Life; Randomized Controlled Trials as Topic; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Signal Transduction; Thrombopoietin; Treatment Outcome | 2021 |
Autoimmune pancytopenia following chronic immune thrombocytopenia: Case report and literature review.
Topics: Aged; Benzoates; Bone Marrow; Chronic Disease; Cyclosporine; Humans; Hydrazines; Immunologic Factors; Immunosuppressive Agents; Male; Pancytopenia; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin; Rituximab | 2020 |
Protein and Small-Molecule Leucopoiesis and Thrombopoiesis Stimulators.
Topics: Benzoates; Blood Platelets; Cell Differentiation; Colony-Stimulating Factors; Humans; Hydrazines; Leukocytes, Mononuclear; Pyrazoles; Receptors, Thrombopoietin; Small Molecule Libraries; Stem Cell Factor; Thrombopoiesis | 2021 |
The role of interferon-gamma and its signaling pathway in pediatric hematological disorders.
Topics: Animals; Antineoplastic Agents; Benzoates; Child; Drug Discovery; Hematologic Neoplasms; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Immunotherapy; Interferon-gamma; Janus Kinases; Nitriles; Pyrazoles; Pyrimidines; Signal Transduction | 2021 |
Acquired severe aplastic anaemia: how medical therapy evolved in the 20th and 21st centuries.
Topics: Anemia, Aplastic; Animals; Benzoates; Disease Management; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Immunosuppression Therapy; Pyrazoles; Severity of Illness Index | 2021 |
A systematic review and meta-analysis of the safety and efficacy of anti-thymocyte globulin combined with eltrombopag in the treatment of severe aplastic anemia.
Topics: Anemia, Aplastic; Antilymphocyte Serum; Benzoates; Humans; Hydrazines; Prospective Studies; Pyrazoles; Treatment Outcome | 2021 |
Has Eltrombopag eliminated the need to use allogeneic HSCT in first line treatment of pediatric aplastic anemia?
Topics: Allografts; Anemia, Aplastic; Benzoates; Child; Female; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Male; Pyrazoles | 2021 |
Thrombopoietin Receptor Agonists (TPO-RAs): Drug Class Considerations for Pharmacists.
Topics: Benzoates; Cinnamates; Dose-Response Relationship, Drug; Drug Monitoring; Health Knowledge, Attitudes, Practice; Humans; Hydrazines; Pharmacists; Platelet Count; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thiazoles; Thiophenes; Thrombocytopenia; Thrombopoietin | 2021 |
Efficacy and Incidence of Treatment-Related Adverse Events of Thrombopoietin Receptor Agonists in Adults with Immune Thrombocytopenia: A Systematic Review and Network Meta-Analysis of Randomized Controlled Study.
Topics: Adult; Benzoates; Humans; Hydrazines; Incidence; Network Meta-Analysis; Purpura, Thrombocytopenic, Idiopathic; Randomized Controlled Trials as Topic; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thrombocytopenia; Thrombopoietin | 2023 |
Eltrombopag in severe immune thrombocytopenia secondary to connective tissue disease: a report of 17 patients and literature review.
Topics: Benzoates; Connective Tissue Diseases; Humans; Hydrazines; Immunosuppressive Agents; Leukopenia; Purpura, Thrombocytopenic, Idiopathic; Thrombocytopenia; Treatment Outcome | 2023 |
Catastrophic antiphospholipid syndrome in lupus-associated immune thrombocytopenia treated with eltrombopag A case series and literature review.
Topics: Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Benzoates; Female; Humans; Hydrazines; Lupus Erythematosus, Systemic; Purpura, Thrombocytopenic, Idiopathic; Thrombocytopenia | 2023 |
Use of thrombopoietin receptor agonists in adults with immune thrombocytopenia: a systematic review and Central European expert consensus.
Topics: Adult; Benzoates; Consensus; COVID-19; Humans; Hydrazines; Purpura, Thrombocytopenic, Idiopathic; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thrombocytopenia; Thrombopoietin | 2023 |
Efficacy and safety of thrombopoietin receptor agonists in children and adults with persistent and chronic immune thrombocytopenia: a meta-analysis.
Topics: Adult; Benzoates; Child; Hemorrhage; Humans; Hydrazines; Purpura, Thrombocytopenic, Idiopathic; Receptors, Thrombopoietin; Recombinant Fusion Proteins | 2023 |
Trials
91 trial(s) available for hydrazine and amg531
| Article | Year |
|---|---|
Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist.
Topics: Administration, Oral; Adult; Benzoates; Blood Platelets; Dose-Response Relationship, Drug; Humans; Hydrazines; Male; Placebos; Platelet Count; Pyrazoles; Receptors, Thrombopoietin; Thrombocytopenia; Thrombopoiesis; Time Factors | 2007 |
Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Benzoates; Double-Blind Method; Female; Headache; Hepatitis C; Humans; Hydrazines; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Platelet Count; Polyethylene Glycols; Pyrazoles; Receptors, Thrombopoietin; Recombinant Proteins; Thrombocytopenia | 2007 |
Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzoates; Chronic Disease; Dose-Response Relationship, Drug; Double-Blind Method; Female; Hemorrhage; Humans; Hydrazines; Male; Middle Aged; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Quality of Life; Receptors, Thrombopoietin; Recurrence; Thrombopoietin | 2007 |
Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Benzoates; Chronic Disease; Female; Hemorrhage; Humans; Hydrazines; Male; Middle Aged; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Young Adult | 2009 |
Effects of food and antacids on the pharmacokinetics of eltrombopag in healthy adult subjects: two single-dose, open-label, randomized-sequence, crossover studies.
Topics: Administration, Oral; Adult; Aluminum Hydroxide; Antacids; Area Under Curve; Benzoates; Biological Availability; Calcium, Dietary; Capsules; Cross-Over Studies; Dietary Fats; Drug Combinations; Drug Interactions; Female; Food-Drug Interactions; Humans; Hydrazines; Magnesium; Male; Middle Aged; Pyrazoles; Receptors, Thrombopoietin; Tablets; Young Adult | 2009 |
Clinical pharmacokinetics, platelet response, and safety of eltrombopag at supratherapeutic doses of up to 200 mg once daily in healthy volunteers.
Topics: Adult; Area Under Curve; Benzoates; Dose-Response Relationship, Drug; Double-Blind Method; Female; Hematologic Agents; Humans; Hydrazines; Male; Middle Aged; Platelet Aggregation; Platelet Count; Pyrazoles; Receptors, Thrombopoietin; Reproducibility of Results; Thrombocytopenia; Thrombopoiesis; Time Factors; Young Adult | 2011 |
Eltrombopag does not affect cardiac repolarization: results from a definitive QTc study in healthy subjects.
Topics: Adolescent; Adult; Anti-Infective Agents; Arrhythmias, Cardiac; Aza Compounds; Benzoates; Dose-Response Relationship, Drug; Electrocardiography; Epidemiologic Methods; Female; Fluoroquinolones; Heart Rate; Humans; Hydrazines; Male; Middle Aged; Moxifloxacin; Pyrazoles; Quinolines; Treatment Outcome; Young Adult | 2010 |
Effect of hepatic or renal impairment on eltrombopag pharmacokinetics.
Topics: Administration, Oral; Adult; Aged; Area Under Curve; Australia; Benzoates; Drug Dosage Calculations; Female; Half-Life; Humans; Hydrazines; Kidney; Kidney Diseases; Liver; Liver Diseases; Male; Metabolic Clearance Rate; Middle Aged; Models, Biological; New Zealand; Pyrazoles; Receptors, Thrombopoietin; Severity of Illness Index; United States | 2011 |
Population pharmacokinetics of eltrombopag in healthy subjects and patients with chronic idiopathic thrombocytopenic purpura.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Asian People; Benzoates; Dose-Response Relationship, Drug; Female; Humans; Hydrazines; Male; Middle Aged; Models, Statistical; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin; Sex Characteristics; White People | 2011 |
A randomized, double-blind, placebo-controlled, dose ranging study to assess the efficacy and safety of eltrombopag in patients receiving carboplatin/paclitaxel for advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzoates; Carboplatin; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Hydrazines; Male; Middle Aged; Neoplasms; Paclitaxel; Placebos; Platelet Count; Polypharmacy; Pyrazoles; Treatment Outcome; Young Adult | 2010 |
Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study.
Topics: Adult; Benzoates; Chronic Disease; Double-Blind Method; Female; Humans; Hydrazines; Male; Middle Aged; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin; Splenectomy | 2011 |
Eltrombopag (75 mg) does not induce photosensitivity: results of a clinical pharmacology trial.
Topics: Adult; Benzoates; Dermatitis, Phototoxic; Double-Blind Method; Female; Humans; Hydrazines; Male; Middle Aged; Pyrazoles; Receptors, Thrombopoietin; Statistics, Nonparametric; Ultraviolet Rays; Young Adult | 2010 |
Eltrombopag for the treatment of the inherited thrombocytopenia deriving from MYH9 mutations.
Topics: Administration, Oral; Adolescent; Adult; Benzoates; Dose-Response Relationship, Drug; Female; Genetic Predisposition to Disease; Humans; Hydrazines; Male; Molecular Motor Proteins; Mutation; Myosin Heavy Chains; Platelet Aggregation; Platelet Count; Pyrazoles; Receptors, Thrombopoietin; Survival Rate; Thrombocytopenia; Treatment Outcome; Young Adult | 2010 |
Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers.
Topics: Adult; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzoates; Drug Interactions; Female; Fluorobenzenes; Humans; Hydrazines; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver-Specific Organic Anion Transporter 1; Male; Multivariate Analysis; Neoplasm Proteins; Organic Anion Transporters; Polymorphism, Genetic; Pyrazoles; Pyrimidines; Receptors, Thrombopoietin; Rosuvastatin Calcium; Sulfonamides | 2011 |
Validation of the FACIT-fatigue subscale, selected items from FACT-thrombocytopenia, and the SF-36v2 in patients with chronic immune thrombocytopenia.
Topics: Benzoates; Chronic Disease; Dose-Response Relationship, Drug; Fatigue; Female; Hemorrhage; Humans; Hydrazines; Male; Prospective Studies; Pyrazoles; Receptors, Thrombopoietin; Reproducibility of Results; Sickness Impact Profile; Thrombocytopenia; Time | 2011 |
Platelet activation and function during eltrombopag treatment in immune thrombocytopenia.
Topics: Adult; Aged; Benzoates; Blood Platelets; Cell Aggregation; Double-Blind Method; Female; Humans; Hydrazines; Male; Middle Aged; Monocytes; P-Selectin; Placebos; Platelet Activation; Platelet Aggregation; Pyrazoles; Thrombocytopenia | 2012 |
Metabolism and disposition of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist, in healthy human subjects.
Topics: Administration, Oral; Adult; Benzoates; Biotransformation; Blood Proteins; Cytochrome P-450 Enzyme System; Feces; Glucuronides; Glutathione; Half-Life; Humans; Hydrazines; Male; Middle Aged; Protein Binding; Pyrazoles; Receptors, Thrombopoietin | 2011 |
Eltrombopag named patient programme for patients with chronic immune thrombocytopenia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzoates; Child; Child, Preschool; Chronic Disease; Female; Humans; Hydrazines; Male; Middle Aged; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles | 2012 |
A randomized, open-label, 5-period, balanced crossover study to evaluate the relative bioavailability of eltrombopag powder for oral suspension (PfOS) and tablet formulations and the effect of a high-calcium meal on eltrombopag pharmacokinetics when admin
Topics: Administration, Oral; Adolescent; Adult; Benzoates; Biological Availability; Calcium; Cross-Over Studies; Female; Food; Food-Drug Interactions; Humans; Hydrazines; Male; Middle Aged; Powders; Pyrazoles; Receptors, Thrombopoietin; Suspensions; Tablets; Time Factors; Young Adult | 2012 |
Assessment of the pharmacokinetic interaction between eltrombopag and lopinavir-ritonavir in healthy adult subjects.
Topics: Adolescent; Adult; Benzoates; Drug Interactions; Female; HIV Protease Inhibitors; Humans; Hydrazines; Lopinavir; Male; Middle Aged; Pyrazoles; Ritonavir; Young Adult | 2012 |
A lower starting dose of eltrombopag is efficacious in Japanese patients with previously treated chronic immune thrombocytopenia.
Topics: Administration, Oral; Adult; Aged; Asian People; Benzoates; Blood Platelets; Chronic Disease; Double-Blind Method; Female; Hematologic Agents; Hemorrhage; Humans; Hydrazines; Japan; Male; Middle Aged; Placebos; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin; Time Factors; Treatment Outcome | 2012 |
Efficacy and safety of eltrombopag in Japanese patients with chronic liver disease and thrombocytopenia: a randomized, open-label, phase II study.
Topics: Adult; Aged; Aged, 80 and over; Benzoates; Chronic Disease; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hematologic Agents; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Hydrazines; Liver Diseases; Male; Middle Aged; Platelet Count; Pyrazoles; Thrombocytopenia; Treatment Outcome | 2012 |
Eltrombopag and improved hematopoiesis in refractory aplastic anemia.
Topics: Adolescent; Adult; Aged; Anemia, Aplastic; Benzoates; Bone Marrow Cells; Chronic Disease; Drug Resistance; Female; Humans; Hydrazines; Male; Middle Aged; Pyrazoles; Recurrence; Young Adult | 2012 |
TGFβ(1) and sCTLA-4 levels are increased in eltrombopag-exposed patients with ITP.
Topics: Benzoates; CTLA-4 Antigen; Dose-Response Relationship, Drug; Female; Humans; Hydrazines; Male; Middle Aged; Purpura, Thrombocytopenic; Pyrazoles; Receptors, Thrombopoietin; Transforming Growth Factor beta1; Treatment Outcome | 2012 |
Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzoates; Chronic Disease; Double-Blind Method; Elective Surgical Procedures; Female; Hemorrhage; Humans; Hydrazines; Liver Cirrhosis; Male; Middle Aged; Platelet Count; Platelet Transfusion; Pyrazoles; Receptors, Thrombopoietin; Thrombocytopenia; Young Adult | 2012 |
Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzoates; Blood Platelets; Bone Marrow Diseases; Chronic Disease; Female; Hematologic Neoplasms; Hemorrhage; Humans; Hydrazines; Liver Diseases; Male; Middle Aged; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin; Treatment Outcome; Young Adult | 2013 |
Repeated short-term use of eltrombopag in patients with chronic immune thrombocytopenia (ITP).
Topics: Adult; Aged; Benzoates; Chronic Disease; Double-Blind Method; Drug Administration Schedule; Female; Hematinics; Humans; Hydrazines; Male; Middle Aged; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Treatment Outcome; Young Adult | 2013 |
Function of eltrombopag-induced platelets compared to platelets from control patients with immune thrombocytopenia.
Topics: Adenosine Diphosphate; Adult; Austria; Benzoates; Blood Platelets; Collagen; Female; Humans; Hydrazines; Male; Middle Aged; Oligopeptides; P-Selectin; Platelet Activation; Platelet Adhesiveness; Platelet Function Tests; Prospective Studies; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin; Time Factors; Treatment Outcome; Young Adult | 2013 |
Efficacy of eltrombopag in management of bleeding symptoms associated with chronic immune thrombocytopenia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzoates; Blood Platelets; Chronic Disease; Double-Blind Method; Drug Administration Schedule; Female; Hemorrhage; Humans; Hydrazines; Male; Middle Aged; Platelet Count; Prospective Studies; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Randomized Controlled Trials as Topic; Receptors, Thrombopoietin | 2013 |
Results of a phase I dose escalation study of eltrombopag in patients with advanced soft tissue sarcoma receiving doxorubicin and ifosfamide.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzoates; Dose-Response Relationship, Drug; Doxorubicin; Female; Humans; Hydrazines; Ifosfamide; Male; Middle Aged; Pyrazoles; Receptors, Thrombopoietin; Sarcoma; Soft Tissue Neoplasms; Thrombocytopenia; Young Adult | 2013 |
Oral eltrombopag for up to three years is safe and well-tolerated in Japanese patients with previously treated chronic immune thrombocytopenia: an open-label, extension study.
Topics: Administration, Oral; Adult; Aged; Asian People; Benzoates; Chronic Disease; Female; Humans; Hydrazines; Male; Middle Aged; Pyrazoles; Receptors, Thrombopoietin; Thrombocytopenia; Time Factors; Treatment Outcome | 2013 |
A phase 1 trial of eltrombopag in patients undergoing stem cell transplantation after total body irradiation.
Topics: Adult; Aged; Benzoates; Dose-Response Relationship, Drug; Female; Hematologic Neoplasms; Humans; Hydrazines; Male; Middle Aged; Pyrazoles; Stem Cell Transplantation; Thrombocytopenia; Transplantation Conditioning; Transplantation, Autologous; Whole-Body Irradiation; Young Adult | 2013 |
Eltrombopag increases platelet numbers in thrombocytopenic patients with HCV infection and cirrhosis, allowing for effective antiviral therapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzoates; Drug Administration Schedule; Female; Follow-Up Studies; Hematologic Agents; Hepatitis C, Chronic; Humans; Hydrazines; Induction Chemotherapy; Intention to Treat Analysis; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Maintenance Chemotherapy; Male; Middle Aged; Platelet Count; Polyethylene Glycols; Pyrazoles; Recombinant Proteins; Ribavirin; Thrombocytopenia; Treatment Outcome; Young Adult | 2014 |
Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug.
Topics: Adolescent; Adult; Aged; Anemia, Aplastic; Benzoates; Bone Marrow; Clonal Evolution; Female; Hematologic Agents; Hematopoiesis; Hematopoietic Stem Cells; Humans; Hydrazines; Immunosuppressive Agents; Male; Middle Aged; Pyrazoles; Receptors, Thrombopoietin; Young Adult | 2014 |
Eltrombopag and high-dose dexamethasone as frontline treatment of newly diagnosed immune thrombocytopenia in adults.
Topics: Adult; Aged; Anti-Inflammatory Agents; Benzoates; Dexamethasone; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Feasibility Studies; Female; Follow-Up Studies; Humans; Hydrazines; Male; Middle Aged; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin; Time Factors; Treatment Outcome | 2014 |
A pilot phase I dose finding safety study of the thrombopoietin-receptor agonist, eltrombopag, in patients with myelodysplastic syndrome treated with azacitidine.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Azacitidine; Benzoates; Blood Platelets; Cell Cycle; Drug Synergism; Drug Therapy, Combination; Female; Hematopoietic Stem Cells; Humans; Hydrazines; Ischemic Attack, Transient; Male; Middle Aged; Myelodysplastic Syndromes; Pilot Projects; Platelet Count; Pyrazoles; Receptors, Thrombopoietin; Remission Induction; Thrombocytopenia; Treatment Outcome; Venous Thrombosis | 2014 |
Lack of clinically significant pharmacokinetic interaction between the thrombopoietin receptor agonist eltrombopag and hepatitis C virus protease inhibitors boceprevir and telaprevir.
Topics: Adult; Area Under Curve; Benzoates; Calcium; Cross-Over Studies; Diet; Drug Interactions; Female; Healthy Volunteers; Hepacivirus; Hepatitis C, Chronic; Humans; Hydrazines; Male; Middle Aged; Oligopeptides; Proline; Purpura, Thrombocytopenic; Pyrazoles; Receptors, Thrombopoietin; Serine Proteinase Inhibitors; Young Adult | 2014 |
Eltrombopag with gemcitabine-based chemotherapy in patients with advanced solid tumors: a randomized phase I study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzoates; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Hydrazines; Male; Middle Aged; Neoplasm Staging; Neoplasms; Platelet Count; Pyrazoles; Treatment Outcome | 2015 |
Reciprocal absence of cross-resistance between eltrombopag and romiplostim in two patients with refractory immune thrombocytopenic purpura.
Topics: Aged; Benzoates; Drug Resistance; Female; Humans; Hydrazines; Middle Aged; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Recombinant Fusion Proteins; Thrombopoietin | 2014 |
Use of eltrombopag after romiplostim in primary immune thrombocytopenia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzoates; Female; Humans; Hydrazines; Male; Middle Aged; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Retrospective Studies; Thrombopoietin | 2015 |
Evaluation of bone marrow reticulin in patients with chronic immune thrombocytopenia treated with eltrombopag: Data from the EXTEND study.
Topics: Adult; Benzoates; Bone Marrow; Bone Marrow Examination; Chronic Disease; Female; Follow-Up Studies; Humans; Hydrazines; Male; Middle Aged; Platelet Count; Primary Myelofibrosis; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin; Reticulin | 2015 |
Eltrombopag dose predictors in thrombocytopenic subjects with hepatitis C virus infection.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzoates; Dose-Response Relationship, Drug; Female; Hepatitis C, Chronic; Humans; Hydrazines; Male; Middle Aged; Pyrazoles; Thrombocytopenia; Treatment Outcome; Young Adult | 2015 |
12 weeks of interferon-based therapy is feasible in patients with hepatitis C-related cirrhosis and thrombocytopenia: A post hoc analysis of eltrombopag studies.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antiviral Agents; Benzoates; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Hydrazines; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Multivariate Analysis; Pyrazoles; Ribavirin; Risk Factors; Severity of Illness Index; Thrombocytopenia; Treatment Outcome | 2015 |
Effects of eltrombopag on platelet count and platelet activation in Wiskott-Aldrich syndrome/X-linked thrombocytopenia.
Topics: Adolescent; Adult; Benzoates; Case-Control Studies; Child; Child, Preschool; Genetic Diseases, X-Linked; Humans; Hydrazines; Infant; Male; Mean Platelet Volume; P-Selectin; Platelet Activation; Platelet Count; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrazoles; Receptors, Thrombopoietin; Thrombocytopenia; Wiskott-Aldrich Syndrome; Young Adult | 2015 |
Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial.
Topics: Adolescent; Benzoates; Child; Child, Preschool; Chronic Disease; Double-Blind Method; Female; Humans; Hydrazines; Infant; Male; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin; Treatment Outcome | 2015 |
Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial.
Topics: Adult; Aged; Aged, 80 and over; Benzoates; Double-Blind Method; Female; Humans; Hydrazines; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Pyrazoles; Receptors, Thrombopoietin; Thrombocytopenia; Treatment Outcome | 2015 |
Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study.
Topics: Adolescent; Benzoates; Canada; Child; Child, Preschool; Double-Blind Method; Female; France; Humans; Hydrazines; Infant; Male; Netherlands; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin; Spain; Treatment Outcome; United Kingdom; United States | 2015 |
[Thrombopoietin receptor agonist arouses new hope].
Topics: Anemia, Aplastic; Benzoates; Drug Approval; Hematopoietic Stem Cells; Humans; Hydrazines; Pyrazoles; Receptors, Thrombopoietin | 2016 |
Thrombopoietin receptor agonists shift the balance of Fcγ receptors toward inhibitory receptor IIb on monocytes in ITP.
Topics: Adult; Aged, 80 and over; Benzoates; Female; Humans; Hydrazines; Male; Middle Aged; Monocytes; Phagocytosis; Prospective Studies; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, IgG; Receptors, Thrombopoietin; Transforming Growth Factor beta1; Young Adult | 2016 |
Eltrombopag Use in Patients With Chronic Myelomonocytic Leukemia (CMML): A Cautionary Tale.
Topics: Aged; Aged, 80 and over; Benzoates; Female; Humans; Hydrazines; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Pyrazoles; Treatment Outcome | 2016 |
Stable Liver Function during Long-Term Administration of Eltrombopag, a Thrombopoietin Receptor Agonist, in Patients with Chronic Liver Disease.
Topics: Aged; Benzoates; Chronic Disease; Humans; Hydrazines; Liver; Liver Diseases; Liver Function Tests; Long-Term Care; Male; Middle Aged; Platelet Count; Pyrazoles; Receptors, Thrombopoietin | 2016 |
A 2-Year, Longitudinal, Prospective Study of the Effects of Eltrombopag on Bone Marrow in Patients with Chronic Immune Thrombocytopenia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzoates; Biopsy; Bone Marrow; Chronic Disease; Collagen; Female; Humans; Hydrazines; Male; Middle Aged; Prospective Studies; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Reticulin | 2017 |
Cytokine changes in response to TPO receptor agonist treatment in primary immune thrombocytopenia.
Topics: Adult; Aged; Aged, 80 and over; Benzoates; Cytokines; Female; Humans; Hydrazines; Male; Middle Aged; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin; RNA, Messenger; Th1 Cells; Th17 Cells; Thrombopoietin | 2017 |
Bidirectional inefficacy or intolerability of thrombopoietin receptor agonists: new data and a concise review.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzoates; Female; Humans; Hydrazines; Male; Middle Aged; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thrombopoietin | 2018 |
Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial.
Topics: Aged; Aged, 80 and over; Benzoates; Disease Progression; Female; Humans; Hydrazines; Male; Middle Aged; Myelodysplastic Syndromes; Platelet Count; Pyrazoles; Receptors, Thrombopoietin; Single-Blind Method; Thrombocytopenia; Treatment Outcome | 2017 |
Bleeding tendency and platelet function during treatment with romiplostim in children with severe immune thrombocytopenic purpura.
Topics: Adolescent; Annexin A5; Antigens, CD; Benzoates; Blood Platelets; Child; Child, Preschool; Female; Hemorrhage; Humans; Hydrazines; Infant; Male; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide, Type I; Recombinant Fusion Proteins; Thrombopoietin | 2017 |
Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia.
Topics: Adolescent; Adult; Aged; Anemia, Aplastic; Antigens, CD34; Antilymphocyte Serum; Benzoates; Cell Count; Cyclosporine; Drug Therapy, Combination; Female; Hematologic Agents; Humans; Hydrazines; Immunosuppression Therapy; Immunosuppressive Agents; Male; Middle Aged; Prospective Studies; Pyrazoles; Receptors, Thrombopoietin; Young Adult | 2017 |
Efficacy and safety of eltrombopag in persistent and newly diagnosed ITP in clinical practice.
Topics: Aged; Benzoates; Chronic Disease; Follow-Up Studies; Humans; Hydrazines; Middle Aged; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles | 2017 |
Eltrombopag for thrombocytopenia in patients with advanced solid tumors receiving gemcitabine-based chemotherapy: a randomized, placebo-controlled phase 2 study.
Topics: Adult; Aged; Aged, 80 and over; Benzoates; Deoxycytidine; Female; Gemcitabine; Humans; Hydrazines; Male; Middle Aged; Neoplasms; Pyrazoles; Thrombocytosis | 2017 |
Persistent elevation of plasma thrombopoietin levels after treatment in severe aplastic anemia.
Topics: Adolescent; Adult; Aged; Anemia, Aplastic; Benzoates; Child; Female; Humans; Hydrazines; Immunosuppression Therapy; Male; Middle Aged; Platelet Count; Pyrazoles; Severity of Illness Index; Thrombopoietin; Time Factors | 2018 |
Eltrombopag for advanced myelodysplastic syndromes or acute myeloid leukaemia and severe thrombocytopenia (ASPIRE): a randomised, placebo-controlled, phase 2 trial.
Topics: Aged; Benzoates; Female; Humans; Hydrazines; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Placebos; Pyrazoles; Safety; Thrombocytopenia | 2018 |
Bayesian Population Pharmacokinetic Modeling of Eltrombopag in Chronic Hepatitis C Patients.
Topics: Antiviral Agents; Bayes Theorem; Benzoates; Female; Hepatitis C, Chronic; Humans; Hydrazines; Male; Middle Aged; Models, Biological; Pyrazoles; Thrombocytopenia | 2019 |
Effect of cyclosporine coadministration on the pharmacokinetics of eltrombopag in healthy volunteers.
Topics: Adolescent; Adult; Area Under Curve; ATP Binding Cassette Transporter, Subfamily G, Member 2; Benzoates; Cross-Over Studies; Cyclosporine; Dose-Response Relationship, Drug; Drug Interactions; Female; Healthy Volunteers; Humans; Hydrazines; Immunosuppressive Agents; Male; Metabolic Clearance Rate; Middle Aged; Neoplasm Proteins; Pyrazoles; Receptors, Thrombopoietin; Substrate Specificity; Young Adult | 2018 |
Addition of eltrombopag to immunosuppressive therapy in patients with newly diagnosed aplastic anemia.
Topics: Adult; Aged; Aged, 80 and over; Anemia, Aplastic; Benzoates; Drug Therapy, Combination; Female; Granulocyte Colony-Stimulating Factor; Humans; Hydrazines; Immunosuppressive Agents; Male; Middle Aged; Pyrazoles; Remission Induction; Survival Analysis; Treatment Outcome; Young Adult | 2018 |
Usefulness of eltrombopag for treating thrombocytopenia after allogeneic stem cell transplantation.
Topics: Adult; Aged; Allografts; Benzoates; Female; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Male; Middle Aged; Pyrazoles; Retrospective Studies; Thrombocytopenia | 2019 |
A phase II trial of eltrombopag for patients with chronic lymphocytic leukaemia (CLL) and thrombocytopenia.
Topics: Aged; Aged, 80 and over; Benzoates; Female; Humans; Hydrazines; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Pyrazoles; Thrombocytopenia | 2019 |
Eltrombopag for Treating Thrombocytopenia after Allogeneic Stem Cell Transplantation.
Topics: Adult; Aged; Allografts; Benzoates; Blood Platelet Disorders; Female; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Male; Middle Aged; Platelet Count; Pyrazoles; Retrospective Studies | 2019 |
A phase 2 clinical trial of eltrombopag for treatment of patients with myelodysplastic syndromes after hypomethylating-agent failure.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Benzoates; Blood Platelets; Disease Progression; DNA Methylation; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Hydrazines; Kaplan-Meier Estimate; Male; Middle Aged; Myelodysplastic Syndromes; Platelet Count; Prognosis; Pyrazoles; Treatment Outcome | 2019 |
Bone marrow characteristics predict outcome in a multicenter cohort of primary immune thrombocytopenia patients treated with thrombopoietin analogs.
Topics: Benzoates; Bone Marrow Cells; Female; Follow-Up Studies; Humans; Hydrazines; Male; Middle Aged; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Recombinant Fusion Proteins; Retrospective Studies; Thrombopoietin | 2019 |
Treatment optimization and genomic outcomes in refractory severe aplastic anemia treated with eltrombopag.
Topics: Anemia, Aplastic; Benzoates; Clonal Evolution; Female; Humans; Hydrazines; Male; Pyrazoles | 2019 |
Thrombopoietin Receptor Agonists for Severe Thrombocytopenia after Allogeneic Stem Cell Transplantation: Experience of the Spanish Group of Hematopoietic Stem Cell Transplant.
Topics: Adolescent; Adult; Allografts; Benzoates; Child; Child, Preschool; Female; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Infant; Male; Platelet Count; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Retrospective Studies; Severity of Illness Index; Spain; Thrombocytopenia; Thrombopoietin | 2019 |
Hematologic recovery induced by eltrombopag in Japanese patients with aplastic anemia refractory or intolerant to immunosuppressive therapy.
Topics: Adult; Aged; Anemia, Aplastic; Benzoates; Blood Transfusion; Cell Lineage; Chemical and Drug Induced Liver Injury; Combined Modality Therapy; Drug Resistance; Drug Substitution; Female; Hematopoiesis; Humans; Hydrazines; Immunosuppressive Agents; Japan; Male; Middle Aged; Pharyngitis; Platelet Count; Pyrazoles; Receptors, Thrombopoietin; Treatment Outcome; Young Adult | 2019 |
Eltrombopag for immune thrombocytopenia secondary to chronic lymphoproliferative disorders: a phase 2 multicenter study.
Topics: Adult; Aged; Aged, 80 and over; Benzoates; Blood Platelets; Chronic Disease; Female; Humans; Hydrazines; Lymphoproliferative Disorders; Male; Middle Aged; Prospective Studies; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles | 2019 |
Eltrombopag for thrombocytopenia following allogeneic hematopoietic stem cell transplantation in children.
Topics: Adolescent; Adult; Allografts; Benzoates; Child; Female; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Infant; Male; Pyrazoles; Thrombocytopenia | 2020 |
A sequential two-stage dose escalation study of eltrombopag in patients with myelodysplastic syndrome and thrombocytopenia after hypomethylating agent failure.
Topics: Azacitidine; Benzoates; Humans; Hydrazines; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Pyrazoles; Thrombocytopenia; Treatment Outcome | 2020 |
Eltrombopag for patients with moderate aplastic anemia or uni-lineage cytopenias.
Topics: Anemia, Aplastic; Benzoates; Humans; Hydrazines; Prospective Studies; Pyrazoles | 2020 |
Longitudinal evaluation of eltrombopag in paediatric acquired severe aplastic anaemia.
Topics: Adolescent; Anemia, Aplastic; Antilymphocyte Serum; Benzoates; Child; Child, Preschool; Cyclosporine; Female; Follow-Up Studies; Humans; Hydrazines; Immunosuppressive Agents; Male; Off-Label Use; Pyrazoles; Receptors, Thrombopoietin; Treatment Outcome | 2020 |
Use of thrombopoietin receptor agonists for immune thrombocytopenia in pregnancy: results from a multicenter study.
Topics: Adult; Benzoates; Female; Follow-Up Studies; Humans; Hydrazines; Pregnancy; Pregnancy Complications, Hematologic; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Retrospective Studies; Thrombopoietin | 2020 |
Treatment outcomes and chronicity predictors for primary immune thrombocytopenia: 10-year data from an academic center.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Benzoates; Child; Child, Preschool; Chronic Disease; Dexamethasone; Female; Humans; Hydrazines; Immunoglobulins, Intravenous; Infant; Infant, Newborn; Male; Middle Aged; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Retrospective Studies; Rituximab; Splenectomy | 2020 |
Eltrombopag in Combination with Rabbit Anti-thymocyte Globulin/Cyclosporine A in Immunosuppressive Therapy-naïve Patients with Aplastic Anemia in Japan.
Topics: Anemia, Aplastic; Antilymphocyte Serum; Benzoates; Cyclosporine; Humans; Hydrazines; Immunosuppressive Agents; Japan; Neoplasm Recurrence, Local; Pyrazoles; Treatment Outcome | 2021 |
Eltrombopag added to immunosuppression for children with treatment-naïve severe aplastic anaemia.
Topics: Adolescent; Anemia, Aplastic; Antilymphocyte Serum; Benzoates; Child; Cyclosporine; Female; Humans; Hydrazines; Immunosuppressive Agents; Male; Pyrazoles; Treatment Outcome | 2021 |
Eltrombopag second-line therapy in adult patients with primary immune thrombocytopenia in an attempt to achieve sustained remission off-treatment: results of a phase II, multicentre, prospective study.
Topics: Adult; Aged; Aged, 80 and over; Benzoates; Cytokines; Drug Tapering; Female; Humans; Hydrazines; Lymphocytes; Male; Middle Aged; Predictive Value of Tests; Prospective Studies; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin; Remission Induction; Withholding Treatment | 2021 |
Real-world use of thrombopoietin receptor agonists in older patients with primary immune thrombocytopenia.
Topics: Aged; Aged, 80 and over; Benzoates; Female; Follow-Up Studies; Hemorrhage; Humans; Hydrazines; Male; Middle Aged; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Retrospective Studies; Thrombopoietin; Thrombosis | 2021 |
Eltrombopag for Post-Transplantation Thrombocytopenia: Results of Phase II Randomized, Double-Blind, Placebo-Controlled Trial.
Topics: Benzoates; Humans; Hydrazines; Neoplasm Recurrence, Local; Pyrazoles; Thrombocytopenia | 2021 |
CALR mutant protein rescues the response of MPL p.R464G variant associated with CAMT to eltrombopag.
Topics: Adult; Amino Acid Substitution; Benzoates; Calreticulin; Child; Child, Preschool; Congenital Bone Marrow Failure Syndromes; Female; HEK293 Cells; Homozygote; Humans; Hydrazines; Infant; Male; Mutation, Missense; Pyrazoles; Receptors, Thrombopoietin; Thrombocytopenia | 2021 |
Phase 3 randomised trial of eltrombopag versus standard first-line pharmacological management for newly diagnosed immune thrombocytopaenia (ITP) in children: study protocol.
Topics: Benzoates; Child; Clinical Trials, Phase III as Topic; Humans; Hydrazines; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Quality of Life; Randomized Controlled Trials as Topic; Treatment Outcome | 2021 |
Long-term outcomes in patients with severe aplastic anemia treated with immunosuppression and eltrombopag: a phase 2 study.
Topics: Adult; Anemia, Aplastic; Benzoates; Cyclosporine; Female; Humans; Hydrazines; Immunosuppressive Agents; Male; Middle Aged; Prospective Studies; Pyrazoles; Survival Analysis; Treatment Outcome; Young Adult | 2022 |
Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anemia, Aplastic; Antilymphocyte Serum; Benzoates; Cyclosporine; Drug Therapy, Combination; Female; Humans; Hydrazines; Immunosuppression Therapy; Immunosuppressive Agents; Male; Middle Aged; Progression-Free Survival; Prospective Studies; Pyrazoles; Receptors, Thrombopoietin; Remission Induction; Young Adult | 2022 |
Phase Ib study of eltrombopag and azacitidine in patients with high-risk myelodysplastic syndromes and related disorders (the ELASTIC study).
Topics: Azacitidine; Benzoates; Drug Combinations; Humans; Hydrazines; Myelodysplastic Syndromes; Pyrazoles; Treatment Outcome | 2022 |
A phase 3, randomized, double-blind, active-controlled trial evaluating efficacy and safety of avatrombopag versus eltrombopag in ITP.
Topics: Benzoates; Humans; Hydrazines; Platelet Count; Purpura, Thrombocytopenic, Idiopathic | 2023 |
Efficacy and safety of eltrombopag in Chinese patients with refractory or relapsed severe aplastic anemia.
Topics: Adult; Anemia, Aplastic; Benzoates; East Asian People; Humans; Hydrazines; Immunosuppressive Agents; Prospective Studies; Treatment Outcome | 2023 |
Other Studies
416 other study(ies) available for hydrazine and amg531
| Article | Year |
|---|---|
[Eltrombopag increases thrombocyte count and reduces the bleeding risk].
Topics: Benzoates; Hemorrhage; Humans; Hydrazines; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles | 2007 |
Immune thrombocytopenic purpura--from agony to agonist.
Topics: Benzoates; Hepatitis C; History, 20th Century; Humans; Hydrazines; Liver Cirrhosis; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin; Thrombocytopenia | 2007 |
Eltrombopag in thrombocytopenia.
Topics: Benzoates; Hepatitis C; Humans; Hydrazines; Interferon alpha-2; Interferon-alpha; Interferons; Liver Cirrhosis; Platelet Count; Polyethylene Glycols; Pyrazoles; Receptors, Thrombopoietin; Recombinant Proteins; Thrombocytopenia | 2008 |
Eltrombopag in thrombocytopenia.
Topics: Adrenal Cortex Hormones; Benzoates; Danazol; Drug Therapy, Combination; Humans; Hydrazines; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin | 2008 |
Boosting platelet production.
Topics: Benzoates; Blood Platelets; Humans; Hydrazines; Models, Immunological; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin | 2008 |
[Thrombopoietin-receptor agonists: a revolution in the therapeutic strategies of immune thrombocytopenic purpura?].
Topics: Administration, Oral; Adult; Antiviral Agents; Benzoates; Carrier Proteins; Controlled Clinical Trials as Topic; Drug Therapy, Combination; Female; Hepatitis C; Humans; Hydrazines; Immunoglobulins, Intravenous; Injections, Subcutaneous; Interferons; Myelodysplastic Syndromes; Placebos; Prospective Studies; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Ribavirin; Splenectomy; Thrombocytopenia; Thrombopoietin; Time Factors | 2009 |
Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist.
Topics: Animals; Antigens, CD34; Benzoates; Blotting, Western; Bone Marrow Cells; Caspase 3; Caspase 7; Cell Differentiation; Cell Line; Cell Proliferation; Cells, Cultured; Electrophoretic Mobility Shift Assay; Humans; Hydrazines; Megakaryocytes; Mice; Molecular Structure; Pan troglodytes; Platelet Membrane Glycoprotein IIb; Pyrazoles; Receptors, Thrombopoietin; Signal Transduction | 2009 |
New options after first-line therapy for chronic immune thrombocytopenic purpura.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Benzoates; Carrier Proteins; Chronic Disease; Drug Resistance; Humans; Hydrazines; Immunologic Factors; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Rituximab; Thrombopoiesis; Thrombopoietin | 2009 |
Role of growth factors and thrombopoietic agents in the treatment of chronic hepatitis C.
Topics: Antiviral Agents; Benzoates; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Hydrazines; Intercellular Signaling Peptides and Proteins; Interferon alpha-2; Interferon-alpha; Platelet Count; Polyethylene Glycols; Pyrazoles; Recombinant Proteins; Ribavirin; Thrombocytopenia; Thrombopoiesis; Treatment Outcome | 2009 |
The identification of orally bioavailable thrombopoietin agonists.
Topics: Administration, Oral; Animals; Benzoates; Biological Availability; Caco-2 Cells; Humans; Hydrazines; Piperidines; Pyrazinamide; Pyrazoles; Pyrimidines; Rats; Receptors, Thrombopoietin | 2009 |
Orphan disease gains second treatment option.
Topics: Benzoates; Carrier Proteins; Drug Delivery Systems; Humans; Hydrazines; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Rare Diseases; Receptors, Fc; Recombinant Fusion Proteins; Thrombopoietin | 2009 |
New therapy options for chronic immune thrombocytopenic purpura: a breath of fresh air. Introduction.
Topics: Benzoates; Chronic Disease; Drug Delivery Systems; Humans; Hydrazines; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thrombopoietin | 2009 |
Eltrombopag in chronic idiopathic thrombocytopenic purpura.
Topics: Benzoates; Chronic Disease; Double-Blind Method; Hemorrhage; Humans; Hydrazines; Multicenter Studies as Topic; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Quality of Life; Randomized Controlled Trials as Topic | 2009 |
Eltrombopag.
Topics: Benzoates; Clinical Trials as Topic; Humans; Hydrazines; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin | 2009 |
New drugs 09, part 2.
Topics: Adrenergic Uptake Inhibitors; Angioedemas, Hereditary; Benzoates; Carrier Proteins; Complement C1 Inactivator Proteins; Complement C1 Inhibitor Protein; Drug Approval; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; Fluprednisolone; Humans; Huntington Disease; Hydrazines; Keratitis; Nurse's Role; Ophthalmologic Surgical Procedures; Pain, Postoperative; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Pyridines; Receptors, Fc; Recombinant Fusion Proteins; Tetrabenazine; Thrombopoietin; Uveitis | 2009 |
Comparative analyses of the small molecule thrombopoietin receptor agonist eltrombopag and thrombopoietin on in vitro platelet function.
Topics: Benzoates; Blood Platelets; Dose-Response Relationship, Drug; Female; Gene Expression Regulation; Humans; Hydrazines; Male; P-Selectin; Platelet Aggregation; Proto-Oncogene Proteins c-akt; Pyrazoles; Receptors, Thrombopoietin; Signal Transduction; STAT Transcription Factors; Thrombocytopenia; Thrombopoietin | 2009 |
Effect of the nonpeptide thrombopoietin receptor agonist Eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome.
Topics: Animals; Apoptosis; Benzoates; Bone Marrow Cells; Cell Differentiation; Cell Proliferation; Dose-Response Relationship, Drug; Hematopoiesis; Humans; Hydrazines; Leukemia, Myeloid, Acute; Leukocytes, Mononuclear; Male; Megakaryocytes; Mice; Mice, Inbred NOD; Myelodysplastic Syndromes; Pyrazoles; Receptors, Thrombopoietin; Thrombocytopenia; Xenograft Model Antitumor Assays | 2009 |
Eltrombopag, an oral thrombopoietin receptor agonist, has no impact on the pharmacokinetic profile of probe drugs for cytochrome P450 isoenzymes CYP3A4, CYP1A2, CYP2C9 and CYP2C19 in healthy men: a cocktail analysis.
Topics: Administration, Oral; Adult; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Benzoates; Caffeine; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Flurbiprofen; Humans; Hydrazines; Isoenzymes; Male; Midazolam; Omeprazole; Pharmaceutical Preparations; Pyrazoles; Receptors, Thrombopoietin | 2010 |
Eltrombopag for the treatment of chronic immune (idiopathic) thrombocytopenic purpura.
Topics: Benzoates; Chronic Disease; Drug Approval; Humans; Hydrazines; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Randomized Controlled Trials as Topic; Treatment Outcome | 2009 |
Update on eltrombopag for ITP.
Topics: Benzoates; Drug Approval; Humans; Hydrazines; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Randomized Controlled Trials as Topic | 2009 |
Reduced proliferation of non-megakaryocytic acute myelogenous leukemia and other leukemia and lymphoma cell lines in response to eltrombopag.
Topics: Base Sequence; Benzoates; Cell Line, Tumor; Cell Proliferation; DNA Primers; Humans; Hydrazines; Leukemia; Leukemia, Myeloid, Acute; Lymphoma; Pyrazoles; Reverse Transcriptase Polymerase Chain Reaction | 2010 |
Eltrombopag, a second-generation thrombopoietin receptor agonist, for chronic lymphocytic leukemia-associated ITP.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzoates; Drug Resistance, Neoplasm; Female; Humans; Hydrazines; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin; Salvage Therapy | 2010 |
Consensus Paper-ICIS Expert Meeting Basel 2009 treatment milestones in immune thrombocytopenia.
Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Benzoates; Child; Hemorrhage; Humans; Hydrazines; Immunologic Factors; Precision Medicine; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Quality of Life; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Rituximab; Severity of Illness Index; Splenectomy; Switzerland; Thrombocytopenia; Thrombopoietin | 2010 |
Increasing platelets without transfusion: is it time to introduce novel thrombopoietic agents in neonatal care?
Topics: Adult; Age Factors; Apoptosis; Benzoates; Brain; Dose-Response Relationship, Drug; Drug Approval; Humans; Hydrazines; Infant, Newborn; Neurons; Patient Selection; Platelet Transfusion; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thrombocytopenia, Neonatal Alloimmune; Thrombopoiesis; Thrombopoietin; United States; United States Food and Drug Administration | 2010 |
Eltrombopag. Idiopathic thrombocytopenic purpura after treatment failure: romiplostim is a better option.
Topics: Benzoates; Hemorrhage; Humans; Hydrazines; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Randomized Controlled Trials as Topic; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thrombopoietin; Treatment Failure | 2010 |
[Diagnosis and therapy of autoimmune thrombocytopenia. Recommendations of a joint Expert Group of DGHO, DGTI, DTH].
Topics: Adrenal Cortex Hormones; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Autoantibodies; Benzoates; Blood Coagulation Tests; Blood Platelets; Blood Transfusion; Child; Cross-Sectional Studies; Diagnosis, Differential; Evidence-Based Medicine; Germany; Hemorrhage; Hospitalization; Humans; Hydrazines; Immunization, Passive; Immunosuppressive Agents; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Recurrence; Rituximab; Splenectomy; Thrombopoietin | 2010 |
Thrombopoietin receptor activation, thrombopoietin mimetic drugs, and hereditary thrombocytosis: remarks on bone marrow fibrosis.
Topics: Benzoates; Humans; Hydrazines; Mutation; Primary Myelofibrosis; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thrombocytopenia; Thrombocytosis; Thrombopoietin; Transcriptional Activation | 2010 |
Zinc is not required for activity of TPO agonists acting at the c-Mpl receptor transmembrane domain.
Topics: Benzoates; Biomimetics; Edetic Acid; Hydrazines; Protein Structure, Tertiary; Pyrazoles; Receptors, Thrombopoietin; Thrombopoietin; Zinc | 2010 |
New thrombopoietic agents: introduction.
Topics: Benzoates; Humans; Hydrazines; Pyrazoles; Thrombocytopenia; Thrombopoietin | 2010 |
Acute renal failure in a patient with antiphospholipid syndrome and immune thrombocytopenic purpura treated with eltrombopag.
Topics: Acute Kidney Injury; Antiphospholipid Syndrome; Benzoates; Humans; Hydrazines; Male; Middle Aged; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles | 2010 |
Effect of the nonpeptide thrombopoietin receptor agonist eltrombopag on megakaryopoiesis of patients with lower risk myelodysplastic syndrome.
Topics: Aged; Aged, 80 and over; Antigens, CD34; Apoptosis; Benzoates; Blotting, Western; Bone Marrow Cells; Cell Proliferation; Female; Humans; Hydrazines; Male; Megakaryocyte Progenitor Cells; Middle Aged; Myelodysplastic Syndromes; Pyrazoles; Receptors, Thrombopoietin; Risk Factors; Thrombopoiesis; Tumor Cells, Cultured | 2011 |
Sustaining platelet counts in chronic ITP.
Topics: Benzoates; Chronic Disease; Humans; Hydrazines; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thrombopoietin | 2011 |
Pharmacological profile of AS1670542, a novel orally-active human thrombopoietin receptor agonist.
Topics: Administration, Oral; Amino Acid Sequence; Animals; Antigens, CD34; Benzoates; Cell Line; Cell Membrane; Dogs; Female; Histidine; Humans; Hydrazines; Liver; Mice; Molecular Sequence Data; Platelet Count; Protein Structure, Tertiary; Pyrazoles; Rats; Receptors, Thrombopoietin; Species Specificity; Stem Cell Transplantation; Thiazoles; Thiophenes | 2011 |
Population PK/PD modeling of eltrombopag in healthy volunteers and patients with immune thrombocytopenic purpura and optimization of response-guided dosing.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aging; Asian People; Benzoates; Case-Control Studies; Computer Simulation; Dose-Response Relationship, Drug; Female; Humans; Hydrazines; Male; Middle Aged; Models, Biological; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Young Adult | 2011 |
[New treatment options for primary immune thrombocytopenia].
Topics: Antibodies, Monoclonal, Murine-Derived; Benzoates; Dexamethasone; Glucocorticoids; Humans; Hydrazines; Immunoglobulins, Intravenous; Immunosuppressive Agents; Prednisolone; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Recombinant Fusion Proteins; Rituximab; Splenectomy; Thrombopoietin | 2011 |
What is publication? The case of eltrombopag.
Topics: Benzoates; Editorial Policies; Humans; Hydrazines; Publishing; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Splenectomy; Thrombopoietin | 2011 |
Successful treatment of amegakaryocytic thrombocytopenia with eltrombopag in a patient with systemic lupus erythematosus (SLE).
Topics: Benzoates; Blood Platelets; Bone Marrow Diseases; Female; Humans; Hydrazines; Lupus Erythematosus, Systemic; Megakaryocytes; Middle Aged; Molecular Mimicry; Purpura, Thrombocytopenic; Pyrazoles; Receptors, Thrombopoietin; Remission Induction; Treatment Outcome | 2010 |
Infection-related transient loss of response and other early side effects in chronic ITP during treatment with thrombopoietin mimetics.
Topics: Adult; Aged; Aged, 80 and over; Benzoates; Chronic Disease; Female; Humans; Hydrazines; Male; Middle Aged; Platelet Activation; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thrombopoietin; Treatment Outcome | 2011 |
Platelet production and platelet destruction: assessing mechanisms of treatment effect in immune thrombocytopenia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzoates; Blood Platelets; Case-Control Studies; Child; Child, Preschool; Female; Humans; Hydrazines; Immunoglobulins, Intravenous; Infant; Isoantibodies; Male; Middle Aged; Platelet Count; Prognosis; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, IgG; Retrospective Studies; Rh-Hr Blood-Group System; Rho(D) Immune Globulin; Thrombocytosis; Thrombopoiesis; Young Adult | 2011 |
Pharmacokinetics and hepatic uptake of eltrombopag, a novel platelet-increasing agent.
Topics: Animals; Benzoates; Blood Platelets; Cell Line; Dose-Response Relationship, Drug; Hepatocytes; Humans; Hydrazines; Injections, Intravenous; Intracellular Signaling Peptides and Proteins; Liver; Liver-Specific Organic Anion Transporter 1; Male; Membrane Proteins; Mice; Mice, Knockout; Organic Anion Transporters; Organic Cation Transporter 1; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptors, Thrombopoietin; Tissue Distribution | 2011 |
Humanized VB22B minibody for human Mpl stimulates human megakaryopoiesis but does not enhance platelet aggregation.
Topics: Animals; Antibodies; Benzoates; Blotting, Western; Bone Marrow Cells; Cells, Cultured; DNA; Erythroid Cells; Flow Cytometry; Humans; Hydrazines; Megakaryocytes; Mice; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Myeloid Cells; Phosphorylation; Platelet Aggregation; Ploidies; Pyrazoles; Receptors, Thrombopoietin; STAT3 Transcription Factor; STAT5 Transcription Factor; Thrombopoiesis; Thrombopoietin | 2011 |
The stingy bone marrow and the wasteful peripheral blood: a tale of two ITPs.
Topics: Animals; Benzoates; Blood Platelets; Bone Marrow; Humans; Hydrazines; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin; Thrombopoiesis | 2011 |
Eltrombopag for chronic immune thrombocytopenia.
Topics: Asia; Benzoates; Chronic Disease; Humans; Hydrazines; Multicenter Studies as Topic; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Randomized Controlled Trials as Topic; Receptors, Thrombopoietin | 2011 |
Investigations of hydrazine cleavage of eltrombopag in humans.
Topics: Administration, Oral; Animals; Anti-Bacterial Agents; Benzoates; Cecum; Cytochrome P-450 Enzyme System; Feces; Female; Hepatocytes; Humans; Hydrazines; Kidney; Liver; Male; Mice; Microsomes; Pyrazoles; Rats, Sprague-Dawley | 2011 |
Eltrombopag for the treatment of immune thrombocytopenia.
Topics: Benzoates; Clinical Trials as Topic; Humans; Hydrazines; Pyrazoles; Receptors, Thrombopoietin; Thrombocytopenia | 2011 |
Eltrombopag for radiation-induced thrombocytopenia in a glioblastoma patient.
Topics: Aged; Benzoates; Central Nervous System Neoplasms; Glioblastoma; Humans; Hydrazines; Male; Pyrazoles; Radiotherapy; Thrombocytopenia | 2012 |
Fibroproliferative activity in patients with immune thrombocytopenia (ITP) treated with thrombopoietic agents.
Topics: Adult; Benzoates; Bone Marrow; Combined Modality Therapy; Cytokines; Female; Hepatocyte Growth Factor; Humans; Hydrazines; Intercellular Signaling Peptides and Proteins; Male; Middle Aged; Peptide Fragments; Primary Myelofibrosis; Procollagen; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Reticulin; Splenectomy; Thrombopoietin | 2011 |
Thrombopoietin-receptor agonists in haematological disorders: the Danish experience.
Topics: Adult; Aged; Aged, 80 and over; Anemia, Hemolytic, Autoimmune; Benzoates; Blood Platelets; Celiac Disease; Denmark; Female; HIV Infections; Humans; Hydrazines; Leukemia, Lymphocytic, Chronic, B-Cell; Lupus Erythematosus, Systemic; Male; Middle Aged; Off-Label Use; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Recurrence; Retrospective Studies; Thrombocytopenia; Thrombopoietin | 2012 |
[Guidelines for diagnosis, treatment and monitoring of primary immune thrombocytopenia].
Topics: Aged; Benzoates; Child; Female; Glucocorticoids; Humans; Hydrazines; Immunoglobulins, Intravenous; Immunologic Factors; Pregnancy; Pregnancy Complications, Hematologic; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Quality of Life; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Splenectomy; Thrombopoietin | 2012 |
A novel and simple hollow-fiber assay for in vivo evaluation of nonpeptidyl thrombopoietin receptor agonists.
Topics: Animals; Benzoates; Cell Line; Colony-Forming Units Assay; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Erythropoietin; Female; Granulocyte Colony-Stimulating Factor; Humans; Hydrazines; Implants, Experimental; Interleukin-3; Mice; Mice, Inbred BALB C; Mice, Nude; Phosphorylation; Protein Processing, Post-Translational; Pyrazoles; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Recombinant Proteins; STAT3 Transcription Factor; Thrombopoietin; Transfection | 2012 |
In vivo effects of eltrombopag on platelet function in immune thrombocytopenia: no evidence of platelet activation.
Topics: Adult; Aged; Aged, 80 and over; Benzoates; Blood Platelets; Case-Control Studies; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Female; Flow Cytometry; Humans; Hydrazines; Male; Middle Aged; P-Selectin; Peptide Fragments; Platelet Activation; Platelet Count; Platelet Glycoprotein GPIIb-IIIa Complex; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Randomized Controlled Trials as Topic | 2012 |
Short-term eltrombopag for surgical preparation of a patient with inherited thrombocytopenia deriving from MYH9 mutation.
Topics: Adult; Benzoates; Bleeding Time; Blood Loss, Surgical; Coagulants; Drug Administration Schedule; Female; Genetic Predisposition to Disease; Heredity; Humans; Hydrazines; Molecular Motor Proteins; Mutation, Missense; Myosin Heavy Chains; Orthopedic Procedures; Phenotype; Postoperative Hemorrhage; Pyrazoles; Severity of Illness Index; Thrombocytopenia; Time Factors; Treatment Outcome | 2012 |
Thrombopoietin: too much or too little.
Topics: Benzoates; Blood Platelets; Humans; Hydrazines; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Secondary Prevention; Thrombopoietin | 2012 |
Use of eltrombopag, a thrombopoietin receptor agonist, in post-transplantation thrombocytopenia.
Topics: Adult; Benzoates; Fatal Outcome; Female; Humans; Hydrazines; Middle Aged; Platelet Count; Pyrazoles; Receptors, Thrombopoietin; Stem Cell Transplantation; Thrombocytopenia; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome | 2012 |
Thrombopoietin receptor agonists in refractory immune thrombocytopenia: differential responses to eltrombopag and romiplostim: a case report and possible explanations.
Topics: Aged, 80 and over; Benzoates; Dose-Response Relationship, Drug; Drug Resistance; Female; Humans; Hydrazines; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thrombopoietin; Treatment Outcome | 2012 |
Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation.
Topics: Animals; Antineoplastic Agents; Benzoates; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; G1 Phase Cell Cycle Checkpoints; HL-60 Cells; Humans; Hydrazines; Iron; Leukemia; Leukemia, Experimental; Mice; Mice, Inbred NOD; Mice, Knockout; Mice, SCID; Pyrazoles; Receptors, Thrombopoietin; U937 Cells | 2012 |
Eltrombopag, a thrombopoietin receptor agonist, enhances human umbilical cord blood hematopoietic stem/primitive progenitor cell expansion and promotes multi-lineage hematopoiesis.
Topics: ADP-ribosyl Cyclase 1; Animals; Antigens, CD34; Benzoates; Blood Platelets; Bone Marrow Cells; Cell Lineage; Cell Proliferation; Cells, Cultured; Fetal Blood; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Hydrazines; Leukocytes; Mice; Mice, SCID; Phosphorylation; Proto-Oncogene Proteins c-akt; Pyrazoles; Receptors, Thrombopoietin; STAT3 Transcription Factor; STAT5 Transcription Factor | 2012 |
Eltrombopag fails to improve severe thrombocytopenia in late-stage dyskeratosis congenita and diamond-blackfan-anaemia.
Topics: Administration, Oral; Adolescent; Adult; Anemia, Diamond-Blackfan; Benzoates; Cardiology; Dyskeratosis Congenita; Female; Humans; Hydrazines; Male; Megakaryocytes; Pyrazoles; Receptors, Thrombopoietin; Thrombocytopenia; Treatment Outcome | 2012 |
A promising new treatment for refractory aplastic anemia.
Topics: Anemia, Aplastic; Benzoates; Female; Humans; Hydrazines; Male; Pyrazoles | 2012 |
Venous thromboembolism and coagulation activity in patients with immune thrombocytopenia treated with thrombopoietin receptor agonists.
Topics: Benzoates; Blood Coagulation; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Fibrin Fibrinogen Degradation Products; Fibrinolysis; Hemorrhage; Humans; Hydrazines; Platelet Count; Pulmonary Embolism; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Retrospective Studies; Thrombophilia; Thrombopoietin; Venous Thrombosis | 2012 |
Thrombopoietin receptor agonists in the treatment of immune thrombocytopenia: a clinician's perspective.
Topics: Benzoates; Clinical Trials as Topic; Hemorrhage; Humans; Hydrazines; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Randomized Controlled Trials as Topic; Receptors, Fc; Recombinant Fusion Proteins; Thrombopoietin | 2012 |
Platelet count or bleeding as the outcome in ITP trials?
Topics: Benzoates; Clinical Trials as Topic; Hemorrhage; Humans; Hydrazines; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Randomized Controlled Trials as Topic; Receptors, Fc; Recombinant Fusion Proteins; Thrombopoietin | 2012 |
TPO-receptor agonists in ITP: a clinician's navigation between Scylla and Charybdis.
Topics: Benzoates; Clinical Trials as Topic; Hemorrhage; Humans; Hydrazines; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Randomized Controlled Trials as Topic; Receptors, Fc; Recombinant Fusion Proteins; Thrombopoietin | 2012 |
Prolonged remission from eltrombopag in chronic refractory idiopathic thrombocytopenic purpura.
Topics: Benzoates; Chronic Disease; Humans; Hydrazines; Male; Middle Aged; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Remission Induction; Treatment Outcome | 2012 |
Low or undetectable TPO receptor expression in malignant tissue and cell lines derived from breast, lung, and ovarian tumors.
Topics: Benzoates; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Hydrazines; Inhibitory Concentration 50; Lung Neoplasms; Male; Ovarian Neoplasms; Pyrazoles; Receptors, Thrombopoietin | 2012 |
Platelet response as the basis for approval in chronic immune (idiopathic) thrombocytopenic purpura (ITP): a regulatory perspective.
Topics: Benzoates; Clinical Trials as Topic; Hemorrhage; Humans; Hydrazines; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Randomized Controlled Trials as Topic; Receptors, Fc; Recombinant Fusion Proteins; Thrombopoietin | 2012 |
Successful use of eltrombopag without splenectomy in refractory HIV-related immune reconstitution thrombocytopenia.
Topics: Adenine; Benzoates; Deoxycytidine; Drug Combinations; Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; HIV Seropositivity; Humans; Hydrazines; Immune Reconstitution Inflammatory Syndrome; Male; Middle Aged; Organophosphonates; Oxazines; Pyrazoles; Reverse Transcriptase Inhibitors; Thrombocytopenia; Treatment Outcome | 2012 |
Usage of eltrombopag for chronic immune thrombocytopenia as a pretreatment for splenectomy.
Topics: Adult; Benzoates; Chronic Disease; Dexamethasone; Female; Glucocorticoids; Humans; Hydrazines; Prednisolone; Pyrazoles; Receptors, Thrombopoietin; Splenectomy; Thrombocytopenia | 2013 |
Severe cutaneous toxicity related to Eltrombopag.
Topics: Aged; Aged, 80 and over; Benzoates; Female; Humans; Hydrazines; Male; Middle Aged; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Skin Diseases | 2013 |
The beta 1 tubulin R307H single nucleotide polymorphism is associated with treatment failures in immune thrombocytopenia (ITP).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alleles; Antibodies, Monoclonal, Murine-Derived; Benzoates; Biomarkers; Child; Child, Preschool; Female; Gene Frequency; Genotype; Humans; Hydrazines; Immunologic Factors; Infant; Male; Middle Aged; Phenotype; Platelet Count; Polymorphism, Single Nucleotide; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Retrospective Studies; Rituximab; Thiazoles; Thiophenes; Thrombopoiesis; Thrombopoietin; Treatment Failure; Tubulin | 2013 |
Eltrombopag inhibition of acute myeloid leukemia cell survival does not depend on c-Mpl expression.
Topics: Benzoates; Cell Line, Tumor; Cell Survival; Humans; Hydrazines; Leukemia, Myeloid, Acute; Pyrazoles; Receptors, Thrombopoietin | 2013 |
Successful treatment of eltrombopag-resistant refractory immune thrombocytopenia with romiplostim.
Topics: Benzoates; Drug Resistance; Humans; Hydrazines; Immunoglobulins, Intravenous; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Recombinant Fusion Proteins; Thrombopoietin | 2013 |
Absence of bi-directional cross-resistance of thrombopoietin receptor agonists in chronic refractory immune thrombocytopenia: possible role of MPL polymorphisms.
Topics: Adult; Aged; Autoimmune Diseases; Benzoates; Drug Resistance; Drug Therapy, Combination; Female; Humans; Hydrazines; Polymorphism, Single Nucleotide; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thrombocytopenia; Thrombopoietin | 2013 |
Extensive cerebral venous sinus thrombosis following a dose increase in eltrombopag in a patient with idiopathic thrombocytopenic purpura.
Topics: Anticoagulants; Benzoates; Female; Humans; Hydrazines; Magnetic Resonance Imaging; Middle Aged; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Sinus Thrombosis, Intracranial; Treatment Outcome | 2014 |
Cardiac and pulmonary thrombosis during multidrug treatment in an idiopathic thrombocytopenic purpura patient.
Topics: Adult; Benzoates; Danazol; Female; Humans; Hydrazines; Immunoglobulins, Intravenous; Methylprednisolone; Pulmonary Embolism; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Venous Thrombosis; Vincristine | 2014 |
Simultaneous romiplostin, eltrombopag, and prednisone were successful in severe thrombocytopenia of Evans syndrome refractory to hydrocortisone, splenectomy, intravenous IgG, and rituximab.
Topics: Acute Disease; Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal, Murine-Derived; Benzoates; Drug Combinations; Female; Humans; Hydrazines; Hydrocortisone; Immunoglobulins, Intravenous; Middle Aged; Prednisone; Pyrazoles; Receptors, Fc; Recombinant Fusion Proteins; Rituximab; Splenectomy; Thrombocytopenia; Thrombopoietin; Treatment Outcome | 2013 |
Profound thrombocytopenia in patient with ITP treated with chemotherapy for breast cancer and subsequent remission after romiplostim.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzoates; Bone Marrow; Breast Neoplasms; Cyclophosphamide; Docetaxel; Drug Resistance; Female; Humans; Hydrazines; Mastectomy, Segmental; Middle Aged; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Estrogen; Receptors, Fc; Recombinant Fusion Proteins; Remission Induction; Splenectomy; Taxoids; Thrombocytopenia; Thrombopoietin | 2013 |
Hemostatic challenges in patients with chronic immune thrombocytopenia treated with eltrombopag.
Topics: Adult; Aged; Benzoates; Blood Loss, Surgical; Blood Platelets; Chronic Disease; Clinical Trials, Phase II as Topic; Female; Humans; Hydrazines; Male; Middle Aged; Platelet Count; Postoperative Hemorrhage; Pyrazoles; Randomized Controlled Trials as Topic; Retrospective Studies; Surgical Procedures, Operative; Thrombocytopenia | 2014 |
No cross-resistance after sequential use of romiplostim and eltrombopag in chronic immune thrombocytopenic purpura.
Topics: Benzoates; Chronic Disease; Drug Resistance; Female; Humans; Hydrazines; Male; Middle Aged; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Salvage Therapy; Thrombopoietin; Treatment Outcome | 2013 |
A retrospective pilot evaluation of switching thrombopoietic receptor-agonists in immune thrombocytopenia.
Topics: Adult; Aged; Aged, 80 and over; Benzoates; Drug Substitution; Female; Humans; Hydrazines; Male; Middle Aged; Pilot Projects; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Retrospective Studies; Thrombopoietin; Treatment Outcome | 2013 |
Sustained remissions of immune thrombocytopenia associated with the use of thrombopoietin receptor agonists.
Topics: Adult; Autoantibodies; Benzoates; Blood Platelets; Chronic Disease; Female; Humans; Hydrazines; Male; Middle Aged; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thrombopoietin | 2013 |
Population PK/PD modeling of eltrombopag in subjects with advanced solid tumors with chemotherapy-induced thrombocytopenia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzoates; Clinical Trials, Phase II as Topic; Computer Simulation; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Hydrazines; Male; Middle Aged; Models, Biological; Neoplasms; Pyrazoles; Receptors, Thrombopoietin; Thrombocytopenia; Treatment Outcome; Young Adult | 2013 |
Refractory idiopathic thrombocytopenic purpura treated with immunoadsorption using tryptophan column.
Topics: Adsorption; Adult; Benzoates; Blood Component Removal; Ecchymosis; Humans; Hydrazines; Immunologic Techniques; Immunosuppressive Agents; Male; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Remission Induction; Splenectomy; Steroids; Treatment Outcome | 2013 |
Retrospective analysis of eltrombopag for the treatment of refractory primary immune thrombocytopenia in Japan.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Benzoates; Female; Humans; Hydrazines; Japan; Male; Middle Aged; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin; Retrospective Studies; Treatment Outcome | 2013 |
Idiopathic thrombocytopenic purpura resistant to eltrombopag, but cured with romiplostim.
Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Anticonvulsants; Benzoates; Drug Interactions; Drug Resistance; Humans; Hydrazines; Immunoglobulins, Intravenous; Male; Prednisone; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Recurrence; Rituximab; Thrombopoietin | 2014 |
Cost effectiveness of romiplostim for the treatment of chronic immune thrombocytopenia in Ireland.
Topics: Antibodies, Monoclonal, Murine-Derived; Benzoates; Chronic Disease; Cost Savings; Cost-Benefit Analysis; Drug Costs; Female; Hemorrhage; Humans; Hydrazines; Immunoglobulins, Intravenous; Ireland; Male; Middle Aged; Platelet Count; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Rituximab; Thrombocytopenia; Thrombopoietin | 2013 |
Safety and efficacy of romiplostim in patients with eltrombopag-resistant or -intolerant immune thrombocytopenia.
Topics: Benzoates; Drug Resistance; Drug Substitution; Humans; Hydrazines; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thrombopoietin; Treatment Outcome | 2013 |
Eltrombopag-associated hyperpigmentation.
Topics: Aged; Benzoates; Female; Humans; Hydrazines; Hyperpigmentation; Pyrazoles; Receptors, Thrombopoietin; Skin Pigmentation | 2013 |
Thrombopoietin levels in patients with disorders of platelet production: diagnostic potential and utility in predicting response to TPO receptor agonists.
Topics: Adult; Aged; Antiphospholipid Syndrome; Benzoates; Bone Marrow Diseases; Drug Evaluation; Enzyme-Linked Immunosorbent Assay; Female; Humans; Hydrazines; Male; Middle Aged; Patient Selection; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Retrospective Studies; Salvage Therapy; Thrombocytopenia; Thrombopoiesis; Thrombopoietin | 2013 |
First successful use of eltrombopag before surgery in a child with MYH9-related thrombocytopenia.
Topics: Adolescent; Benzoates; Chromosome Aberrations; Female; Humans; Hydrazines; Molecular Motor Proteins; Mutation, Missense; Myosin Heavy Chains; Otitis Media; Platelet Count; Preoperative Care; Pyrazoles; Receptors, Thrombopoietin; Thrombocytopenia; Tympanic Membrane Perforation; Tympanoplasty | 2013 |
[Case report; a thromboembolic event in a patient with antiphospholipid antibody associated thrombocytopenia during eltrombopag therapy].
Topics: Aged; Antibodies, Antiphospholipid; Benzoates; Female; Heparin; Humans; Hydrazines; Pyrazoles; Thrombocytopenia; Thromboembolism; Treatment Outcome; Warfarin | 2013 |
Eltrombopag and serum of a different hue.
Topics: Aged; Aged, 80 and over; Benzoates; Bilirubin; Humans; Hydrazines; Hydrogen-Ion Concentration; Leukemia, Myeloid, Acute; Pigmentation; Pyrazoles; Receptors, Thrombopoietin; Thrombocytopenia | 2013 |
Sudden blindness due to bilateral central retinal artery occlusion in a patient on eltrombopag.
Topics: Benzoates; Blindness; Female; Fibrinolytic Agents; Humans; Hydrazines; Methylprednisolone; Middle Aged; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin; Recovery of Function; Retinal Artery Occlusion | 2014 |
Population pharmacokinetic/pharmacodynamic modelling of eltrombopag in healthy volunteers and subjects with chronic liver disease.
Topics: Adult; Aged; Aged, 80 and over; Asian People; Benzoates; Blood Platelets; Chronic Disease; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Computer Simulation; Female; Healthy Volunteers; Humans; Hydrazines; Liver Diseases; Male; Middle Aged; Models, Biological; Nonlinear Dynamics; Platelet Count; Pyrazoles; Randomized Controlled Trials as Topic; Thrombocytopenia; Treatment Outcome; Young Adult | 2014 |
Immune thrombocytopenia successfully treated with eltrombopag following multiple therapies including romiplostim.
Topics: Benzoates; Humans; Hydrazines; Male; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Recombinant Fusion Proteins; Thrombopoietin | 2014 |
Does eltrombopag really ENABLE SVR?
Topics: Antiviral Agents; Benzoates; Female; Hematologic Agents; Hepatitis C, Chronic; Humans; Hydrazines; Liver Cirrhosis; Male; Pyrazoles; Thrombocytopenia | 2014 |
Dental procedures in 24 patients with chronic immune thrombocytopenia in prospective clinical studies of eltrombopag.
Topics: Benzoates; Chronic Disease; Dentistry, Operative; Hemorrhage; Humans; Hydrazines; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin; Treatment Outcome | 2015 |
Interaction of novel platelet-increasing agent eltrombopag with rosuvastatin via breast cancer resistance protein in humans.
Topics: Adult; Animals; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzoates; Biological Transport; Blood Platelets; Computer Simulation; Dogs; Drug Interactions; Fluorobenzenes; HEK293 Cells; Hepatocytes; Humans; Hydrazines; Intestine, Small; Liver-Specific Organic Anion Transporter 1; LLC-PK1 Cells; Madin Darby Canine Kidney Cells; Male; Mice; Models, Biological; Neoplasm Proteins; Organic Anion Transporters; Pyrazoles; Pyrimidines; Receptors, Thrombopoietin; Rosuvastatin Calcium; Sulfonamides; Swine | 2014 |
Sustained response after discontinuation of short-and medium-term treatment with eltrombopag in patients with immune thrombocytopenia.
Topics: Adult; Aged; Benzoates; Female; Humans; Hydrazines; Male; Middle Aged; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin; Treatment Outcome | 2015 |
Effects of thrombopoietin receptor agonists on procoagulant state in patients with immune thrombocytopenia.
Topics: Adult; Aged; Apoptosis; Autoantibodies; Benzoates; Blood Coagulation; Blood Platelets; Cell-Derived Microparticles; Female; Humans; Hydrazines; Male; Middle Aged; Plasma; Platelet Activation; Prospective Studies; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thrombopoietin | 2014 |
Eltrombopag therapy in newly diagnosed steroid non-responsive ITP patients.
Topics: Adolescent; Adult; Benzoates; Drug Resistance; Female; Humans; Hydrazines; Male; Middle Aged; Platelet Count; Prospective Studies; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin; Steroids; Time Factors; Treatment Outcome; Young Adult | 2014 |
Use of eltrombopag for the treatment of thrombocytopenia in hypoplastic myelodysplastic syndrome.
Topics: Aged, 80 and over; Benzoates; Bone Marrow; Erythrocyte Transfusion; Female; Hemorrhagic Disorders; Humans; Hydrazines; Myelodysplastic Syndromes; Platelet Transfusion; Pyrazoles; Receptors, Thrombopoietin; Thrombocytopenia | 2014 |
Effect of thrombopoietin-receptor agonists on a proliferation-inducing ligand (APRIL) plasma levels in patients with immune thrombocytopaenia.
Topics: Aged; Benzoates; Case-Control Studies; Female; Humans; Hydrazines; Immunoglobulins, Intravenous; Male; Middle Aged; Myelodysplastic Syndromes; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thrombopoietin; Tumor Necrosis Factor Ligand Superfamily Member 13 | 2014 |
Eltrombopag can overcome the anti-megakaryopoietic effects of lenalidomide without increasing proliferation of the malignant myelodysplastic syndrome/acute myelogenous leukemia clone.
Topics: Adult; Aged; Aged, 80 and over; Apoptosis; Benzoates; Cell Line, Tumor; Cell Proliferation; Clonal Evolution; Female; Humans; Hydrazines; Lenalidomide; Leukemia, Myeloid, Acute; Male; Megakaryocyte Progenitor Cells; Middle Aged; Myelodysplastic Syndromes; Pyrazoles; Thalidomide; Thrombopoiesis | 2014 |
Eltrombopag: a stem cell cookie?
Topics: Anemia, Aplastic; Benzoates; Female; Hematopoiesis; Humans; Hydrazines; Male; Pyrazoles | 2014 |
The temporary use of thrombopoietin-receptor agonists may induce a prolonged remission in adult chronic immune thrombocytopenia. Results of a French observational study.
Topics: Adult; Aged; Aged, 80 and over; Benzoates; Drug Therapy, Combination; Female; France; Humans; Hydrazines; Immunologic Factors; Male; Middle Aged; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Splenectomy; Thrombopoietin; Treatment Outcome; Young Adult | 2014 |
Successful platelet count recovery in lupus-associated thrombocytopenia with the thrombopoietin agonist eltrombopag.
Topics: Adult; Benzoates; Female; Humans; Hydrazines; Lupus Erythematosus, Systemic; Platelet Count; Pyrazoles; Receptors, Thrombopoietin; Thrombocytopenia; Treatment Outcome | 2014 |
[Effectiveness of perioperative administration of eltrombopag in a patient with idiopathic thrombocytopenic purpura undergoing cardiovascular surgery].
Topics: Aged; Aortic Aneurysm; Aortic Dissection; Benzoates; Coronary Artery Bypass; Coronary Disease; Humans; Hydrazines; Male; Perioperative Period; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Thrombopoietin | 2014 |
Thrombopoietin receptor agonists in immune thrombocytopenia of less than 6 months duration.
Topics: Aged; Benzoates; Drug Evaluation; Drug Therapy, Combination; Female; Hepatitis C; HIV Infections; Humans; Hydrazines; Immunosuppressive Agents; Male; Middle Aged; Platelet Count; Prednisolone; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thrombopoietin; Time Factors | 2014 |
Thrombopoietic agents for the treatment of persistent and chronic immune thrombocytopenia in children.
Topics: Adolescent; Benzoates; Child; Child, Preschool; Chronic Disease; Female; Humans; Hydrazines; Male; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Recombinant Fusion Proteins; Retrospective Studies; Thrombopoietin; Young Adult | 2014 |
Liquid chromatography-tandem mass spectrometric assay for eltrombopag in 50μL of human plasma: a pharmacokinetic study.
Topics: Benzoates; Biological Assay; Chromatography, Liquid; Drug Stability; Humans; Hydrazines; Plasma; Pyrazoles; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry | 2014 |
Immune thrombocytopenia during childhood: new approaches to classification and management.
Topics: Benzoates; Female; Humans; Hydrazines; Male; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Recombinant Fusion Proteins; Thrombopoietin | 2014 |
Platelet fluctuations during thrombopoietin-receptor agonist treatment: correlation with platelet apoptosis.
Topics: Adult; Apoptosis; Benzoates; Blood Platelets; Female; Humans; Hydrazines; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thrombopoietin; Time Factors | 2015 |
Eltrombopag for resistant immune thrombocytopenia secondary to chronic lymphocytic leukaemia.
Topics: Benzoates; Humans; Hydrazines; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles | 2014 |
Successful treatment of severe thrombocytopenia with the use of thrombopoeitin receptor agonist eltrombopag in a patient with chronic myelomonocytic leukemia.
Topics: Benzoates; Humans; Hydrazines; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Pyrazoles; Receptors, Thrombopoietin; Thrombocytopenia; Treatment Outcome | 2015 |
Effect of thrombopoietin receptor agonists on the apoptotic profile of platelets in patients with chronic immune thrombocytopenia.
Topics: Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; bcl-X Protein; Benzoates; Blood Platelets; Case-Control Studies; Chronic Disease; Gene Expression Regulation; Humans; Hydrazines; Megakaryocytes; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Signal Transduction; Thrombopoietin | 2014 |
Is there a role for low-dose eltrombopag as maintenance therapy in the treatment of immune thrombocytopenia?
Topics: Adult; Aged; Benzoates; Female; Humans; Hydrazines; Male; Middle Aged; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Treatment Outcome | 2015 |
Effectiveness of thrombopoietin-receptor agonists in the treatment of refractory immune thrombocytopenia associated to systemic lupus erythematosus.
Topics: Adult; Aged; Benzoates; Female; Humans; Hydrazines; Lupus Erythematosus, Systemic; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thrombopoietin; Treatment Outcome | 2014 |
Severe thrombocytopenia in a patient with hepatitis C treated with eltrombopag from off-label drug use to on-label drug use: a case report.
Topics: Benzoates; Female; Hepatitis C; Humans; Hydrazines; Middle Aged; Off-Label Use; Pyrazoles; Severity of Illness Index; Thrombocytopenia; Treatment Outcome | 2014 |
Transfusion medicine illustrated: Muddy waters in therapeutic plasma exchange.
Topics: Benzoates; Humans; Hydrazines; Male; Middle Aged; Plasma Exchange; Pyrazoles; Serum; Transfusion Medicine | 2014 |
Are adverse drug reaction patterns different between romiplostim and eltrombopag? 2009-2013 French PharmacoVigilance assessment.
Topics: Aged; Benzoates; Female; France; Gastrointestinal Tract; Humans; Hydrazines; Male; Middle Aged; Pharmacovigilance; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thrombopoietin | 2014 |
Successful treatment of aplastic anaemia associated with HIV infection with eltrombopag: implications for a possible immunomodulatory role.
Topics: Aged; Anemia, Aplastic; Benzoates; HIV Infections; Humans; Hydrazines; Immunologic Factors; Male; Pyrazoles; T-Lymphocyte Subsets; T-Lymphocytes, Regulatory; Th1 Cells; Th17 Cells | 2014 |
Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia.
Topics: Adult; Aged; Benzoates; Blood Platelets; Chronic Disease; Drug Administration Schedule; Drug Monitoring; Erythropoiesis; Female; Follow-Up Studies; Hematinics; Humans; Hydrazines; Male; Middle Aged; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin; Recurrence; Remission Induction; Retrospective Studies; Splenectomy; Treatment Outcome | 2015 |
Eltrombopag as steroid sparing therapy for immune thrombocytopenic purpura in systemic lupus erythematosus.
Topics: Adrenal Cortex Hormones; Adult; Benzoates; Female; Humans; Hydrazines; Lupus Erythematosus, Systemic; Middle Aged; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin; Retrospective Studies; Thrombopoietin | 2015 |
Successful eltrombopag treatment of refractory idiopathic thrombocytopenic purpura associated with Crohn disease.
Topics: Adult; Benzoates; Crohn Disease; Female; Humans; Hydrazines; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Remission Induction | 2015 |
Thrombopoietin receptor agonists protect human cardiac myocytes from injury by activation of cell survival pathways.
Topics: Benzoates; Cardiotonic Agents; Cell Hypoxia; Cell Survival; Cells, Cultured; Dose-Response Relationship, Drug; Humans; Hydrazines; Myocytes, Cardiac; Proto-Oncogene Mas; Pyrazoles; Receptors, Thrombopoietin; Signal Transduction; Thrombopoietin | 2015 |
Modeling and simulation support eltrombopag dosing in thrombocytopenic patients with chronic HCV infection.
Topics: Adult; Aged; Antiviral Agents; Benzoates; Blood Platelets; Case-Control Studies; Computer Simulation; Drug Administration Schedule; Drug Dosage Calculations; Drug Interactions; Female; Hepatitis C, Chronic; Humans; Hydrazines; Interferon alpha-2; Interferon-alpha; Linear Models; Male; Metabolic Clearance Rate; Middle Aged; Models, Biological; Platelet Count; Polyethylene Glycols; Polypharmacy; Pyrazoles; Recombinant Proteins; Thrombocytopenia; Thrombopoiesis; Young Adult | 2015 |
Treatment patterns and clinical outcomes in patients with chronic immune thrombocytopenia (ITP) switched to eltrombopag or romiplostim.
Topics: Benzoates; Chronic Disease; Female; Humans; Hydrazines; Male; Middle Aged; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thrombopoietin; Treatment Outcome | 2015 |
Successful management of refractory immune thrombocytopenia associated with massive alveolar hemorrhage.
Topics: Adult; Benzoates; Factor VIIa; Hemorrhage; Humans; Hydrazines; Immunosuppressive Agents; Male; Platelet Count; Prednisone; Pulmonary Alveoli; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Radiography, Thoracic; Skull; Tomography, X-Ray Computed; Vincristine | 2015 |
Are risk evaluation and mitigation strategies associated with less off-label use of medications? The case of immune thrombocytopenia.
Topics: Adolescent; Adult; Aged; Benzoates; Female; Hepatitis C; Humans; Hydrazines; Male; Middle Aged; Off-Label Use; Patient Safety; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Recombinant Fusion Proteins; Retrospective Studies; Risk Assessment; Risk Reduction Behavior; Thrombopoietin; United States; Young Adult | 2015 |
Chronic lymphocytic leukemia-associated refractory immune thrombocytopenia successfully treated with eltrombopag.
Topics: Adrenal Cortex Hormones; Aged; Antibodies, Monoclonal, Murine-Derived; Benzoates; Hemorrhage; Humans; Hydrazines; Immunoglobulins; Immunologic Factors; Leukemia, Lymphocytic, Chronic, B-Cell; Lung Diseases; Male; Platelet Count; Platelet Transfusion; Pyrazoles; Rituximab; Thrombocytopenia | 2015 |
[Development of chronic myelogenous leukemia during treatment with TPO receptor agonist for ITP].
Topics: Aged; Benzoates; Biopsy; Bone Marrow; Fatal Outcome; Humans; Hydrazines; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin | 2014 |
The non-peptide thrombopoietin receptor agonist eltrombopag stimulates megakaryopoiesis in bone marrow cells from patients with relapsed multiple myeloma.
Topics: Benzoates; Cell Line, Tumor; Hematopoiesis; Humans; Hydrazines; In Vitro Techniques; Megakaryocytes; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazoles; Receptors, Thrombopoietin; Thrombocytopenia | 2015 |
Eltrombopag for the Treatment of Immune Thrombocytopenia: The Aegean Region of Turkey Experience.
Topics: Adrenal Cortex Hormones; Adult; Benzoates; Combined Modality Therapy; Drug Evaluation; Drug Resistance; Female; Hemorrhage; Humans; Hydrazines; Male; Middle Aged; Myocardial Infarction; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin; Retrospective Studies; Sinus Thrombosis, Intracranial; Splenectomy; Turkey | 2015 |
Population Pharmacokinetic and Pharmacodynamic Modeling and Effects on Platelet Counts of Different Dosages of Eltrombopag in Chinese Patients With Chronic Primary Immune Thrombocytopenia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Asian People; Benzoates; Blood Platelets; China; Female; Humans; Hydrazines; Male; Middle Aged; Models, Theoretical; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin; Young Adult | 2015 |
Treating chemotherapy-induced thrombocytopenia: is it time for oncologists to use thrombopoietin agonists?
Topics: Benzoates; Humans; Hydrazines; Pyrazoles; Receptors, Fc; Recombinant Fusion Proteins; Thrombocytopenia; Thrombopoietin | 2015 |
Thrombocytopenia: optimizing approaches in cancer patients.
Topics: Benzoates; Humans; Hydrazines; Pyrazoles; Receptors, Fc; Recombinant Fusion Proteins; Thrombocytopenia; Thrombopoietin | 2015 |
Identification of anti-thrombopoietin receptor antibody in prolonged thrombocytopenia after allogeneic hematopoietic stem cell transplantation treated successfully with eltrombopag.
Topics: Allografts; Autoantibodies; Benzoates; Female; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Lymphoma, Follicular; Middle Aged; Pyrazoles; Receptors, Thrombopoietin; Thrombocytopenia | 2015 |
[Experience of off-label use of Eltrombopag in the treatment of thrombocytopenia associated with solid tumors].
Topics: Aged; Antineoplastic Agents; Benzoates; Female; Humans; Hydrazines; Male; Middle Aged; Neoplasms; Off-Label Use; Pyrazoles; Retrospective Studies; Thrombocytopenia | 2015 |
Successful switching from eltrombopag to romiplostim in a pediatric patient with refractory chronic ITP.
Topics: Benzoates; Child; Female; Humans; Hydrazines; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thrombopoietin; Treatment Outcome | 2015 |
Economic assessment of eltrombopag in the treatment of thrombocytopenia.
Topics: Antiviral Agents; Benzoates; Cost-Benefit Analysis; Disease Progression; Hepatitis C, Chronic; Humans; Hydrazines; Markov Chains; Pyrazoles; Quality-Adjusted Life Years; Thrombocytopenia | 2015 |
Efficacy and safety of eltrombopag in treatment-refractory primary immune thrombocytopenia: a retrospective study.
Topics: Adult; Benzoates; Female; Humans; Hydrazines; Male; Middle Aged; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Retrospective Studies; Treatment Outcome | 2016 |
Signal for Thrombosis with Eltrombopag and Romiplostim: A Disproportionality Analysis of Spontaneous Reports Within VigiBase®.
Topics: Adverse Drug Reaction Reporting Systems; Aging; Benzoates; Humans; Hydrazines; Myocardial Infarction; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Risk Factors; Stroke; Thrombopoietin; Thrombosis | 2015 |
The Eltrombopag antitumor effect on hepatocellular carcinoma.
Topics: Apoptosis; Benzoates; Carcinoma, Hepatocellular; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Drug Synergism; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Hydrazines; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyrazoles; Receptors, Thrombopoietin; Sorafenib | 2015 |
Eltrombopag (Revolade ) and thrombocytopenia in patients with hepatitis C. Hepatotoxic drug; more harms than benefits.
Topics: Antiviral Agents; Benzoates; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Drug Interactions; Drug Therapy, Combination; Hepatitis C; Humans; Hydrazines; Pyrazoles; Receptors, Thrombopoietin; Thrombocytopenia | 2015 |
Is there still a place for "old therapies" in the management of immune thrombocytopenia?
Topics: Benzoates; Danazol; Dapsone; Humans; Hydrazines; Hydroxychloroquine; Immunoglobulins, Intravenous; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Recombinant Fusion Proteins; Rituximab; Thrombopoietin; Vinca Alkaloids | 2016 |
Eltrombopag enhances platelet adhesion by upregulating the expression of glycoprotein VI in patients with chronic immune thrombocytopenic purpura.
Topics: Adult; Aged; Benzoates; Blood Platelets; Cell Adhesion; Chronic Disease; Female; Humans; Hydrazines; Male; Middle Aged; Platelet Membrane Glycoproteins; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Up-Regulation; Young Adult | 2015 |
Eltrombopag interference in routine chemistry testing.
Topics: Anemia, Aplastic; Artifacts; Benzoates; Blood Chemical Analysis; Cholesterol; Female; Humans; Hydrazines; Middle Aged; Phosphates; Pyrazoles; Thrombocytopenia; Triglycerides | 2016 |
Successful Use of Eltrombopag in a Child With Hurler Syndrome After Haploidentical Hematopoietic Stem Cell Transplantation.
Topics: Benzoates; Child, Preschool; Cytomegalovirus Infections; Gram-Negative Bacterial Infections; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Male; Mucopolysaccharidosis I; Pyrazoles; Sepsis; Stenotrophomonas maltophilia; Thrombocytopenia | 2016 |
Age and Bone Marrow Cellularity are Associated with Response to Eltrombopag in Japanese Adult Immune Thrombocytopenia Patients: A Retrospective Single-Center Study.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Asian People; Benzoates; Bone Marrow Cells; Female; Hematopoietic Stem Cells; Humans; Hydrazines; Male; Middle Aged; Pluripotent Stem Cells; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Retrospective Studies; Treatment Outcome; Young Adult | 2015 |
Supportive Care and Newer Therapies in Aplastic Anaemia.
Topics: Anemia, Aplastic; Benzoates; Blood Transfusion; Hematologic Agents; Hematopoietic Stem Cell Transplantation; Hemorrhage; Humans; Hydrazines; Immunosuppression Therapy; Opportunistic Infections; Prognosis; Pyrazoles; Secondary Prevention | 2015 |
Eltrombopag Induced Thrombosis: A Case with Acute Myocardial Infarction.
Topics: Benzoates; Humans; Hydrazines; Male; Middle Aged; Myocardial Infarction; Pyrazoles; Receptors, Thrombopoietin; Thrombosis | 2016 |
Guidelines for the diagnosis and management of adult aplastic anaemia.
Topics: Aged; Anemia, Aplastic; Benzoates; Blood Component Transfusion; Female; Hematopoietic Stem Cell Transplantation; Hemoglobinuria, Paroxysmal; Humans; Hydrazines; Immunosuppressive Agents; Opportunistic Infections; Pregnancy; Pregnancy Complications, Hematologic; Pyrazoles; Severity of Illness Index | 2016 |
The use of thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): a "real life" retrospective multicenter experience of the Rete Ematologica Pugliese (REP).
Topics: Aged; Benzoates; Cohort Studies; Female; Hospitals; Humans; Hydrazines; Italy; Male; Middle Aged; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Retrospective Studies; Thrombopoietin | 2016 |
Eltrombopag safety and efficacy for primary chronic immune thrombocytopenia in clinical practice.
Topics: Aged; Benzoates; Chronic Disease; Female; Humans; Hydrazines; Immunosuppressive Agents; Male; Middle Aged; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Retreatment; Retrospective Studies; Spain; Treatment Outcome | 2016 |
Eltrombopag: How secure in triple therapy of HCV?
Topics: Benzoates; Female; Hepatitis C, Chronic; Humans; Hydrazines; Middle Aged; Pyrazoles; Thrombocytopenia | 2015 |
Eltrombopag for Treatment of Thrombocytopenia after Allogeneic Hematopoietic Cell Transplantation.
Topics: Adult; Allografts; Benzoates; Blood Platelets; Female; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Male; Megakaryocytes; Middle Aged; Platelet Count; Pyrazoles; Recovery of Function; Retrospective Studies; Thrombocytopenia | 2016 |
A Challenging Case of Splenomegaly and Refractory Thrombocytopenia.
Topics: Benzoates; Biomarkers, Tumor; Biopsy; Hemangiosarcoma; Humans; Hydrazines; Immunohistochemistry; Male; Middle Aged; Pyrazoles; Splenectomy; Splenic Neoplasms; Splenomegaly; Thrombocytopenia; Tomography, X-Ray Computed; Treatment Outcome | 2016 |
Thrombopoietin receptor agonists for preparing adult patients with immune thrombocytopenia to splenectomy: results of a retrospective, observational GIMEMA study.
Topics: Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Benzoates; Combined Modality Therapy; Drug Resistance; Female; Humans; Hydrazines; Immunoglobulins, Intravenous; Italy; Male; Middle Aged; Platelet Count; Portal Vein; Postoperative Complications; Premedication; Preoperative Care; Pulmonary Embolism; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Retrospective Studies; Salvage Therapy; Splenectomy; Thrombophilia; Thrombopoiesis; Thrombopoietin; Venous Thrombosis; Young Adult | 2016 |
Spontaneous regression of adult T cell leukemia/lymphoma following development of immune thrombocytopenia.
Topics: Adrenal Cortex Hormones; Allografts; Antineoplastic Combined Chemotherapy Protocols; Benzoates; Carboplatin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Leukemia-Lymphoma, Adult T-Cell; Middle Aged; Nitrosourea Compounds; Prednisolone; Prednisone; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Remission, Spontaneous; Vincristine; Vindesine | 2016 |
Health-related quality of life in thrombocytopenic patients with chronic hepatitis C with or without cirrhosis in the ENABLE-1 and ENABLE-2 studies.
Topics: Adult; Aged; Antiviral Agents; Benzoates; Female; Hepatitis C, Chronic; Humans; Hydrazines; Interferons; Liver Cirrhosis; Male; Middle Aged; Pyrazoles; Quality of Life; Surveys and Questionnaires; Thrombocytopenia; United States | 2016 |
Use of Thrombopoietin-Receptor Agonist in CVID-Associated Immune Thrombocytopenia.
Topics: Adult; Benzoates; Common Variable Immunodeficiency; Female; Humans; Hydrazines; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin | 2016 |
Immune Thrombocytopenia Resolved by Eltrombopag in a Carrier of Glucose-6-Phosphate Dehydrogenase Deficiency.
Topics: Benzoates; Blood Platelets; Elective Surgical Procedures; Female; Glycogen Storage Disease Type I; Hemolysis; Heterozygote; Humans; Hydrazines; Middle Aged; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Splenectomy | 2016 |
The thrombopoietin mimetics eltrombopag and romiplostim in the treatment of refractory aplastic anaemia.
Topics: Adult; Aged; Anemia, Aplastic; Benzoates; Female; Humans; Hydrazines; Male; Middle Aged; Pyrazoles; Receptors, Fc; Recombinant Fusion Proteins; Thrombopoietin; Young Adult | 2017 |
Eltrombopag: Investigation of Previously Reported Serum Discoloration and Negative Interference on a Total Bilirubin Diazo Method.
Topics: Adult; Azo Compounds; Benzoates; Bilirubin; Color; Coloring Agents; Diagnosis, Differential; Hematinics; Humans; Hydrazines; Hyperbilirubinemia; Leukemia, Myeloid, Acute; Osmolar Concentration; Pyrazoles; Receptors, Thrombopoietin; Reproducibility of Results; Serum; Spectrophotometry; Thrombocytopenia | 2016 |
Thrombopoietin Receptor Agonist Use in Children: Data From the Pediatric ITP Consortium of North America ICON2 Study.
Topics: Adolescent; Benzoates; Child; Female; Humans; Hydrazines; Male; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Retrospective Studies; Thrombopoietin | 2016 |
Development of myelofibrosis during eltrombopag treatment in a patient with immune thrombocytopenia.
Topics: Aged; Benzoates; Biopsy; Humans; Hydrazines; Male; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin; Treatment Outcome | 2016 |
Successful use of eltrombopag for surgical preparation in a patient with ANKRD26-related thrombocytopenia.
Topics: Aged; Benzoates; Humans; Hydrazines; Intercellular Signaling Peptides and Proteins; Male; Mutation; Nuclear Proteins; Preoperative Care; Pyrazoles; Thrombocytopenia; Treatment Outcome | 2016 |
Revealing eltrombopag's promotion of human megakaryopoiesis through AKT/ERK-dependent pathway activation.
Topics: Benzoates; Biomarkers; Blood Platelets; Cell Differentiation; Extracellular Signal-Regulated MAP Kinases; Hematopoietic Stem Cells; Humans; Hydrazines; MAP Kinase Signaling System; Megakaryocytes; Phenotype; Proto-Oncogene Proteins c-akt; Pyrazoles; Receptors, Thrombopoietin; Signal Transduction; Thrombopoiesis | 2016 |
Disease characteristics and prognosis of myelodysplastic syndrome presenting with isolated thrombocytopenia.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Benzoates; Decitabine; Female; Humans; Hydrazines; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Retrospective Studies; Risk; Thrombocytopenia; Thrombopoietin | 2017 |
Morbilliform eruption related to eltrombopag: emerging data on the cutaneous toxicity of thrombopoietin receptor agonists.
Topics: Adult; Anemia, Aplastic; Back; Benzoates; Drug Eruptions; Humans; Hydrazines; Male; Pyrazoles; Receptors, Thrombopoietin; Thrombocytopenia | 2016 |
Cytomegalovirus-associated thrombocytopenia treated with thrombopoietin receptor agonist.
Topics: Antiviral Agents; Benzoates; Cytomegalovirus; Cytomegalovirus Infections; Female; Humans; Hydrazines; Middle Aged; Prednisone; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin | 2016 |
Management of Primary Immune Thrombocytopenia With Eltrombopag in a Patient With Recent Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Benzoates; Electrocardiography; Humans; Hydrazines; Male; Middle Aged; Percutaneous Coronary Intervention; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Splenectomy | 2017 |
Eltrombopag (thrombopoietin-receptor agonist) and plasmapheresis as rescue therapy of acute post-renal transplant immune thrombocytopenia in a child with Schimke immuno-osseous dysplasia-case report.
Topics: Arteriosclerosis; Benzoates; Child; DNA Helicases; Humans; Hydrazines; Immunologic Deficiency Syndromes; Kidney Transplantation; Male; Mutation; Nephrotic Syndrome; Osteochondrodysplasias; Plasmapheresis; Platelet Count; Primary Immunodeficiency Diseases; Pulmonary Embolism; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Thrombopoietin; Time Factors | 2016 |
Eltrombopag: liver toxicity, kidney injury or assay interference?
Topics: Benzoates; Bilirubin; Chemical and Drug Induced Liver Injury; Creatinine; Drug Monitoring; Female; Humans; Hydrazines; Kidney; Kidney Function Tests; Liver Function Tests; Myelodysplastic Syndromes; Pyrazoles | 2016 |
[Thrombosis during thrombopoietin receptor agonist treatment for immune thrombocytopenia. A French multicentric observational study].
Topics: Adult; Aged; Aged, 80 and over; Benzoates; Female; France; Humans; Hydrazines; Male; Middle Aged; Pharmacovigilance; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Retrospective Studies; Thrombopoietin; Thrombosis; Young Adult | 2017 |
Use of a thrombopoietin receptor agonist in von Willebrand disease type 2B (p.V1316M) with severe thrombocytopenia and intracranial hemorrhage.
Topics: Amino Acid Substitution; Benzoates; Female; Humans; Hydrazines; Intracranial Hemorrhages; Middle Aged; Mutation, Missense; Pyrazoles; Receptors, Thrombopoietin; Thrombocytopenia; von Willebrand Disease, Type 2; von Willebrand Factor | 2017 |
Eltrombopag, a potent stimulator of megakaryopoiesis.
Topics: Benzoates; Humans; Hydrazines; Pyrazoles; Thrombopoiesis | 2016 |
Acute Myocardial Infarction Due to Eltrombopag Therapy in a Patient with Immune Thrombocytopenic Purpura.
Topics: Acute Disease; Benzoates; Humans; Hydrazines; Male; Middle Aged; Myocardial Infarction; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles | 2017 |
Sequential treatment with thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): experience in our center.
Topics: Benzoates; Female; Humans; Hydrazines; Male; Middle Aged; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thrombopoietin; Treatment Outcome | 2017 |
Eltrombopag, a thrombopoietin mimetic, crosses the blood-brain barrier and impairs iron-dependent hippocampal neuron dendrite development.
Topics: Anemia, Iron-Deficiency; Animals; Benzoates; Biological Transport; Biomimetics; Blood-Brain Barrier; Cattle; Chelating Agents; Deferoxamine; Dendrites; Green Fluorescent Proteins; Hippocampus; Hydrazines; Iron; Mice; Microcirculation; Neuroglia; Neurons; Pyrazoles; Thrombocytopenia; Thrombopoietin | 2017 |
Hepatitis B Leading to Megaloblastic Anemia and Catastrophic Peripheral Thrombocytopenia.
Topics: Adult; Anemia, Megaloblastic; Benzoates; Folic Acid; Folic Acid Deficiency; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B virus; Humans; Hydrazines; Male; Platelet Count; Polymerase Chain Reaction; Pyrazoles; Tenofovir; Thrombocytopenia; Vitamin B 12; Vitamin B 12 Deficiency; Vitamin B Complex | 2016 |
Therapy induced iron deficiency in children treated with eltrombopag for immune thrombocytopenia.
Topics: Adolescent; Anemia, Iron-Deficiency; Benzoates; Drug Therapy, Combination; Female; Ferritins; Humans; Hydrazines; Iron; Iron Chelating Agents; Male; Molecular Structure; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Recombinant Fusion Proteins; Thrombopoietin; Young Adult | 2017 |
Use of eltrombopag for treatment of myelodysplastic syndromes.
Topics: Benzoates; Dose-Response Relationship, Drug; Humans; Hydrazines; Myelodysplastic Syndromes; Pyrazoles; Treatment Outcome | 2017 |
Thrombopoetin receptor agonist therapy in thrombocytopenia: ITP and beyond.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzoates; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Hydrazines; Male; Middle Aged; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin; Retrospective Studies; Thrombocytopenia; Treatment Outcome; Young Adult | 2017 |
Use of eltrombopag for secondary immune thrombocytopenia in clinical practice.
Topics: Adult; Aged; Autoimmune Diseases; Benzoates; Drug Administration Schedule; Female; Humans; Hydrazines; Lymphoproliferative Disorders; Male; Middle Aged; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin; Retrospective Studies; Virus Diseases | 2017 |
U.S. Food and Drug Administration approval summary: Eltrombopag for the treatment of pediatric patients with chronic immune (idiopathic) thrombocytopenia.
Topics: Adolescent; Benzoates; Child; Child, Preschool; Chronic Disease; Drug Approval; Female; Humans; Hydrazines; Infant; Male; Pyrazoles; Thrombocythemia, Essential; United States; United States Food and Drug Administration | 2017 |
Eltrombopag use in a patient with Wiskott-Aldrich syndrome.
Topics: Benzoates; Child, Preschool; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Male; Pyrazoles; Wiskott-Aldrich Syndrome | 2017 |
Eltrombopag for secondary failure of platelet recovery post-allogeneic hematopoietic stem cell transplant in children.
Topics: Benzoates; Child; Hematologic Agents; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Male; Pyrazoles; Thrombocytopenia | 2017 |
Primary immune thrombocytopenia in adults: clinical practice versus management guidelines.
Topics: Adrenal Cortex Hormones; Adult; Autoimmune Diseases; Benzoates; Humans; Hydrazines; Immunoglobulins; Immunologic Factors; Practice Guidelines as Topic; Pyrazoles; Receptors, Fc; Recombinant Fusion Proteins; Rituximab; Splenectomy; Thrombocytopenia; Thrombopoietin | 2017 |
Thrombopoietin receptor agonist switch in adult primary immune thrombocytopenia patients: A retrospective collaborative survey involving 4 Spanish centres.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzoates; Drug Substitution; Female; Humans; Hydrazines; Male; Middle Aged; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thrombopoietin; Time Factors; Treatment Outcome; Young Adult | 2017 |
Eltrombopag to Treat Thrombocytopenia During Last Month of Pregnancy in a Woman With MYH9-Related Disease: A Case Report.
Topics: Adult; Benzoates; Female; Hearing Loss, Sensorineural; Humans; Hydrazines; Pregnancy; Pregnancy Complications, Hematologic; Pyrazoles; Receptors, Thrombopoietin; Thrombocytopenia | 2018 |
Eltrombopag: a powerful chelator of cellular or extracellular iron(III) alone or combined with a second chelator.
Topics: Animals; Benzoates; Cell Line, Tumor; Deferoxamine; Extracellular Space; Ferritins; Hepatocytes; Humans; Hydrazines; Insulin; Insulin Secretion; Insulin-Secreting Cells; Iron; Iron Chelating Agents; Myocytes, Cardiac; Pyrazoles; Pyridones; Rats; Reactive Oxygen Species | 2017 |
Comparative treatment-related adverse event cost burden in immune thrombocytopenic purpura.
Topics: Adult; Aged; Benzoates; Female; Humans; Hydrazines; Immunoglobulins, Intravenous; Immunologic Factors; Insurance Claim Review; Male; Middle Aged; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Recombinant Fusion Proteins; Retrospective Studies; Rho(D) Immune Globulin; Rituximab; Thrombopoietin | 2017 |
Successful eltrombopag treatment of severe refractory thrombocytopenia in chronic myelomonocytic leukemia: Two cases reports: A CARE-compliant article.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Benzoates; Decitabine; Dioxygenases; DNA-Binding Proteins; Drug Monitoring; Female; Hematologic Agents; Humans; Hydrazines; Leukemia, Myelomonocytic, Chronic; Middle Aged; Mutation; Nuclear Proteins; Platelet Count; Proto-Oncogene Proteins; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Ribonucleoproteins; Serine-Arginine Splicing Factors; Thrombocytopenia; Thrombopoietin; Treatment Outcome | 2017 |
A sticky situation: myocardial infarction in a young woman with immune thrombocytopenia on eltrombopag and a history of mediastinal radiation.
Topics: Benzoates; Female; Humans; Hydrazines; Mediastinal Neoplasms; Myocardial Infarction; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin; Risk Factors; Splenectomy; Young Adult | 2018 |
Nationwide survey on the use of eltrombopag in patients with severe aplastic anemia: a report on behalf of the French Reference Center for Aplastic Anemia.
Topics: Aged; Anemia, Aplastic; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Benzoates; Female; France; Humans; Hydrazines; Male; Middle Aged; Pyrazoles; Retrospective Studies; Salvage Therapy; Surveys and Questionnaires; Treatment Outcome | 2018 |
[Novelties in the treatment of pediatric immune thrombocytopenia - 2017].
Topics: Adolescent; Benzoates; Child; Child, Preschool; Drug Resistance; Humans; Hydrazines; Immunoglobulins, Intravenous; Infant; Infant, Newborn; Medication Therapy Management; Pediatrics; Prognosis; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Splenectomy; Steroids | 2017 |
A low birth weight infant with no malformations delivered by a primary immune thrombocytopenia patient treated with eltrombopag.
Topics: Adult; Benzoates; Cesarean Section; Female; Humans; Hydrazines; Infant, Low Birth Weight; Platelet Count; Pregnancy; Pregnancy Complications, Hematologic; Pregnancy Outcome; Pyrazoles; Receptors, Thrombopoietin; Thrombocytopenia; Treatment Outcome | 2018 |
Eltrombopag reduces clinically relevant thrombocytopenic events in higher risk MDS and AML.
Topics: Benzoates; Clinical Trials as Topic; Humans; Hydrazines; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Pyrazoles; Risk; Thrombocytopenia | 2018 |
Thrombopoietin receptor agonists in patients with persistent or chronic immune thrombocytopenia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzoates; Blood Platelets; Child; Child, Preschool; Chronic Disease; Female; Gene Expression Regulation; Humans; Hydrazines; Male; Middle Aged; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Retrospective Studies; Splenectomy; Thrombopoietin; Time-to-Treatment; Treatment Outcome | 2018 |
Eltrombopag, low-dose rituximab, and dexamethasone combination as frontline treatment of newly diagnosed immune thrombocytopaenia.
Topics: Adolescent; Adult; Benzoates; Dexamethasone; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hydrazines; Male; Middle Aged; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Rituximab | 2019 |
Eltrombopag with i.v. immunoglobulin for safe splenectomy in refractory immune thrombocytopenia.
Topics: Benzoates; Child, Preschool; Combined Modality Therapy; Drug Therapy, Combination; Female; Humans; Hydrazines; Immunoglobulins, Intravenous; Immunologic Factors; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Splenectomy | 2018 |
Thrombosis of a Left Atrial Appendage Occluder After Treatment With Thrombopoietin Receptor Agonists.
Topics: Aged; Atrial Appendage; Atrial Fibrillation; Benzoates; Cardiac Catheterization; Device Removal; Echocardiography, Three-Dimensional; Hematologic Agents; Humans; Hydrazines; Male; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin; Risk Factors; Thrombectomy; Thrombosis; Treatment Outcome | 2018 |
Eltrombopag in the management of aplastic anaemia: real-world experience in a non-trial setting.
Topics: Adult; Anemia, Aplastic; Benzoates; Biomarkers; Combined Modality Therapy; Disease Management; Drug Resistance; Female; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Male; Pyrazoles; Recurrence; Thrombopoietin; Transplantation, Homologous; Treatment Outcome; Young Adult | 2018 |
iPSC modeling of severe aplastic anemia reveals impaired differentiation and telomere shortening in blood progenitors.
Topics: Anemia, Aplastic; Benzoates; Case-Control Studies; Cell Differentiation; Cell Line; Cell Proliferation; Colony-Forming Units Assay; Fibroblasts; Hematopoietic Stem Cells; Humans; Hydrazines; Induced Pluripotent Stem Cells; Models, Biological; Pyrazoles; Telomerase; Telomere; Telomere Shortening | 2018 |
Modeling and Simulation Support Eltrombopag Dosing in Pediatric Patients With Immune Thrombocytopenia.
Topics: Adolescent; Age Factors; Benzoates; Blood Platelets; Child; Child, Preschool; Computer Simulation; Drug Dosage Calculations; Female; Hematinics; Humans; Hydrazines; Infant; Male; Models, Biological; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Treatment Outcome | 2018 |
Eltrombopag as initial monotherapy for severe aplastic anemia-a case report.
Topics: Anemia, Aplastic; Benzoates; Female; Humans; Hydrazines; Middle Aged; Pyrazoles; Severity of Illness Index | 2018 |
Eltrombopag mobilizes iron in patients with aplastic anemia.
Topics: Anemia, Aplastic; Benzoates; Biomarkers; Humans; Hydrazines; Iron; Pyrazoles; Treatment Outcome | 2018 |
Trilineage Hematopoiesis Induced by Low-dose Eltrombopag in a Patient With Fanconi Anemia can be Used as a Bridge to Hematopoietic Stem Cell Transplant.
Topics: Benzoates; Drug Therapy, Combination; Fanconi Anemia; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Oxymetholone; Pancytopenia; Pyrazoles | 2019 |
Safety and efficacy of thrombopoeitin mimetics for refractory immune thrombocytopenia purpura in patients with systemic lupus erythematosus or antiphospholipid syndrome: a case series.
Topics: Antiphospholipid Syndrome; Autoimmunity; Benzoates; Blood Platelets; Female; Hemorrhage; Humans; Hydrazines; Lupus Erythematosus, Systemic; Middle Aged; Molecular Mimicry; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombin; Recombinant Fusion Proteins; Retrospective Studies; Risk Factors; Thrombopoietin; Treatment Outcome; Virginia; Young Adult | 2018 |
Eltrombopag-Induced Acute Liver Failure in a Pediatric Patient: A Pharmacokinetic and Pharmacogenetic Analysis.
Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; Benzoates; Child, Preschool; Cytochrome P-450 CYP2C8; Drug Monitoring; Female; Glucuronosyltransferase; Humans; Hydrazines; Liver Failure, Acute; Neoplasm Proteins; Pharmacogenomic Testing; Pyrazoles; Receptors, Thrombopoietin | 2018 |
Eltrombopag for the Treatment of Refractory Pure RBC Aplasia after Major ABO Incompatible Hematopoietic Stem Cell Transplantation.
Topics: ABO Blood-Group System; Allografts; Benzoates; Blood Group Incompatibility; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Male; Pyrazoles; Red-Cell Aplasia, Pure; Treatment Outcome | 2018 |
Treatment characteristics, efficacy and safety of thrombopoietin analogues in routine management of primary immune thrombocytopenia.
Topics: Adult; Aged; Benzoates; Disease Management; Female; Humans; Hydrazines; Male; Middle Aged; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Retrospective Studies; Thrombopoietin; Treatment Outcome | 2018 |
Risk of thrombosis with anti-phospholipid syndrome in systemic lupus erythematosus treated with thrombopoietin-receptor agonists.
Topics: Adolescent; Adult; Aged; Antiphospholipid Syndrome; Benzoates; Female; Follow-Up Studies; France; Humans; Hydrazines; Incidence; Lupus Erythematosus, Systemic; Male; Middle Aged; Prognosis; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Retrospective Studies; Thrombopoietin; Thrombosis; Young Adult | 2018 |
[Safety and efficacy of the use of eltrombopag in a case of severe acquired bone marrow aplasia].
Topics: Anemia, Aplastic; Benzoates; Child; Female; Humans; Hydrazines; Pyrazoles; Receptors, Thrombopoietin; Severity of Illness Index | 2019 |
A decision framework for treating chronic immune thrombocytopenia with thrombopoietin receptor agonists.
Topics: Benzoates; Chronic Disease; Clinical Decision-Making; Cost-Benefit Analysis; Costs and Cost Analysis; Decision Support Techniques; Drug Costs; Hemorrhage; Humans; Hydrazines; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thrombopoietin; United States | 2018 |
Efficacy and tolerability of old and new drugs used in the treatment of immune thrombocytopenia: Results from a long-term observation in clinical practice.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Azathioprine; Benzoates; Child; Child, Preschool; Combined Modality Therapy; Cyclosporine; Dapsone; Dexamethasone; Drug Resistance; Drug Therapy, Combination; Female; Humans; Hydrazines; Immunoglobulins, Intravenous; Immunosuppressive Agents; Male; Middle Aged; Prednisolone; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Recombinant Fusion Proteins; Remission Induction; Retrospective Studies; Rho(D) Immune Globulin; Rituximab; Splenectomy; Thrombopoietin; Treatment Outcome; Young Adult | 2018 |
Immune Thrombocytopenia in a Child With Refractory Langerhans Cell Histiocytosis Following Cladribine Containing Therapy.
Topics: Benzoates; Cladribine; Dexamethasone; Female; Histiocytosis, Langerhans-Cell; Humans; Hydrazines; Immunoglobulins, Intravenous; Infant; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles | 2019 |
Upfront eltrombopag monotherapy induces stable hematologic remission in pediatric patients with nonsevere idiopathic aplastic anemia.
Topics: Anemia, Aplastic; Benzoates; Child; Female; Humans; Hydrazines; Male; Pyrazoles; Remission Induction | 2018 |
Therapeutic Doses of Eltrombopag do not Inhibit Hepatic BCRP in Healthy Volunteers: Intravenous Ceftriaxone as a Model.
Topics: Administration, Intravenous; Administration, Oral; Adult; ATP Binding Cassette Transporter, Subfamily G, Member 2; Benzoates; Ceftriaxone; Female; Healthy Volunteers; Hepatocytes; Humans; Hydrazines; Intestines; Liver; Male; Multidrug Resistance-Associated Protein 2; Neoplasm Proteins; Pyrazoles; Young Adult | 2018 |
Thrombopoietin mimetics for systemic lupus erythematosus with antiphospholipid antibodies should be discussed separately.
Topics: Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Benzoates; Humans; Hydrazines; Lupus Erythematosus, Systemic; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Recombinant Fusion Proteins; Thrombopoietin; Venous Thromboembolism | 2018 |
Relative potency of the thrombopoietin receptor agonists eltrombopag, avatrombopag and romiplostim in a patient with chronic immune thrombocytopenia.
Topics: Benzoates; Dose-Response Relationship, Drug; Female; Hematologic Agents; Humans; Hydrazines; Middle Aged; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thiazoles; Thiophenes; Thrombopoietin; Treatment Outcome | 2018 |
Severe immune thrombocytopenia in pregnancy treated with Eltrombopag - A case report.
Topics: Adult; Benzoates; Female; Humans; Hydrazines; Live Birth; Pregnancy; Pregnancy Complications, Hematologic; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin | 2018 |
Cost per response analysis of strategies for chronic immune thrombocytopenia.
Topics: Adult; Bayes Theorem; Benzoates; Cost-Benefit Analysis; Decision Trees; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Costs; Female; Humans; Hydrazines; Male; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Recombinant Fusion Proteins; Thrombopoietin; Treatment Failure; Treatment Outcome | 2018 |
An alternative intermittent eltrombopag dosing protocol for the treatment of chronic immune thrombocytopenia.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Benzoates; Drug Administration Schedule; Female; Hemorrhage; Humans; Hydrazines; Male; Middle Aged; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Quality of Life; Receptors, Thrombopoietin; Retrospective Studies; Treatment Outcome; Young Adult | 2018 |
Are eltrombopag plasma and skin hyperpigmentation related? The eyes have it.
Topics: Adult; Anemia, Aplastic; Benzoates; Color; Female; Gene Expression; Humans; Hydrazines; Hyperpigmentation; Pyrazoles; Receptors, Thrombopoietin; Severity of Illness Index | 2019 |
Eltrombopag for Delayed Platelet Recovery and Secondary Thrombocytopenia Following Allogeneic Stem Cell Transplantation in Children.
Topics: Adolescent; Allografts; Anemia, Aplastic; Benzoates; Child; Gaucher Disease; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Male; Platelet Count; Pyrazoles; Receptors, Fc; Recombinant Fusion Proteins; Recovery of Function; Thrombocytopenia; Thrombopoietin | 2019 |
Thrombopoietin level predicts response to treatment with eltrombopag and romiplostim in immune thrombocytopenia.
Topics: Benzoates; Female; Humans; Hydrazines; Logistic Models; Male; Predictive Value of Tests; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Retrospective Studies; Thrombopoietin | 2018 |
Thrombopoietin receptor-independent stimulation of hematopoietic stem cells by eltrombopag.
Topics: Animals; Benzoates; Cell Differentiation; Cell Line; Cell Lineage; Cell Self Renewal; Hematopoietic Stem Cells; Homeostasis; Hydrazines; Iron; Iron Chelating Agents; Mice; Pyrazoles; Receptors, Thrombopoietin; Signal Transduction | 2018 |
Aptamer-based proteomics of serum and plasma in acquired aplastic anemia.
Topics: Adolescent; Adult; Aged; Anemia, Aplastic; Aptamers, Nucleotide; Benzoates; Biomarkers; Blood Proteins; Child; Child, Preschool; Female; Humans; Hydrazines; Immunosuppressive Agents; Male; Middle Aged; Molecular Targeted Therapy; Proteomics; Pyrazoles; Receptors, Thrombopoietin; Young Adult | 2018 |
Eltrombopag interferes with the measurement of plasma total bilirubin in pediatric patients in an automated colorimetric method.
Topics: Automation; Benzoates; Bilirubin; Child; Clinical Chemistry Tests; Colorimetry; Humans; Hydrazines; Limit of Detection; Pyrazoles; Reagent Kits, Diagnostic | 2019 |
Iron chelating properties of Eltrombopag: Investigating its role in thalassemia-induced osteoporosis.
Topics: Adult; Benzoates; Blood Transfusion; Bone and Bones; Cell Differentiation; Deferasirox; Drug Evaluation; Female; Ferritins; Healthy Volunteers; Humans; Hydrazines; Iron; Iron Chelating Agents; Iron Overload; Leukocytes, Mononuclear; Osteoclasts; Osteoporosis; Primary Cell Culture; Pyrazoles; Receptors, Thrombopoietin; Thalassemia; Transfusion Reaction | 2018 |
Health-related quality of life in children with chronic immune thrombocytopenia treated with eltrombopag in the PETIT study.
Topics: Adolescent; Benzoates; Child; Child, Preschool; Female; Humans; Hydrazines; Infant; Male; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Quality of Life; Thrombopoietin; Treatment Outcome | 2019 |
Eltrombopag for post-transplant cytopenias due to poor graft function.
Topics: Adult; Aged; Benzoates; Female; Humans; Hydrazines; Male; Middle Aged; Pyrazoles; Retrospective Studies; Thrombocytopenia | 2019 |
Thrombopoietin Receptor Agonists in the Treatment of Chronic Resistant Primary Immune Thrombocytopenia: Efficacy and Safety Data in Real Clinical Practice.
Topics: Benzoates; Blood Platelets; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Hydrazines; Male; Middle Aged; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thrombopoietin; Treatment Outcome | 2018 |
Eltrombopag use in higher risk myeloid cancers: fitting a square "pag" into a round hole?
Topics: Benzoates; Clinical Trials as Topic; Humans; Hydrazines; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Pyrazoles; Risk | 2019 |
[Hereditary thrombocytopenia associated with a mutation in the MYH-9 gene. Report of one case].
Topics: Benzoates; Biopsy; Female; Genetic Diseases, Inborn; Hearing Loss, Sensorineural; Humans; Hydrazines; Middle Aged; Mutation; Platelet Count; Pyrazoles; Thrombocytopenia | 2018 |
Eltrombopag maintains human hematopoietic stem and progenitor cells under inflammatory conditions mediated by IFN-γ.
Topics: Animals; Benzoates; Cell Survival; Female; Hematopoietic Stem Cells; Heterografts; Humans; Hydrazines; Inflammation; Interferon-gamma; Male; Mice; Mice, Inbred NOD; Mice, SCID; Pyrazoles; Receptors, Thrombopoietin; Signal Transduction; Thrombopoietin | 2019 |
Thrombopoietin receptor agonist switch in children with persistent and chronic severe immune thrombocytopenia: A retrospective analysis in a large tertiary center.
Topics: Adolescent; Benzoates; Child; Child, Preschool; Chronic Disease; Female; Follow-Up Studies; Humans; Hydrazines; Male; Platelet Count; Prognosis; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Retrospective Studies; Severity of Illness Index; Tertiary Care Centers; Thrombopoietin | 2019 |
Eltrombopag induces major non-toxic hypersiderraemia.
Topics: Aged; Allografts; Anemia, Hypochromic; Benzoates; Female; Humans; Hydrazines; Myelodysplastic Syndromes; Pyrazoles; Stem Cell Transplantation | 2019 |
Clinical and morphological predictors of outcome in older aplastic anemia patients treated with eltrombopag.
Topics: Aged; Aged, 80 and over; Anemia, Aplastic; Benzoates; Biomarkers; Biopsy; Bone Marrow; Humans; Hydrazines; Molecular Targeted Therapy; Prognosis; Pyrazoles; Treatment Outcome | 2019 |
Eltrombopag combined with cyclosporine may have an effect on very severe aplastic anemia.
Topics: Anemia, Aplastic; Benzoates; Cyclosporine; Drug Therapy, Combination; Female; Hematopoiesis; Humans; Hydrazines; Immunosuppressive Agents; Middle Aged; Pyrazoles; Uterine Hemorrhage | 2019 |
Use of eltrombopag in aplastic anemia in Europe.
Topics: Adult; Aged; Anemia, Aplastic; Benzoates; Drug Evaluation; Drug Utilization; Europe; Female; Follow-Up Studies; Humans; Hydrazines; Kaplan-Meier Estimate; Male; Middle Aged; Myelodysplastic Syndromes; Proportional Hazards Models; Pyrazoles; Receptors, Thrombopoietin; Retrospective Studies; Young Adult | 2019 |
The oral microbiome of patients undergoing treatment for severe aplastic anemia: a pilot study.
Topics: Adult; Aged; Anemia, Aplastic; Anti-Bacterial Agents; Antilymphocyte Serum; Benzoates; Biodiversity; Cyclosporine; Dental Health Surveys; DNA, Bacterial; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Immunocompromised Host; Immunosuppressive Agents; Male; Microbiota; Middle Aged; Mouth; Pilot Projects; Pyrazoles; Ribotyping; Sequence Analysis, DNA; Smoking; T-Lymphocytes; Tongue; Young Adult | 2019 |
Glucocorticoids promote response to thrombopoietin-receptor agonists in refractory ITP: a case series.
Topics: Adolescent; Adult; Aged; Benzoates; Child, Preschool; Combined Modality Therapy; Drug Synergism; Drug Therapy, Combination; Female; Humans; Hydrazines; Male; Middle Aged; Platelet Count; Prednisone; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Splenectomy; Thrombopoietin | 2019 |
Eltrombopag promotes DNA repair in human hematopoietic stem and progenitor cells.
Topics: Benzoates; Cells, Cultured; DNA Breaks, Double-Stranded; DNA End-Joining Repair; Hematopoietic Stem Cells; Humans; Hydrazines; Pyrazoles; Receptors, Thrombopoietin | 2019 |
Screening of an FDA-Approved Drug Library with a Two-Tier System Identifies an Entry Inhibitor of Severe Fever with Thrombocytopenia Syndrome Virus.
Topics: Antiviral Agents; Benzoates; Bunyaviridae Infections; Drug Approval; Drug Discovery; Drug Repositioning; Hydrazines; Inhibitory Concentration 50; Molecular Docking Simulation; Phlebovirus; Pyrazoles; Small Molecule Libraries; Triclosan; United States; United States Food and Drug Administration; Virus Internalization | 2019 |
Eltrombopag in preparation for surgery in patients with severe MYH9-related thrombocytopenia.
Topics: Benzoates; Blood Loss, Surgical; Female; Humans; Hydrazines; Male; Myosin Heavy Chains; Postoperative Hemorrhage; Pyrazoles; Thrombocytopenia; Treatment Outcome | 2019 |
IFN-γ binds TPO to inhibit hematopoiesis.
Topics: Benzoates; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Pyrazoles | 2019 |
A rare side effect: eltrombopag associated hyperpigmentation.
Topics: Aged; Anemia, Aplastic; Benzoates; Cyclosporine; Drug Therapy, Combination; Female; Humans; Hydrazines; Melanosis; Pyrazoles | 2020 |
Management of acquired aplastic anemia in children : A single center experience.
Topics: Adolescent; Allografts; Anemia, Aplastic; Benzoates; Child; Child, Preschool; Cyclophosphamide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Immunosuppression Therapy; Levamisole; Male; Pyrazoles; Retrospective Studies | 2019 |
Eltrombopag: Efficacy and Safety in Steroid Refractory Lupus-Associated Immune Thrombocytopenia.
Topics: Benzoates; Humans; Hydrazines; Lupus Erythematosus, Systemic; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Steroids | 2020 |
Iron mobilization in a real life cohort of aplastic anemia patients treated with eltrombopag.
Topics: Anemia, Aplastic; Benzoates; Female; Follow-Up Studies; Humans; Hydrazines; Iron; Male; Prospective Studies; Pyrazoles | 2019 |
Eltrombopag: wielding a double-edged sword?
Topics: Anemia, Aplastic; Benzoates; Genomics; Humans; Hydrazines; Pyrazoles | 2019 |
Eltrombopag Therapy in Children With Rare Disorders Associated With Thrombocytopenia.
Topics: Acyl-CoA Dehydrogenase, Long-Chain; Adolescent; Benzoates; Child; Child, Preschool; Congenital Bone Marrow Failure Syndromes; DiGeorge Syndrome; Female; Graft Rejection; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Lipid Metabolism, Inborn Errors; Male; Mitochondrial Diseases; Muscular Diseases; Prognosis; Pyrazoles; Receptors, Thrombopoietin; Thrombocytopenia; Wiskott-Aldrich Syndrome | 2020 |
Thrombopoietin receptor agonists as second-line therapy in splenectomy-eligible persistent immune thrombocytopenia: a case series.
Topics: Adrenal Cortex Hormones; Benzoates; Chronic Disease; Drug Resistance; Female; Humans; Hydrazines; Immunoglobulins, Intravenous; Male; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Splenectomy; Thrombopoietin | 2019 |
Blood transcriptome and clonal T-cell correlates of response and non-response to eltrombopag therapy in a cohort of patients with chronic immune thrombocytopenia.
Topics: Benzoates; Humans; Hydrazines; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; T-Lymphocytes; Transcriptome | 2020 |
Repurposing the thrombopoietin receptor agonist eltrombopag as an anticryptococcal agent.
Topics: Antifungal Agents; Arthrodermataceae; Benzoates; Biofilms; Candida glabrata; Cryptococcus; Cryptococcus gattii; Cryptococcus neoformans; Drug Repositioning; Drug Synergism; Hydrazines; Metabolic Networks and Pathways; Microbial Sensitivity Tests; Pyrazoles; Receptors, Thrombopoietin; Small Molecule Libraries; Tacrolimus | 2020 |
The Successful Sequential Use of Plerixafor and Eltrombopag For Hematopoietic Cell Transplantation in a Child With High-risk Neuroblastoma.
Topics: Anti-HIV Agents; Benzoates; Benzylamines; Child, Preschool; Combined Modality Therapy; Cyclams; Drug Therapy, Combination; Female; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Humans; Hydrazines; Neuroblastoma; Prognosis; Pyrazoles | 2020 |
Thrombopoietin receptor agonists to control immune thrombocytopenia in patients with active lymphoma.
Topics: Adult; Aged; Benzoates; Female; Humans; Hydrazines; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Neoplasm Proteins; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thrombopoietin | 2019 |
Eltrombopag treatment for severe refractory thrombocytopenia caused by pembrolizumab.
Topics: Aged; Antibodies, Monoclonal, Humanized; Benzoates; Carcinoma, Non-Small-Cell Lung; Drug Resistance; Humans; Hydrazines; Lung Neoplasms; Male; Pyrazoles; Severity of Illness Index; Thrombocytopenia; Treatment Outcome | 2019 |
Comprehensive characterization and resolution of discrepant spectrophotometric bilirubin results in patients on eltrombopag therapy.
Topics: Aged; Benzoates; Bilirubin; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Female; Humans; Hydrazines; Pyrazoles; Tandem Mass Spectrometry | 2020 |
Healthcare resource use and direct costs in severe aplastic anemia (SAA) patients before and after treatment with eltrombopag.
Topics: Adult; Age Factors; Aged; Anemia, Aplastic; Antineoplastic Agents; Benzoates; Comorbidity; Female; Health Expenditures; Health Resources; Hospitalization; Humans; Hydrazines; Insurance Claim Review; Male; Middle Aged; Patient Acceptance of Health Care; Pyrazoles; Residence Characteristics; Retrospective Studies; Sex Factors; Socioeconomic Factors | 2020 |
Deciphering predictive factors for choice of thrombopoietin receptor agonist, treatment free responses, and thrombotic events in immune thrombocytopenia.
Topics: Adult; Aged; Aged, 80 and over; Benzoates; Female; Follow-Up Studies; Humans; Hydrazines; Male; Middle Aged; Prognosis; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Retrospective Studies; Survival Rate; Thrombopoietin; Young Adult | 2019 |
Transfusion confusion: hemolysis or eltrombopag?
Topics: Aged; Benzoates; Bilirubin; Blood Transfusion; Female; Hemoglobins; Hemolysis; Humans; Hydrazines; L-Lactate Dehydrogenase; Pyrazoles | 2020 |
Cutaneous thrombosis associated with eltrombopag treatment for immune thrombocytopenia.
Topics: Aged; Benzoates; Biopsy; Clopidogrel; Computed Tomography Angiography; Conservative Treatment; Female; Humans; Hydrazines; Hyperbaric Oxygenation; Ischemia; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Skin; Thrombosis; Tibial Arteries; Toes; Treatment Outcome; Warfarin | 2020 |
Concerning survival signal for eltrombopag in MDS/AML.
Topics: Benzoates; Humans; Hydrazines; Leukemia, Myeloid, Acute; Pyrazoles | 2020 |
Use of eltrombopag for patients 65 years old or older with immune thrombocytopenia.
Topics: Age Factors; Aged; Aged, 80 and over; Benzoates; Biomarkers; Combined Modality Therapy; Comorbidity; Drug Therapy, Combination; Female; Humans; Hydrazines; Male; Prognosis; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Retrospective Studies; Treatment Outcome | 2020 |
The Thrombopoietin Receptor Agonist Eltrombopag Inhibits Human Cytomegalovirus Replication Via Iron Chelation.
Topics: Animals; Benzoates; Cells, Cultured; Cytomegalovirus; Drug Synergism; Fibroblasts; Ganciclovir; Humans; Hydrazines; Iron Chelating Agents; Mesenchymal Stem Cells; Mice; NIH 3T3 Cells; Pyrazoles; Virus Replication | 2019 |
MPL mutations in essential thrombocythemia uncover a common path of activation with eltrombopag dependent on W491.
Topics: Alleles; Amino Acid Substitution; Benzoates; Cell Line; Genetic Association Studies; Genetic Predisposition to Disease; Humans; Hydrazines; Mutation; Phenotype; Pyrazoles; Receptors, Thrombopoietin; Signal Transduction; Thrombocythemia, Essential | 2020 |
A Sticky Situation: Aortic Valve Thrombus in Patient with Antiphospholipid Antibody Syndrome and Immune Thrombocytopenia.
Topics: Adult; Anticoagulants; Antiphospholipid Syndrome; Aortic Valve; Aortic Valve Stenosis; Benzoates; Bicuspid Aortic Valve Disease; Bioprosthesis; Chest Pain; Craniotomy; Echocardiography; Echocardiography, Three-Dimensional; Echocardiography, Transesophageal; Enoxaparin; Female; Heart Valve Diseases; Heart Valve Prosthesis; Heart Valve Prosthesis Implantation; Hematoma, Subdural, Acute; Humans; Hydrazines; Immunologic Factors; Plasma Exchange; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Recurrence; Rituximab; Stroke Volume; Thrombosis; Ventricular Dysfunction, Left; Warfarin | 2020 |
Distinctive and common features of moderate aplastic anaemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Algorithms; Anemia, Aplastic; Autoimmune Diseases; Benzoates; Blood Transfusion; Bone Marrow; Child; Child, Preschool; Clonal Evolution; Combined Modality Therapy; Danazol; Disease Management; Disease Progression; Female; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Hemoglobinuria, Paroxysmal; Humans; Hydrazines; Immunosuppressive Agents; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Pyrazoles; Severity of Illness Index; Young Adult | 2020 |
Burden of illness among patients with severe aplastic anemia who have had insufficient response to immunosuppressive therapy: a multicenter retrospective chart review study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anemia, Aplastic; Antilymphocyte Serum; Benzoates; Blood Transfusion; Boston; Combined Modality Therapy; Cost of Illness; Drug Resistance; Female; Follow-Up Studies; Health Resources; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Immunosuppressive Agents; Infections; Kaplan-Meier Estimate; Male; Middle Aged; Paris; Pyrazoles; Retrospective Studies; Sample Size; Young Adult | 2020 |
Eltrombopag treatment of a dog with idiopathic aplastic pancytopenia.
Topics: Administration, Oral; Animals; Benzoates; Dog Diseases; Dogs; Hydrazines; Immunosuppressive Agents; Male; Pancytopenia; Pedigree; Pyrazoles; Remission Induction | 2020 |
Thrombopoietin receptor agonists for the treatment of inherited thrombocytopenia.
Topics: Benzoates; Humans; Hydrazines; Pyrazoles; Receptors, Thrombopoietin; Thrombocytopenia | 2020 |
Prediction of Clinical Transporter-Mediated Drug-Drug Interactions via Comeasurement of Pitavastatin and Eltrombopag in Human Hepatocyte Models.
Topics: Adult; Area Under Curve; Benzoates; Biological Transport; Drug Interactions; Hepatocytes; Humans; Hydrazines; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Membrane Transport Proteins; Models, Biological; Pyrazoles; Quinolines | 2020 |
No increased risk of cataract in adult patients with primary immune thrombocytopenia treated with eltrombopag. A French nationwide nested case-control study.
Topics: Aged; Aged, 80 and over; Benzoates; Case-Control Studies; Cataract; Female; France; Humans; Hydrazines; Male; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles | 2020 |
Real-world evidence on clinical outcomes in immune thrombocytopenia treated with thrombopoietin receptor agonists.
Topics: Adult; Aged; Benzoates; Cross-Sectional Studies; Female; Humans; Hydrazines; Male; Middle Aged; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Retrospective Studies; Thrombopoietin | 2020 |
Outcomes of Eltrombopag Treatment and Development of Iron Deficiency in Children with Immune Thrombocytopenia in Turkey
Topics: Administration, Oral; Adolescent; Anemia, Iron-Deficiency; Benzoates; Child; Child, Preschool; Female; Humans; Hydrazines; Infant; Male; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Retrospective Studies; Treatment Outcome; Turkey | 2020 |
Novel ET mutations: stuck in the MPL with you.
Topics: Benzoates; Humans; Hydrazines; Mutation; Pyrazoles; Receptors, Thrombopoietin; Thrombocythemia, Essential | 2020 |
The Cost-effectiveness of Eltrombopag for the Treatment of Immune Thrombocytopenia in the United States.
Topics: Benzoates; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Hemorrhage; Humans; Hydrazines; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thrombopoietin; United States | 2020 |
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Benzoates; Humans; Hydrazines; Middle Aged; Myelodysplastic Syndromes; Pyrazoles; Thrombopoiesis | 2021 |
Deficit of circulating CD19
Topics: Adolescent; ADP-ribosyl Cyclase 1; Adult; Aged; Anemia, Aplastic; Antigens, CD19; Antilymphocyte Serum; B-Lymphocyte Subsets; B-Lymphocytes, Regulatory; Benzoates; Bone Marrow; CD24 Antigen; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cyclosporine; Female; Humans; Hydrazines; Immunosuppressive Agents; Interleukin-10; Killer Cells, Natural; Lymphocyte Count; Lymphopenia; Male; Membrane Glycoproteins; Middle Aged; Pyrazoles; Receptors, Thrombopoietin; Young Adult | 2020 |
Disappearance of monosomy 7 in a patient with aplastic anemia after eltrombopag treatment.
Topics: Aged; Anemia, Aplastic; Benzoates; Chromosome Deletion; Chromosomes, Human, Pair 7; Female; Humans; Hydrazines; Pyrazoles | 2020 |
[Eltrombopag combined with cyclosporine alone for treatment of very severe aplastic anemia: a case report].
Topics: Anemia, Aplastic; Benzoates; Cyclosporine; Humans; Hydrazines; Immunosuppressive Agents; Pyrazoles | 2019 |
"ITP" is not always immune thrombocytopenia.
Topics: Adrenal Cortex Hormones; Amino Acid Substitution; Benzoates; Bernard-Soulier Syndrome; Child; Diagnosis, Differential; Humans; Hydrazines; Immunoglobulins, Intravenous; Male; Mutation, Missense; Platelet Glycoprotein GPIb-IX Complex; Platelet Transfusion; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Recombinant Fusion Proteins; Thrombopoietin | 2020 |
Secondary myelodysplastic syndrome and leukemia in acquired aplastic anemia and paroxysmal nocturnal hemoglobinuria.
Topics: Age of Onset; Anemia, Aplastic; Antibodies, Monoclonal, Humanized; Benzoates; Bone Marrow; Chromosome Aberrations; Chromosomes, Human, Pair 7; Clonal Evolution; Clone Cells; Disease Progression; Granulocyte Colony-Stimulating Factor; Hemoglobinuria, Paroxysmal; Humans; Hydrazines; Leukemia, Myeloid, Acute; Models, Biological; Monosomy; Mutation; Myelodysplastic Syndromes; Oncogene Proteins, Fusion; Pyrazoles; Selection, Genetic; Telomere Shortening | 2020 |
A novel PrECOG (PrE0901) dose-escalation trial using eltrombopag: enhanced platelet recovery during consolidation therapy in acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzoates; Consolidation Chemotherapy; Cytarabine; Humans; Hydrazines; Leukemia, Myeloid, Acute; Pyrazoles | 2020 |
COVID-19 presenting with autoimmune hemolytic anemia in the setting of underlying immune dysregulation.
Topics: Adolescent; Adrenal Cortex Hormones; Anemia, Hemolytic, Autoimmune; Benzoates; Betacoronavirus; Coronavirus Infections; COVID-19; Erythrocyte Transfusion; Humans; Hydrazines; Male; Mycophenolic Acid; Oxygen; Pandemics; Pneumonia, Viral; Pyrazoles; SARS-CoV-2 | 2020 |
Eltrombopag olamine for refractory immune-related thrombocytopenia induced by pembrolizumab in a non-small cell lung cancer patient.
Topics: Antibodies, Monoclonal, Humanized; Benzoates; Carcinoma, Non-Small-Cell Lung; Humans; Hydrazines; Lung Neoplasms; Pyrazoles; Thrombocytopenia | 2020 |
Severe macrothrombocytopenia with platelet CD9 deficiency responsive to romiplostim.
Topics: Benzoates; Blood Platelets; Bone Marrow; Combined Modality Therapy; Consanguinity; Drug Substitution; Ecchymosis; Exome Sequencing; Female; Humans; Hydrazines; Immunophenotyping; Infant; Platelet Transfusion; Pyrazoles; Receptors, Fc; Recombinant Fusion Proteins; Tetraspanin 29; Thrombocytopenia; Thrombopoietin | 2020 |
Eltrombopag treatment promotes platelet recovery and reduces platelet transfusion for patients with post-transplantation thrombocytopenia.
Topics: Adolescent; Adult; Benzoates; Female; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Male; Middle Aged; Platelet Count; Platelet Transfusion; Pyrazoles; Retrospective Studies; Risk Factors; Thrombocytopenia | 2020 |
Eltrombopag is a potential target for drug intervention in SARS-CoV-2 spike protein.
Topics: Algorithms; Angiotensin-Converting Enzyme 2; Benzoates; Computer Simulation; Drug Design; Drug Repositioning; Humans; Hydrazines; Models, Molecular; Protein Binding; Protein Stability; Pyrazoles; SARS-CoV-2; Severe acute respiratory syndrome-related coronavirus; Spike Glycoprotein, Coronavirus; Structure-Activity Relationship | 2020 |
Eltrombopag to allow chemotherapy in a patient with MYH9-related inherited thrombocytopenia and pancreatic cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzoates; Blood Loss, Surgical; Endoscopy, Digestive System; Female; Humans; Hydrazines; Myosin Heavy Chains; Pancreatic Neoplasms; Platelet Count; Pyrazoles; Receptors, Thrombopoietin; Thrombocytopenia | 2020 |
Therapy of posttransplant poor graft function with eltrombopag.
Topics: Benzoates; Humans; Hydrazines; Pyrazoles | 2021 |
High-dose romiplostim accelerates hematologic recovery in patients with aplastic anemia refractory to eltrombopag.
Topics: Adult; Aged; Anemia, Aplastic; Benzoates; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Hydrazines; Male; Middle Aged; Prognosis; Pyrazoles; Receptors, Fc; Recombinant Fusion Proteins; Recovery of Function; Retrospective Studies; Thrombopoietin; Young Adult | 2021 |
An Eltrombopag Red (Plasma) Alert.
Topics: Anemia, Aplastic; Benzoates; Bilirubin; Female; Humans; Hydrazines; Middle Aged; Plasma; Pyrazoles | 2021 |
Evaluation of Eltrombopag in Thrombocytopenia Post Hematopoietic Cell Transplantation: Rertrospective Observational Trial.
Topics: Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Retrospective Studies; Thrombocytopenia | 2022 |
Initial
Topics: Animals; Bacterial Outer Membrane Proteins; Benzoates; Disease Models, Animal; Escherichia coli Proteins; Female; Humans; Hydrazines; Male; Mice; Multienzyme Complexes; Osteosarcoma; Pyrazoles; Xenograft Model Antitumor Assays | 2021 |
Efficacy and safety of eltrombopag during conception and first trimester of pregnancy in a case of refractory severe immune thrombocytopenia.
Topics: Adolescent; Benzoates; Female; Humans; Hydrazines; Pregnancy; Pregnancy Complications, Hematologic; Pregnancy Trimester, First; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Treatment Outcome | 2020 |
Preparing patients with immune thrombocytopenia for surgery: what are the options?
Topics: Benzoates; Humans; Hydrazines; Immunoglobulins, Intravenous; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Thrombocytopenia | 2020 |
Romiplostim is effective for eltrombopag-refractory aplastic anemia: results of a retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Anemia, Aplastic; Anemia, Refractory; Benzoates; Drug Substitution; Drug Tolerance; Female; Follow-Up Studies; Humans; Hydrazines; Male; Middle Aged; Platelet Count; Prospective Studies; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Retrospective Studies; Thrombopoietin | 2020 |
46th virtual annual meeting of the EBMT.
Topics: Antibodies, Bispecific; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzoates; Busulfan; Clinical Trials as Topic; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Immunosuppressive Agents; Pyrazoles; Societies, Medical | 2020 |
Eltrombopag is effective in patients with relapse/refractory aplastic anemia-report from a single center in China.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anemia, Aplastic; Benzoates; China; Female; Follow-Up Studies; Hospitals, University; Humans; Hydrazines; Male; Middle Aged; Pyrazoles; Recurrence; Retrospective Studies; Treatment Outcome; Young Adult | 2020 |
Aplastic anemia in a patient with CVID due to NFKB1 haploinsufficiency.
Topics: Anemia, Aplastic; Benzoates; Bone Marrow; Common Variable Immunodeficiency; Cyclosporine; Exome Sequencing; Female; Genetic Predisposition to Disease; Haploinsufficiency; Humans; Hydrazines; Middle Aged; NF-kappa B; NF-kappa B p50 Subunit; Pyrazoles; Signal Transduction | 2020 |
Eltrombopag for the Treatment of Severe Inherited Thrombocytopenia.
Topics: Adult; Benzoates; Blood Cell Count; Blood Platelets; Core Binding Factor Alpha 2 Subunit; ETS Translocation Variant 6 Protein; Female; Heterozygote; Humans; Hydrazines; Pedigree; Proto-Oncogene Proteins c-ets; Pyrazoles; Repressor Proteins; Severity of Illness Index; Thrombocytopenia | 2021 |
The effect of eltrombopag in managing thrombocytopenia associated with tyrosine kinase therapy in patients with chronic myeloid leukemia and myelofibrosis.
Topics: Benzoates; Humans; Hydrazines; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Primary Myelofibrosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Thrombocytopenia; Treatment Outcome | 2021 |
Eltrombopag as first-line treatment for thrombocytopenia among paediatric patients after allogeneic haematopoietic stem cell transplantation.
Topics: Benzoates; Child; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Pyrazoles; Retrospective Studies; Thrombocytopenia | 2021 |
Cost-per-responder analysis for eltrombopag and rituximab in the treatment of primary immune thrombocytopenia in Spain.
Topics: Adult; Benzoates; Humans; Hydrazines; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Rituximab; Spain; Thrombopoietin | 2020 |
Eltrombopag preferentially expands haematopoietic multipotent progenitors in human aplastic anaemia.
Topics: Adolescent; Adult; Anemia, Aplastic; Antigens, CD34; Benzoates; Biopsy, Needle; Bone Marrow Cells; Brazil; Female; Flow Cytometry; Hematopoietic Stem Cells; Humans; Hydrazines; Immunosuppressive Agents; Male; Middle Aged; Multipotent Stem Cells; Pyrazoles; Receptors, Thrombopoietin | 2021 |
Eltrombopag monotherapy can improve hematopoiesis in patients with low to intermediate risk-1 myelodysplastic syndrome.
Topics: Benzoates; Hematopoiesis; Humans; Hydrazines; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Pyrazoles | 2020 |
Eltrombopag inhibits the proliferation of Ewing sarcoma cells via iron chelation and impaired DNA replication.
Topics: Benzoates; Cell Proliferation; DNA Replication; Humans; Hydrazines; Iron Chelating Agents; Pyrazoles; Sarcoma, Ewing | 2020 |
Treatment of severe thrombocytopenia associated with systemic lupus erythematosus in pregnancy with eltrombopag: A case report and literature review.
Topics: Adult; Benzoates; Female; Humans; Hydrazines; Lupus Erythematosus, Systemic; Platelet Count; Pregnancy; Pregnancy Complications, Hematologic; Pyrazoles; Thrombocytopenia; Thrombopoietin | 2021 |
A simple HPLC assay for determining eltrombopag concentration in human serum.
Topics: Benzoates; Chromatography, High Pressure Liquid; Diclofenac; Drug Monitoring; Humans; Hydrazines; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin; Reference Standards | 2021 |
Comment on: Eltrombopag for thrombocytopenia following allogeneic hematopoietic stem cell transplantation in children.
Topics: Benzoates; Child; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Pyrazoles; Thrombocytopenia | 2020 |
Efficacy and safety of eltrombopag in the treatment of Chinese children with chronic immune thrombocytopenia.
Topics: Benzoates; Child; Child, Preschool; China; Chronic Disease; Female; Humans; Hydrazines; Infant; Male; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin; Retrospective Studies; T-Lymphocytes, Regulatory; Treatment Outcome | 2021 |
Effects of Eltrombopag on In Vitro Macrophage Polarization in Pediatric Immune Thrombocytopenia.
Topics: B-Lymphocytes, Regulatory; Benzoates; Child; Child, Preschool; Female; Humans; Hydrazines; Macrophage Activation; Macrophages; Male; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; T-Lymphocytes, Regulatory; Th1 Cells; Th2 Cells | 2020 |
Preparation and Solid-State Characterization of Eltrombopag Crystal Phases.
Topics: Benzoates; Crystallization; Crystallography, X-Ray; Humans; Hydrazines; Hydrogen Bonding; Molecular Structure; Powder Diffraction; Pyrazoles; Solvents; Thermogravimetry; Thrombocytopenia; Water; X-Ray Diffraction | 2020 |
Effects of Iron Chelation in Osteosarcoma.
Topics: Apoptosis; Benzoates; Bone Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deferasirox; Drug Therapy, Combination; Humans; Hydrazines; Iron Chelating Agents; Osteosarcoma; Pyrazoles; Treatment Outcome | 2021 |
Paediatric severe aplastic anaemia treatment: where to start?
Topics: Anemia, Aplastic; Benzoates; Child; Humans; Hydrazines; Immunosuppression Therapy; Pyrazoles | 2021 |
Thrombopoietin receptor agonists as an emergency treatment for severe newly diagnosed immune thrombocytopenia in children.
Topics: Adolescent; Benzoates; Child; Child, Preschool; Emergency Treatment; Female; Hemorrhage; Humans; Hydrazines; Infant; Male; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thrombopoietin | 2021 |
Effectiveness and safety of tacrolimus with or without eltrombopag, as a part of immunosuppressive treatment of aplastic anemia in adults: a retrospective case series.
Topics: Adult; Aged; Anemia, Aplastic; Antilymphocyte Serum; Benzoates; Cyclosporine; Drug Eruptions; Female; Gingival Hypertrophy; Hirsutism; Humans; Hydrazines; Immunosuppressive Agents; Male; Middle Aged; Pyrazoles; Retrospective Studies; Tacrolimus | 2021 |
Eltrombopag for treatment of thrombocytopenia after allogeneic hematopoietic cell transplantation in children: Single-centre experience.
Topics: Adolescent; Benzoates; Child; Child, Preschool; Female; Follow-Up Studies; Hematologic Agents; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Male; Platelet Count; Platelet Transfusion; Pyrazoles; Receptors, Thrombopoietin; Retrospective Studies; Thrombocytopenia; Treatment Outcome | 2021 |
Misevaluation of Hemolysis and Icterus Indexes Due to Eltrombopag: A Case Report.
Topics: Benzoates; Hemolysis; Humans; Hydrazines; Jaundice; Pyrazoles | 2021 |
Eltrombopag inhibits Type I interferon-mediated antiviral signaling by decreasing cellular iron.
Topics: Adult; Animals; Antiviral Agents; Benzoates; Cell Survival; Cells, Cultured; Female; Hepatitis B, Chronic; Humans; Hydrazines; Interferon-alpha; Iron; Leukocytes, Mononuclear; Male; Mice; Mice, Inbred C57BL; Middle Aged; Pyrazoles; Receptors, Thrombopoietin; THP-1 Cells; Thrombocytopenia | 2021 |
Eltrombopag reduces bleeding complications and the need of platelet transfusions in cirrhotic thrombocytopenic patients subjected to invasive procedures.
Topics: Aged; Benzoates; Female; Hemorrhage; Humans; Hydrazines; Liver Cirrhosis; Male; Middle Aged; Platelet Count; Platelet Transfusion; Pyrazoles; Receptors, Thrombopoietin; Thrombocytopenia | 2021 |
Eltrombopag Add-on Treatment in a Child With Fanconi Aplastic Anemia Awaiting Hematopoietic Stem Cell Transplantation.
Topics: Allografts; Benzoates; Child, Preschool; Fanconi Anemia; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Male; Pyrazoles | 2022 |
Eltrombopag directly inhibits BAX and prevents cell death.
Topics: 3T3 Cells; Animals; Apoptosis; bcl-2-Associated X Protein; Benzoates; Cell Death; Humans; Hydrazines; Magnetic Resonance Spectroscopy; Mice; Models, Biological; Models, Molecular; Protein Stability; Pyrazoles | 2021 |
Identification of Eltrombopag as a Repurposing Drug Against Staphylococcus epidermidis and its Biofilms.
Topics: Animals; Anti-Bacterial Agents; Benzoates; Biofilms; Drug Repositioning; Humans; Hydrazines; Microbial Sensitivity Tests; Pharmaceutical Preparations; Pyrazoles; Staphylococcus epidermidis | 2021 |
Eltrombopag restores erythropoiesis in refractory adult acquired pure red cell aplasia.
Topics: Benzoates; Bone Marrow; Erythropoiesis; Humans; Hydrazines; Male; Middle Aged; Pyrazoles; Receptors, Thrombopoietin; Red-Cell Aplasia, Pure; Treatment Outcome | 2021 |
Establishment of a novel mesenchymal stem cell-based regimen for chronic myeloid leukemia differentiation therapy.
Topics: Animals; Benzoates; Cell Lineage; Coculture Techniques; Gene Expression Regulation, Leukemic; Humans; Hydrazines; Janus Kinases; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mesenchymal Stem Cell Transplantation; Mesenchymal Stem Cells; Mice, Nude; Mitogen-Activated Protein Kinases; Pyrazoles; Receptors, Thrombopoietin; Signal Transduction; STAT Transcription Factors; Thrombopoiesis; Umbilical Cord; Xenograft Model Antitumor Assays | 2021 |
An escalating treatment strategy for children with severe chronic immune thrombocytopenia: Preliminary report from a single center.
Topics: Adolescent; Anti-Inflammatory Agents; Benzoates; Child; Child, Preschool; Dexamethasone; Drug Therapy, Combination; Female; Humans; Hydrazines; Immunologic Factors; Infant; Male; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin; Retrospective Studies; Rituximab; Treatment Outcome | 2021 |
Use of eltrombopag for the treatment of poor graft function after hematopoietic stem cell transplantation in children.
Topics: Adolescent; Benzoates; Blood Cell Count; Child; Female; Hematologic Agents; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Male; Pyrazoles; Receptors, Thrombopoietin; Retrospective Studies; Treatment Outcome | 2021 |
Eltrombopag for the treatment of refractory thrombocytopenia associated with connective tissue disease.
Topics: Adult; Benzoates; Connective Tissue Diseases; Female; Humans; Hydrazines; Male; Middle Aged; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin; Retrospective Studies; Young Adult | 2021 |
Pharmacokinetics of Eltrombopag in Healthy Chinese Subjects and Effect of Sex and Genetic Polymorphism on its Pharmacokinetic and Pharmacodynamic Variability.
Topics: Adolescent; Adult; Asian People; Benzoates; Chromatography, Liquid; Cytochrome P-450 CYP1A2; Female; Genotype; Humans; Hydrazines; Male; Neural Networks, Computer; Polymorphism, Single Nucleotide; Pyrazoles; Sex Factors; Tandem Mass Spectrometry; Young Adult | 2021 |
Eltrombopag-induced recurrent stroke in idiopathic thrombocytopenic purpura.
Topics: Benzoates; Humans; Hydrazines; Purpura, Thrombocytopenic; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Stroke | 2021 |
Tapering and Discontinuation of Thrombopoietin Receptor Agonist Therapy in Patients with Immune Thrombocytopenia: Results from a Modified Delphi Panel.
Topics: Benzoates; Humans; Hydrazines; Medication Adherence; Physicians; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Recurrence; Remission Induction; Retreatment; Self Report; Surveys and Questionnaires; Thrombopoietin | 2021 |
Efficacy and safety of eltrombopag in the first-line therapy of severe aplastic anemia in children.
Topics: Anemia, Aplastic; Animals; Antilymphocyte Serum; Benzoates; Child; Cyclosporine; Female; Humans; Hydrazines; Immunosuppressive Agents; Male; Pyrazoles; Rabbits; Retrospective Studies; Treatment Outcome | 2021 |
Eltrombopag Improves Erythroid Differentiation in a Human Induced Pluripotent Stem Cell Model of Diamond Blackfan Anemia.
Topics: Anemia, Diamond-Blackfan; Animals; Base Sequence; Benzoates; Cell Differentiation; Cell Line; Erythroid Cells; Erythropoiesis; Humans; Hydrazines; Induced Pluripotent Stem Cells; Intracellular Space; Iron; Mice, Inbred NOD; Mice, SCID; Models, Biological; Mutation; Pyrazoles | 2021 |
Acute kidney injury and nephrotic syndrome associated with eltrombopag therapy in chronic idiopathic thrombocytopenic purpura.
Topics: Acute Kidney Injury; Adrenal Cortex Hormones; Aged; Benzoates; Humans; Hydrazines; Kidney; Male; Nephrotic Syndrome; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles | 2021 |
Management of primary immune thrombocytopenia in a real-world setting in Japan: eltrombopag versus corticosteroids.
Topics: Adrenal Cortex Hormones; Benzoates; Disease Management; Disease Susceptibility; Drug Therapy, Combination; Hemorrhage; Humans; Hydrazines; Japan; Kaplan-Meier Estimate; Patient Acceptance of Health Care; Platelet Count; Practice Patterns, Physicians'; Prevalence; Prognosis; Proportional Hazards Models; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Retrospective Studies; Treatment Outcome | 2021 |
Eltrombopag in children with severe aplastic anemia.
Topics: Anemia, Aplastic; Antilymphocyte Serum; Benzoates; Child; Cyclosporine; Humans; Hydrazines; Immunosuppressive Agents; Pyrazoles; Retrospective Studies; Treatment Outcome | 2021 |
Eltrombopag for the treatment of poor graft function following allogeneic stem cell transplant: a retrospective multicenter study.
Topics: Adult; Aged; Benzoates; Female; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Italy; Male; Middle Aged; Primary Graft Dysfunction; Pyrazoles; Retrospective Studies; Transplantation, Homologous; Treatment Outcome; Young Adult | 2021 |
Predicting response of severe aplastic anemia to immunosuppression combined with eltrombopag.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anemia, Aplastic; Benzoates; Child; Child, Preschool; Humans; Hydrazines; Immunosuppression Therapy; Immunosuppressive Agents; Middle Aged; Pyrazoles; Retrospective Studies; Young Adult | 2022 |
Adding eltrombopag to immunosuppression: the importance of predicting outcome.
Topics: Benzoates; Humans; Hydrazines; Immunosuppression Therapy; Pyrazoles | 2022 |
[Improvement in platelet count and bleeding symptom during treatment with eltrombopag in a patient with X-linked thrombocytopenia].
Topics: Adolescent; Benzoates; Genetic Diseases, X-Linked; Humans; Hydrazines; Male; Platelet Count; Pyrazoles; Thrombocytopenia | 2021 |
Eltrombopag for enhancement of platelet engraftment in patients undergoing allogeneic cord blood transplantation.
Topics: Adolescent; Adult; Aged; Benzoates; Child; Cord Blood Stem Cell Transplantation; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Middle Aged; Pyrazoles; Young Adult | 2021 |
Immune thrombocytopenia in two infant cases managed with eltrombopag.
Topics: Benzoates; Humans; Hydrazines; Infant; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Thrombocytopenia; Treatment Outcome | 2021 |
Miniaturized 3D bone marrow tissue model to assess response to Thrombopoietin-receptor agonists in patients.
Topics: Adult; Aged; Benzoates; Bioreactors; Blood Platelets; Cell Culture Techniques; Cells, Cultured; Female; Fibroins; Hematopoietic Stem Cells; Humans; Hydrazines; Induced Pluripotent Stem Cells; Intercellular Signaling Peptides and Proteins; Male; Megakaryocytes; Middle Aged; Miniaturization; Mutation; Myosin Heavy Chains; Pyrazoles; Receptors, Thrombopoietin; Stem Cell Niche; Thrombocytopenia; Thrombopoiesis; Young Adult | 2021 |
Efficacy and cost analysis of eltrombopag in thrombocytopenia and poor graft function post allogeneic hematopoietic cell transplantation.
Topics: Benzoates; Costs and Cost Analysis; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Male; Middle Aged; Pyrazoles; Retrospective Studies; Thrombocytopenia | 2021 |
Interference of eltrombopag with bilirubin measurements on the Vitros 5600 analyzer.
Topics: Artifacts; Benzoates; Bilirubin; Blood Chemical Analysis; Humans; Hydrazines; Pyrazoles; Reference Values | 2021 |
Eltrombopag for myelodysplastic syndromes or chronic myelomonocytic leukaemia with no excess blasts and thrombocytopenia: a French multicentre retrospective real-life study.
Topics: Aged; Aged, 80 and over; Benzoates; Blood Platelets; Female; France; Humans; Hydrazines; Leukemia, Myelomonocytic, Chronic; Male; Myelodysplastic Syndromes; Pyrazoles; Receptors, Thrombopoietin; Retrospective Studies; Thrombocytopenia | 2021 |
Clinical outcomes in eight patients with immune thrombocytopenia each treated with the three approved thrombopoietin receptor agonists.
Topics: Adult; Aged; Benzoates; Female; Humans; Hydrazines; Male; Middle Aged; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thiazoles; Thiophenes; Thrombocytopenia; Thrombopoietin; Treatment Outcome | 2021 |
Could Antinuclear Antibody Positivity Be a Factor Affecting Treatment Response in Immune Thrombocytopenia Patients on Eltrombopag?
Topics: Antibodies, Antinuclear; Benzoates; Female; Humans; Hydrazines; Male; Middle Aged; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Treatment Outcome | 2022 |
Comparison of Splenectomy and Eltrombopag Treatment in the Second-Line Treatment of Immune Thrombocytopenic Purpura
Topics: Adult; Benzoates; Humans; Hydrazines; Middle Aged; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Retrospective Studies; Splenectomy | 2021 |
Preclinical evaluation of eltrombopag in a PDX model of myelodysplastic syndromes.
Topics: Aged; Aged, 80 and over; Animals; Apoptosis; Benzoates; Cell Proliferation; Female; Humans; Hydrazines; Male; Mice; Mice, Inbred NOD; Mice, SCID; Middle Aged; Myelodysplastic Syndromes; Prognosis; Pyrazoles; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2022 |
Elucidating the Mechanism of Action of the Attributed Immunomodulatory Role of Eltrombopag in Primary Immune Thrombocytopenia: An In Silico Approach.
Topics: Benzoates; Biomarkers; Disease Management; Disease Susceptibility; Humans; Hydrazines; Immunomodulation; Models, Biological; Models, Molecular; Molecular Targeted Therapy; Protein Interaction Mapping; Protein Interaction Maps; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin; Signal Transduction; Structure-Activity Relationship; T-Lymphocytes; Treatment Outcome | 2021 |
QBD-driven HPLC method of eltrombopag olamine: Degradation pathway proposal, structure elucidation, and in silico toxicity prediction.
Topics: Benzoates; Chromatography, High Pressure Liquid; Chromatography, Liquid; Computer Simulation; Drug Contamination; Drug Stability; Hydrazines; Pyrazoles; Tandem Mass Spectrometry | 2021 |
Is the increase in eltrombopag dose cause of myocardial infarction?
Topics: Benzoates; Humans; Hydrazines; Myocardial Infarction; Pyrazoles | 2021 |
Eltrombopag-induced liver dysfunction during the treatment of immune thrombocytopenia and its risk factors.
Topics: Benzoates; Diabetes Mellitus, Type 2; Female; Humans; Hydrazines; Liver Diseases; Male; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin; Retrospective Studies; Risk Factors | 2021 |
Successful treatment of refractory pure red cell aplasia with eltrombopag after ABO-incompatible allogeneic hematopoietic stem cell transplantation.
Topics: Adult; Benzoates; Blood Group Incompatibility; Female; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Pyrazoles; Red-Cell Aplasia, Pure | 2021 |
Role of eltrombopag in severe aplastic anemia treatment in children.
Topics: Anemia, Aplastic; Benzoates; Child; Humans; Hydrazines; Pyrazoles | 2021 |
Treatment of immune thrombocytopenia with eltrombopag in patients who had and who had not received prior rituximab: post-hoc analysis of the EXTEND study.
Topics: Benzoates; Clinical Trials, Phase III as Topic; Humans; Hydrazines; Molecular Targeted Therapy; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin; Retreatment; Rituximab; Treatment Outcome | 2022 |
Eltrombopag-induced Metabolic Acidosis and Hepatic Encephalopathy in Pediatric ITP.
Topics: Acidosis; Benzoates; Child; Child, Preschool; Hepatic Encephalopathy; Humans; Hydrazines; Male; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles | 2022 |
Eltrombopag treatment of patients with secondary immune thrombocytopenia: retrospective EHR analysis.
Topics: Adult; Aged; Benzoates; Female; Hemorrhage; Humans; Hydrazines; Male; Middle Aged; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin; Retrospective Studies; Thrombosis; Treatment Outcome | 2022 |
Eltrombopag treatment for severe immune thrombocytopenia during pregnancy: a case report.
Topics: Adolescent; Benzoates; Female; Humans; Hydrazines; Infant, Newborn; Platelet Count; Pregnancy; Pregnancy Complications, Hematologic; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin | 2021 |
Treatment patterns in adults with immune thrombocytopenia before, during and after use of thrombopoietin receptor agonists: a longitudinal prescription database study from Germany.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzoates; Databases, Factual; Drug Prescriptions; Female; Germany; Humans; Hydrazines; Longitudinal Studies; Male; Middle Aged; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Retrospective Studies; Thrombopoietin | 2021 |
Spotlight on eltrombopag in pediatric ITP in China: a long-term observational study in real-world practice.
Topics: Benzoates; Child; Child, Preschool; China; Humans; Hydrazines; Longitudinal Studies; Prospective Studies; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Thrombocytopenia; Treatment Outcome | 2021 |
Iron status influences the response of cord blood megakaryocyte progenitors to eltrombopag in vitro.
Topics: Benzoates; Cell Differentiation; Fetal Blood; Hydrazines; Iron; Megakaryocyte Progenitor Cells; Pyrazoles | 2022 |
Efficiency and safety of eltrombopag for multi-line failed Chinese patients with immune thrombocytopenia: cases with decreased megakaryocyte response well from single-center experience.
Topics: Benzoates; China; Humans; Hydrazines; Megakaryocytes; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Retrospective Studies; Thrombocytopenia | 2022 |
Eltrombopag-associated erythromelalgia in idiopathic thrombocytopenic purpura.
Topics: Benzoates; Erythromelalgia; Humans; Hydrazines; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles | 2022 |
Eltrombopag as second line treatment in patients with primary immune thrombocytopenia: A single center real life experience.
Topics: Adult; Aged; Aged, 80 and over; Benzoates; Female; Glucocorticoids; Humans; Hydrazines; Male; Middle Aged; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin; Retrospective Studies; Treatment Outcome; Young Adult | 2021 |
[Treatment of secondary engraftment failure with granulocyte colony-stimulating factor and eltrombopag after allogeneic peripheral blood stem cell transplantation in adult T-cell leukemia/lymphoma].
Topics: Aged; Benzoates; Bone Marrow Transplantation; Female; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Leukemia-Lymphoma, Adult T-Cell; Lymphoma; Peripheral Blood Stem Cell Transplantation; Pyrazoles; Transplantation, Homologous | 2021 |
Eltrombopag in adult patients with immune thrombocytopenia in the real-world in France, including off-label use before 6 months of disease duration: The multicenter, prospective ELEXTRA study.
Topics: Adult; Aged; Benzoates; Female; France; Humans; Hydrazines; Male; Middle Aged; Off-Label Use; Prospective Studies; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Treatment Outcome | 2022 |
Cost-effectiveness of eltrombopag vs intravenous immunoglobulin for the perioperative management of immune thrombocytopenia.
Topics: Benzoates; Canada; Cost-Benefit Analysis; Humans; Hydrazines; Immunoglobulins, Intravenous; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Thrombocytopenia | 2022 |
Eltrombopag for refractory vaccine-induced immune thrombotic thrombocytopenia.
Topics: Antibodies; Benzoates; COVID-19; COVID-19 Vaccines; Female; Humans; Hydrazines; Middle Aged; Platelet Factor 4; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Thrombocytopenia; Thrombosis; Vaccines | 2022 |
Successful treatment of acquired amegakaryocytic thrombocytopenia with eltrombopag and immunosuppressant.
Topics: Benzoates; Bone Marrow Diseases; Humans; Hydrazines; Immunoglobulins, Intravenous; Immunosuppressive Agents; Purpura, Thrombocytopenic; Pyrazoles; Thrombopoietin | 2022 |
Deferasirox combination with eltrombopag shows anti-myelodysplastic syndrome effects by enhancing iron deprivation-related apoptosis.
Topics: Apoptosis; Benzoates; Deferasirox; Humans; Hydrazines; Iron; Iron Chelating Agents; Myelodysplastic Syndromes; Pyrazoles; Thrombocytopenia | 2022 |
Catastrophic anti-phospholipid syndrome with Libman-Sacks endocarditis following eltrombopag therapy for immune thrombocytopenic purpura: A case report.
Topics: Adult; Antiphospholipid Syndrome; Benzoates; Endocarditis; Female; Humans; Hydrazines; Lupus Erythematosus, Systemic; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles | 2021 |
Chronic Myeloid Leukemia in a Patient with Previous Idiopathic Thrombocytopenic Purpura: How to Manage Imatinib Together with Eltrombopag.
Topics: Benzoates; Humans; Hydrazines; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles | 2021 |
Eltrombopag in paediatric immune thrombocytopenia: Iron metabolism modulation in mesenchymal stromal cells.
Topics: Anti-Inflammatory Agents; Benzoates; Child; Humans; Hydrazines; Iron; Mesenchymal Stem Cells; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Thrombocytopenia | 2022 |
Eltrombopag: a springboard to early responses in SAA.
Topics: Benzoates; Hydrazines; Pyrazoles | 2022 |
Early treatment of rituximab combined with eltrombopag for secondary thrombocytopenic purpura in rheumatoid arthritis: A case report.
Topics: Aged; Arthritis, Rheumatoid; Benzoates; Female; Humans; Hydrazines; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Rituximab | 2022 |
[Efficacy and safety analysis of eltrombopag and recombinant human thrombopoietin combined with immunosuppressive therapy for severe aplastic anemia].
Topics: Anemia, Aplastic; Benzoates; Humans; Hydrazines; Immunosuppression Therapy; Immunosuppressive Agents; Pyrazoles; Retrospective Studies; Thrombopoietin | 2021 |
Eltrombopag inhibits TET dioxygenase to contribute to hematopoietic stem cell expansion in aplastic anemia.
Topics: Anemia, Aplastic; Animals; Benzoates; Cell Proliferation; Dioxygenases; DNA-Binding Proteins; Hematopoietic Stem Cells; Humans; Hydrazines; Mice; Mice, Knockout; Pyrazoles | 2022 |
Changes in bone marrow and peripheral blood lymphocyte subset findings with onset of hepatitis-associated aplastic anemia.
Topics: Anemia, Aplastic; Benzoates; Bone Marrow; Cytomegalovirus Infections; Hepatitis; Humans; Hydrazines; Infant; Killer Cells, Natural; Lymphocyte Subsets; Lymphocytes; Male; Pyrazoles; Receptors, Thrombopoietin | 2022 |
Effects of eltrombopag on mesenchymal stem cells in immune thrombocytopenia purpura.
Topics: Benzoates; Humans; Hydrazines; Mesenchymal Stem Cells; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles | 2022 |
Long-term eltrombopag for bone marrow failure depletes iron.
Topics: Anemia, Aplastic; Benzoates; Ferritins; Humans; Hydrazines; Iron; Iron Overload; Pancytopenia; Pyrazoles; Recurrence; Thrombocytopenia | 2022 |
[The efficacy of eltrombopag plus cyclosporine A in patients with transfusion-dependent non-severe aplastic anemia: a retrospective study from single center].
Topics: Anemia, Aplastic; Antilymphocyte Serum; Benzoates; Cyclosporine; Humans; Hydrazines; Immunosuppressive Agents; Pyrazoles; Retrospective Studies | 2022 |
[Successful treatment of secondary graft failure after allogeneic stem cell transplantation for aplastic anemia with eltrombopag].
Topics: Adult; Anemia, Aplastic; Benzoates; Female; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Male; Pyrazoles | 2022 |
Eltrombopag as frontline treatment of aplastic anaemia in routine practice: implications on cost and efficacy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anemia, Aplastic; Antilymphocyte Serum; Benzoates; Cyclosporine; Female; Humans; Hydrazines; Immunosuppressive Agents; Male; Middle Aged; Pyrazoles; Treatment Outcome; Young Adult | 2022 |
Treatment of Severe Refractory Thrombocytopenia in Brucellosis with Eltrombopag: A Case Report.
Topics: Benzoates; Brucellosis; Child, Preschool; Female; Humans; Hydrazines; Pyrazoles; Thrombocytopenia | 2022 |
Tapering of the thrombopoietin receptor agonist in paediatric patients with chronic immune thrombocytopenia: Is it possible?
Topics: Benzoates; Blood Platelets; Child; Hematologic Agents; Humans; Hydrazines; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thrombopoietin | 2022 |
Frontline Therapy Options for Adults With Newly Diagnosed Severe Aplastic Anemia: Intensive immunosuppressive Therapy Plus Eltrombopag or Matched Sibling Donor Hematopoietic Stem Cell Transplantation?
Topics: Anemia, Aplastic; Animals; Benzoates; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Immunosuppression Therapy; Pyrazoles; Siblings; Swine | 2022 |
Does eltrombopag lead to thrombotic events? A pharmacovigilance study of the FDA adverse event reporting system.
Topics: Adverse Drug Reaction Reporting Systems; Bayes Theorem; Benzoates; Glucocorticoids; Humans; Hydrazines; Pharmacovigilance; Pyrazoles; Thrombosis; United States; United States Food and Drug Administration | 2022 |
Eltrombopag may induce bone marrow fibrosis in allogeneic hematopoietic stem cell transplant recipients with prolonged thrombocytopenia.
Topics: Benzoates; Female; Fibrosis; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Male; Middle Aged; Primary Myelofibrosis; Pyrazoles; Retrospective Studies; Thrombocytopenia | 2022 |
An eltrombopag-induced remission of bone-marrow aplasia accompanied by marked leukoerythroblastosis and splenomegaly.
Topics: Anemia, Aplastic; Benzoates; Bone Marrow; Humans; Hydrazines; Pyrazoles; Splenomegaly | 2022 |
Pembrolizumab-Induced Acquired Amegakaryocytic Thrombocytopenia and Successful Combination Treatment With Eltrombopag, Romiplostim and Cyclosporine: A Brief Communication.
Topics: Antibodies, Monoclonal, Humanized; Benzoates; Bone Marrow Diseases; Communication; Cyclosporine; Humans; Hydrazines; Purpura, Thrombocytopenic; Pyrazoles; Receptors, Fc; Recombinant Fusion Proteins; Thrombopoietin | 2022 |
Avatrombopag improves thrombocytopenia in MYH9-related disorder following eltrombopag treatment failure.
Topics: Benzoates; Hearing Loss, Sensorineural; Humans; Hydrazines; Male; Molecular Motor Proteins; Mutation; Myosin Heavy Chains; Pyrazoles; Thiazoles; Thiophenes; Thrombocytopenia; Treatment Failure | 2022 |
In Silico Drug Repurposing of FDA-Approved Drugs Highlighting Promacta as a Potential Inhibitor of H7N9 Influenza Virus.
Topics: Antiviral Agents; Benzoates; Drug Repositioning; Humans; Hydrazines; Influenza A Virus, H7N9 Subtype; Influenza, Human; Lurasidone Hydrochloride; Neuraminidase; Pyrazoles | 2022 |
Relationship between CYP2C8, UGT1A1, and ABCG2 gene polymorphisms and the exposure, efficacy, and toxicity of eltrombopag in the treatment of refractory aplastic anemia.
Topics: Anemia, Aplastic; ATP Binding Cassette Transporter, Subfamily G, Member 2; Benzoates; Camptothecin; Cytochrome P-450 CYP2C8; Genotype; Glucuronosyltransferase; Humans; Hydrazines; Neoplasm Proteins; Polymorphism, Genetic; Pyrazoles | 2022 |
Matched related transplantation versus immunosuppressive therapy plus eltrombopag for first-line treatment of severe aplastic anemia: a multicenter, prospective study.
Topics: Adult; Anemia, Aplastic; Benzoates; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Immunosuppression Therapy; Immunosuppressive Agents; Prospective Studies; Pyrazoles; Retrospective Studies; Treatment Outcome | 2022 |
A real-word experience of eltrombopag plus rabbit antithymocyte immunoglobulin-based IST in Chinese patients with severe aplastic anemia.
Topics: Anemia, Aplastic; Antilymphocyte Serum; Benzoates; China; Cyclosporine; Humans; Hydrazines; Immunosuppression Therapy; Immunosuppressive Agents; Pyrazoles; Receptors, Thrombopoietin; Treatment Outcome | 2022 |
Eltrombopag in patients with chronic immune thrombocytopenia in Asia-Pacific, the Middle East, and Turkey: final analysis of CITE.
Topics: Adult; Asia; Chronic Disease; Humans; Hydrazines; Prospective Studies; Purpura, Thrombocytopenic, Idiopathic; Quality of Life; Turkey | 2023 |
Efficacy of eltrombopag in thrombocytopenia after hematopoietic stem celltransplantation.
Topics: Benzoates; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Pyrazoles; Retrospective Studies; Thrombocytopenia | 2022 |
Treatment patterns and outcomes of second-line rituximab and thrombopoietin receptor agonists in adult immune thrombocytopenia: A Canadian retrospective cohort study.
Topics: Adult; Canada; Chronic Disease; Hemorrhage; Humans; Hydrazines; Intracranial Hemorrhages; Purpura, Thrombocytopenic, Idiopathic; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Retrospective Studies; Rituximab; Thrombocytopenia; Thrombopoietin | 2022 |
Eltrombopag modulates the phenotypic evolution and potential immunomodulatory roles of monocytes/macrophages in immune thrombocytopenia.
Topics: Benzoates; Humans; Hydrazines; Interleukin-4; Macrophages; Monocytes; Phenotype; Purpura, Thrombocytopenic, Idiopathic; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thrombocytopenia; Thrombopoietin | 2023 |
Switching between eltrombopag and recombinant human thrombopoietin in patients with immune thrombocytopenia: an observational study.
Topics: Adult; Benzoates; Drug Substitution; Humans; Hydrazines; Prospective Studies; Purpura, Thrombocytopenic, Idiopathic; Recombinant Proteins; Thrombocytopenia; Thrombopoietin | 2022 |
Evaluation of the procoagulant state in chronic immune thrombocytopenia before and after eltrombopag treatment-a prospective cohort study.
Topics: Adult; Factor VIII; Humans; Hydrazines; Prospective Studies; Purpura, Thrombocytopenic, Idiopathic; Thrombin; Thrombocytopenia; Thrombophilia; von Willebrand Factor | 2023 |
Sustained response off treatment in eltrombopag for children with persistent/chronic primary immune thrombocytopenia: A multicentre observational retrospective study in China.
Topics: Adult; Benzoates; Child; China; Humans; Hydrazines; Purpura, Thrombocytopenic, Idiopathic; Receptors, Thrombopoietin; Retrospective Studies; Treatment Outcome | 2023 |
Pediatric immune thrombocytopenia: a focus on eltrombopag as second-line therapy.
Topics: Adult; Benzoates; Child; Humans; Hydrazines; Purpura, Thrombocytopenic, Idiopathic; Thrombocytopenia | 2023 |
Long-Term Safety and Efficacy of Eltrombopag for Advanced Myelodysplastic Syndromes or Acute Myeloid Leukemia and Severe Thrombocytopenia: Results of the ASPIRE Extension Study.
Topics: Benzoates; Humans; Hydrazines; Leukemia, Myeloid, Acute; Leukopenia; Myelodysplastic Syndromes; Thrombocytopenia; Treatment Outcome | 2023 |
Eltrombopag in Lower-Risk Myelodysplastic Syndrome: Revival of Its Use in Thrombocytopenia.
Topics: Benzoates; Humans; Hydrazines; Myelodysplastic Syndromes; Thrombocytopenia | 2023 |
Patient preferences and experiences regarding thrombopoietin-receptor agonists for immune thrombocytopenia in The Netherlands (TRAPeze Netherlands study).
Topics: Adult; Aged; Aged, 80 and over; Benzoates; Female; Humans; Hydrazines; Male; Middle Aged; Netherlands; Patient Preference; Purpura, Thrombocytopenic, Idiopathic; Quality of Life; Receptors, Fc; Recombinant Fusion Proteins; Thrombocytopenia; Thrombopoietin; Young Adult | 2023 |
Multicenter evaluation of the addition of eltrombopag to immunosuppressive therapy for adults with severe aplastic anemia.
Topics: Adult; Anemia, Aplastic; Benzoates; Humans; Hydrazines; Immunosuppression Therapy; Immunosuppressive Agents; Retrospective Studies | 2023 |